<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005181.pub2" GROUP_ID="MS" ID="645203052709433664" MERGED_FROM="" MODIFIED="2011-11-29 12:30:44 +0100" MODIFIED_BY="Liliana Coco" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2011-11-29 12:30:44 +0100" MODIFIED_BY="Liliana Coco">
<TITLE>Interferon beta for secondary progressive multiple sclerosis</TITLE>
<CONTACT MODIFIED="2011-11-29 12:30:44 +0100" MODIFIED_BY="Liliana Coco"><PERSON ID="14862" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Loredana</FIRST_NAME><LAST_NAME>La Mantia</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>lamantialore@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Unit of Neurology - Multiple Sclerosis Center</DEPARTMENT><ORGANISATION>I.R.C.C.S. Santa Maria Nascente Fondazione Don Gnocchi</ORGANISATION><ADDRESS_1>Via Capecelatro 66</ADDRESS_1><CITY>Milano</CITY><ZIP>20148</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 339 8006211</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-11-29 12:30:44 +0100" MODIFIED_BY="Liliana Coco"><PERSON ID="14862" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Loredana</FIRST_NAME><LAST_NAME>La Mantia</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>lamantialore@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Unit of Neurology - Multiple Sclerosis Center</DEPARTMENT><ORGANISATION>I.R.C.C.S. Santa Maria Nascente Fondazione Don Gnocchi</ORGANISATION><ADDRESS_1>Via Capecelatro 66</ADDRESS_1><CITY>Milano</CITY><ZIP>20148</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 339 8006211</PHONE_1></ADDRESS></PERSON><PERSON ID="35099785379539858003100804162135" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Laura</FIRST_NAME><LAST_NAME>Vacchi</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>laura.vacchi@hotmail.it</EMAIL_1><ADDRESS><DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT><ORGANISATION>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</ORGANISATION><ADDRESS_1>Via Celoria 11</ADDRESS_1><CITY>Milano</CITY><ZIP>20133</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="11438" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlo</FIRST_NAME><LAST_NAME>Di Pietrantonj</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>cdipietrantonj@aslal.it</EMAIL_1><ADDRESS><DEPARTMENT>Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field</DEPARTMENT><ORGANISATION>Azienda Sanitaria Locale ASL AL</ORGANISATION><ADDRESS_1>Via Venezia 6</ADDRESS_1><CITY>Alessandria</CITY><ZIP>15100</ZIP><REGION>Piemonte</REGION><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0131 306709</PHONE_1><PHONE_2>+39 0131 307821</PHONE_2><FAX_1>+39 0131 307847</FAX_1></ADDRESS></PERSON><PERSON ID="14847" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>George</FIRST_NAME><LAST_NAME>Ebers</LAST_NAME><POSITION>Action Research Professor of Clinical University of Oxford</POSITION><EMAIL_1>george.ebers@clneuro.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Neurology</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>3rd Floor - West Wing</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44-1865 231911</PHONE_1><FAX_1>+44-1865 231914</FAX_1></ADDRESS></PERSON><PERSON ID="11537" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marco</FIRST_NAME><LAST_NAME>Rovaris</LAST_NAME><EMAIL_1>mrovaris@dongnocchi.it</EMAIL_1><ADDRESS><DEPARTMENT>U.O. Sclerosi Multipla</DEPARTMENT><ORGANISATION>I.R.C.S.S.  S. Maria Nascente - Fondazione Don Gnocchi</ORGANISATION><ADDRESS_1>Via Capecelatro, 66</ADDRESS_1><CITY>Milano</CITY><ZIP>20148</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39-02-40308037</PHONE_1><FAX_1>+39-02-40308353</FAX_1></ADDRESS></PERSON><PERSON ID="11634" ROLE="AUTHOR"><FIRST_NAME>Sten</FIRST_NAME><LAST_NAME>Fredrikson</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>sten.fredrikson@ki.se</EMAIL_1><MOBILE_PHONE>+46736841179</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Neurology R54 - Department of Clinical Neuroscience</DEPARTMENT><ORGANISATION>Karolinska Institutet</ORGANISATION><ADDRESS_1>Karolinska University Hospital Huddinge</ADDRESS_1><CITY>Stockholm</CITY><ZIP>SE-14186</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46-858582053</PHONE_1><PHONE_2>+46-736841179</PHONE_2><FAX_1>+46-87744822</FAX_1></ADDRESS></PERSON><PERSON ID="6231" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Graziella</FIRST_NAME><LAST_NAME>Filippini</LAST_NAME><EMAIL_1>gfilippini@istituto-besta.it</EMAIL_1><URL>http://www.msg.cochrane.org</URL><ADDRESS><DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT><ORGANISATION>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</ORGANISATION><ADDRESS_1>via Celoria, 11</ADDRESS_1><CITY>Milano</CITY><ZIP>20133</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 23942381</PHONE_1><FAX_1>+39 02 23942713</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-11-25 10:11:50 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="8" MONTH="8" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="6" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2011-07-07 10:44:46 +0200" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2011-07-07 10:44:46 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-07-07 10:44:46 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>The review team has been reformed. References have been updated. The outcome measures have been redefined. The text has been amended throughout.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MINOR" MODIFIED="2009-11-25 09:51:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>The byline and the contact person have been modified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-25 09:51:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-11-25 10:11:26 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Clinical Neurological Sciences, University of Western Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>National Neurological Institute "Carlo Besta"</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-29 12:28:33 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-11-25 11:30:48 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-11-24 10:08:04 +0100" MODIFIED_BY="[Empty name]">Interferon beta for Secondary Progressive Multiple Sclerosis</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-25 11:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>Interferon beta, an anti-inflammatory therapy for patients with Relapsing Remitting Multiple Sclerosis(RRMS), is also used for patients with the secondary progressive type.</P>
<P>Although it remains unclear how either beta-1a or beta-1b interferons (IFNs) work in MS, these therapies have been  well established in RRMS. Currently, IFNs' therapies are also the first line treatment for Secondary Progressive Multiple Sclerosis (SPMS), since  other drugs, such as mitoxantrone, have a worse risk/benefit profile.  A major unanswered question is whether and to what extent IFNs are really effective in SPMS.</P>
<P>The main objective of this review was to verify whether IFNs in patients with SPMS are more effective than placebo in reducing the number of patients who experience disability progression during the 2-3 years follow-up.</P>
<P>Among the pertinent literature, only  five studies met the criteria of the inclusion in the review, comprising a total of 3122 participants (1829 treated with IFN and 1293 with placebo).</P>
<P>Overall, these results show that IFNs are unable to retard the progression once it is established, making INFs not useful in the secondary progressive phase of the disease. </P>
<P>The well known adverse events related to IFNs' treatment such as injection site reactions, influenza like syndrome, and leukopenia occurred frequently also in SPMS patients, while serious and  life-threatening adverse events were not increased in the treated group of patients.</P>
<P>Because this review has considered well designed studies with a high number of patients, the authors believe that its results give conclusive evidence on the clinical efficacy of IFN beta versus placebo in patients with SPMS. Research focused on innovative drugs is mandatory.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-25 11:28:22 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-11-20 10:39:06 +0100" MODIFIED_BY="[Empty name]">
<P>Therapy with either recombinant beta-1a or beta-1b interferons (IFNs) is worldwide approved for Relapsing Remitting Multiple Sclerosis (RRMS). A major unanswered question is whether this treatment is able to safely reverse or retard the progressive phase of the disease.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-11-20 10:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>The main objective was to verify whether IFNs treatment in Secondary Progressive Multiple Sclerosis (SPMS) is more effective than placebo in reducing the number of patients who experience disability progression.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-11-24 10:53:07 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Multiple Sclerosis Group's Trials Register (1995 to 15 February 2011), the reference lists of relevant articles and conference proceedings. Regulatory agencies were used as additional sources of information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-20 10:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised, double or single blind, placebo-controlled trials (RCTs) evaluating the efficacy of IFNs versus placebo in SPMS patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-24 09:54:59 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed all reports retrieved from the search. They independently extracted clinical, safety and MRI data, using a predefined data extraction form, resolving disagreements after discussion with a third reviewer. Risk of bias was evaluated to assess the quality of the studies. Treatment effect was measured using Risk Ratio (RR) with 95% confidence intervals (CI) for the binary outcomes and Standard Mean Difference with 95% CI for the continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-25 11:28:22 +0100" MODIFIED_BY="[Empty name]">
<P>Five RCTs met the inclusion criteria, from which 3122 (1829 IFN and 1293 placebo) treated patients contributed to the analysis. Included population was heterogeneous in terms of baseline clinical characteristics of the disease, in particular the percentage of patients affected by secondary progression with superimposed relapse ranging from 72% to 44%. IFN beta 1a and 1b did not decrease the risk of progression sustained at 6 months (RR, 95% CI: 0.98, [0.82-1.16]) after three years of treatment. A significant decrease of the risk of progression sustained at 3 months (RR, 95% CI: 0.88 [0.80, 0.97]) and of the risk of developing new relapses at three years (RR 0.91, [0.84-0.97]) were found. The risk of developing new active brain lesions decreased over time but this data was obtained from single studies on Magnetic Resonance Imaging (MRI), performed in subgroups of patients; in spite of no effect on progression, the radiological data supported an effect on MRI parameters. The safety profile reflects what is commonly reported in MS IFN-treated patients.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-25 09:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>Well designed RCTs, evaluating a high number of patients were included in the review. Recombinant IFN beta does not prevent the development of permanent physical disability in SPMS. We were unable to verify the effect on cognitive function for the lack of comparable data. This treatment significantly reduces the risk of relapse and of short -term relapse-related disability.</P>
<P>Overall, these results show that IFNs' anti-inflammatory effect is unable to retard progression, when established. In the future, no new RCTs for IFNs versus placebo in SPMS will probably be undertaken, because research is now focusing on innovative drugs. We believe that this review gives conclusive evidence on the clinical efficacy of IFNs versus placebo in SPMS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-29 12:25:07 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-11-25 11:32:47 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-11-25 11:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>The natural history of multiple sclerosis (MS) evolves over 30 to 40 years (<LINK REF="REF-Paty-1998" TYPE="REFERENCE">Paty 1998</LINK>). A secondary progressive phase (SP) supervenes in more than 50% of relapsing-remitting (RR) patients within 15 years (<LINK REF="REF-Weinshenker-1989a" TYPE="REFERENCE">Weinshenker 1989a</LINK>); walking aid is needed about five years from its onset, the median rate of EDSS increase being 0.53 <U>+</U> 0.02 DSS point per year (<LINK REF="REF-Weinshenker-1989a" TYPE="REFERENCE">Weinshenker 1989a</LINK>).</P>
<P>Understanding when a RR course shifts to a progressive phase, which is characterised by a progressive physical or cognitive disability, is not an easy clinical task. Natural history studies show that at least one year is needed to confirm disease progression (<LINK REF="REF-Cottrell-1999" TYPE="REFERENCE">Cottrell 1999</LINK>; <LINK REF="REF-Kremenchutzky-2006" TYPE="REFERENCE">Kremenchutzky 2006</LINK>; <LINK REF="REF-Ebers-2008" TYPE="REFERENCE">Ebers 2008</LINK>). Progression may occur without a convincing link to clinical or magnetic resonance imaging (MRI) flares of the disease and in particular cognitive decline may indicate disease progression in the absence of worsening physical disability (<LINK REF="REF-Amato-2006" TYPE="REFERENCE">Amato 2006</LINK>; <LINK REF="REF-Duque-2008" TYPE="REFERENCE">Duque 2008</LINK>).</P>
<P>It remains uncertain how the first phases of immune-mediated inflammation correlate with the development of progression and if immunological events are primarily or secondarily related to the progression of the disease (<LINK REF="REF-Compston-2002" TYPE="REFERENCE">Compston 2002</LINK>).</P>
<P>What is the relationship between relapse frequency and progression? Progression in SPMS is strongly influenced by prior relapses in the first years after disease onset, but it is uncertain if this mechanism is causal (<LINK REF="REF-Ebers-2000" TYPE="REFERENCE">Ebers 2000</LINK>; <LINK REF="REF-Weinshenker-1989" TYPE="REFERENCE">Weinshenker 1989</LINK>). In patients with SPMS, superimposed relapses seem to be associated with a slower rate of progression (<LINK REF="REF-Confavreux-2000" TYPE="REFERENCE">Confavreux 2000</LINK>). The results of more recent studies with a mean follow-up over 20 years demonstrate that the progressive course is independent from relapses either preceding or subsequent to progression (<LINK REF="REF-Kremenchutzky-2006" TYPE="REFERENCE">Kremenchutzky 2006</LINK>). Relapses during SPMS had no measurable impact on time to EDSS 6 (<LINK REF="REF-Tremlett-2009" TYPE="REFERENCE">Tremlett 2009</LINK>). Epidemiological studies show that the shift from RRMS to SPMS follows the achievement of EDSS 4 (<LINK REF="REF-Confavreux-2006" TYPE="REFERENCE">Confavreux 2006</LINK>) when clinical predictors are no longer influent for prognosis (<LINK REF="REF-Confavreux-2003" TYPE="REFERENCE">Confavreux 2003</LINK>).</P>
<P>The physiopathological factors which underlie progression of MS are not completely understood, but it is widely believed that they include axonal and neuronal injury and loss, oligodendrocyte damage and extensive lesions of the white matter (WM) (<LINK REF="REF-Glass-2010" TYPE="REFERENCE">Glass 2010</LINK>; <LINK REF="REF-Frisher-2009" TYPE="REFERENCE">Frisher 2009</LINK>; <LINK REF="REF-Noseworthy-2000" TYPE="REFERENCE">Noseworthy 2000</LINK>). Diffuse abnormalities in the WM, i.e. the so-called diffusely abnormal WM, may contribute to the development of clinical disability (<LINK REF="REF-Seewann-2009" TYPE="REFERENCE">Seewann 2009</LINK>; <LINK REF="REF-Lassmann-2009" TYPE="REFERENCE">Lassmann 2009</LINK>). A significant association between inflammation and axonal injury has been reported, showing that active progressive MS has a more aggressive course compared with inactive disease (<LINK REF="REF-Frisher-2009" TYPE="REFERENCE">Frisher 2009</LINK>).</P>
<P>MRI studies have showed that cortical lesions and tissue loss in RRMS and SPMS (<LINK REF="REF-Tekok_x002d_Kilic-2007" TYPE="REFERENCE">Tekok-Kilic 2007</LINK>; <LINK REF="REF-Calabrese-2009" TYPE="REFERENCE">Calabrese 2009</LINK>) as well as diffuse brain lesions, T1-T2 -lesion load in progressive MS (<LINK REF="REF-Ukkonen-2009" TYPE="REFERENCE">Ukkonen 2009)</LINK> are associated with cognitive impairment.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-11-25 11:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>Recombinant IFN-beta (rIFNb) products licensed for MS treatment are IFN beta-1b (Betaferon-Bayer® or Extavia-Novartis®) and two IFN beta-1a preparations (Avonex-Biogen Dompé® and Rebif-Serono®).</P>
<P>IFN beta-1b is a lyophilised protein produced by DNA recombinant technology using E. Coli. The approved dose is 250 mcg every other day by subcutaneous injection.</P>
<P>IFN beta 1-a is a lyophilised glycoprotein produced in mammalian cells using the natural human gene sequence. Two preparations are licensed for the treatment of MS, i.e. 30 mcg (Avonex®) once a week administered by intramuscular injection, and 22 or 44 mcg (Rebif®) administered three times a week by subcutaneous injections.</P>
</INTERVENTION>
<THEORY MODIFIED="2011-11-24 10:22:59 +0100" MODIFIED_BY="[Empty name]">
<P>It remains unclear how rIFNb works in MS. The suggested mechanisms include inhibition of T-cell proliferation, regulation of many cytokines and blocking of blood-brain barrier opening by interference with cell adhesion molecules. Therapy with either beta-1a or beta-1b interferons is now established in RRMS, although their medium and long term effect has been challenged by a previous systematic review (<LINK REF="REF-Rice-2001" TYPE="REFERENCE">Rice 2001</LINK>). A major unanswered question is whether pharmacological inhibition of in&#64258;ammation pathways is able to safely reverse or delay the course of the disease (<LINK REF="REF-Rice-2001" TYPE="REFERENCE">Rice 2001</LINK>; <LINK REF="REF-Filippini-2003" TYPE="REFERENCE">Filippini 2003</LINK>; <LINK REF="REF-Glass-2010" TYPE="REFERENCE">Glass 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-11-24 10:28:44 +0100" MODIFIED_BY="[Empty name]">
<P>Interferon beta-1b was approved for SPMS treatment on 1999 by <LINK REF="REF-EMEA-2000" TYPE="REFERENCE">EMEA 2000</LINK> and by the <LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>. In 2006 it was confirmed that Betaferon® was indicated for SPMS patients with active disease, evidenced by relapses (<LINK REF="REF-EMEA-2006" TYPE="REFERENCE">EMEA 2006</LINK>). Extavia®, which is the same interferon beta-1b product as Betaferon, was approved with the same indications (<LINK REF="REF-EMEA-2008" TYPE="REFERENCE">EMEA 2008</LINK>; <LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>).</P>
<P>This therapy is currently the first line treatment for SPMS, as mitoxantrone shows a worse risk/benefit profile (<LINK REF="REF-FDA-2000" TYPE="REFERENCE">FDA 2000</LINK>).</P>
<P>A meta-analysis of Interferon-Beta in Multiple Sclerosis (<LINK REF="REF-Nikfar-2010" TYPE="REFERENCE">Nikfar 2010</LINK>), showed that the effectiveness of IFNs depends on the type of IFNs used and the subtype of MS treated; the results did not confirm the efficacy of IFN in SPMS.</P>
<P>A systematic review is warranted to verify rIFNb use in clinical practice for SPMS.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-25 09:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Our primary questions were:</P>
<P>Are rIFNbs more effective than placebo in reduction of disability progression or cognitive impairment in SPMS patients?</P>
<P>What is the incidence and severity of adverse events during this treatment in this form of disease?</P>
<P>Our secondary objectives were to assess the effect of rIFNb on the reduction of clinical relapses, on the quality of life and on depression/other psychological aspects.</P>
<P>Finally, MRI data were also considered to verify the effect of interferons on cerebral lesions.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-28 09:42:27 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-25 11:06:04 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-11-08 12:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed only randomised, double or single blind, placebo-controlled trials of recombinant interferon beta for SPMS patients. Randomised crossover trials were included if results were available for all phases. Uncontrolled or non-randomised trials were excluded. Trials in which the comparisons of interest were confounded by other treatments, such as immunosuppressive drugs, were excluded. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-20 16:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>Patients diagnosed as having clinically definite MS according to Poser (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>), Mc Donald (<LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>) or Polman (<LINK REF="REF-Polman-2005" TYPE="REFERENCE">Polman 2005</LINK>) criteria were included. According to accepted criteria (<LINK REF="REF-Lublin-1996" TYPE="REFERENCE">Lublin 1996</LINK>), SPMS was defined as a clinical course, characterised by an initial relapsing-remitting phase followed by progression with or without superimposed relapses, minor remissions and plateaus. We excluded patients with primary progressive MS.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-24 10:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>Beta recombinant interferons (rIFNb) <I>v</I>ersus<I> </I>placebo. Trials were not excluded on the basis of dose, treatment duration, administration route. Length of follow-up of at least one year was required. For trials in which treatment effects were reported for more than one dose, we considered the treated groups together.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-25 11:06:04 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-11-25 11:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome measures were the proportion of patients who had disability progression or cognitive impairment after two and three years. Progression of disability, was defined as a 6 month sustained increase in Expanded Disability Status Scale (EDSS) (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>) of at least one point (0.5 point if baseline EDSS &#8805;5.5) recorded in a period without relapses. Less stringent criteria (sustained disability at 3 months without mention of intercurrent relapses) have been accepted. Diagnostic criteria of cognitive impairment were taken from articles, provided they had been validated.</P>
<P>Safety was evaluated in terms of:<I> </I>
</P>
<OL>
<LI>patients with serious adverse events (SAE), defined as any untoward medical occurrence at any dose that results in death, requires patients hospitalisation (excluding hospitalisation for relapses), results in persistent or significant disability/incapacity or is life-threatening (WHO www.who-umc.org/umc.html);</LI>
<LI>proportion of patients who withdrew or dropped out from the study because of adverse events (AE), i.e. an adverse event for which the causal relation between treatment and the event is at least a reasonable possibility;</LI>
<LI>number of patients with any AE.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-11-25 11:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated the proportion of patients who had one or more relapses during the treatment and follow-up periods. Relapses were defined as newly developed or recently worsened neurological dysfunction symptoms that lasted more than 24 hours, with or without objective confirmation, and that stabilised or resolved either partially or completely. We also assessed relapse rate, quality of life (QOL) measured by validated questionnaires such as the "Multiple Sclerosis Quality of Life-54 " (MSQOL-54), activities of daily living (ADL), psychological aspects measured by validated scales or other instruments for depression or anxiety, and the effect of treatment on cerebral MRI findings, i.e. number and/or volume of enhancing T1 and new T2 lesions, and cerebral atrophy.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-25 11:09:44 +0100" MODIFIED_BY="[Empty name]">
<P>No language restrictions were applied to the search.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-11-25 11:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>The first search for this review covers the years 1995 to 2009 and the details of the search methods are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For the most recent search the Trials Search Co-ordinator searched the Cochrane Multiple Sclerosis Group's Specialised Register (2010 to 15 February 2011). The keywords used to search for this review are listed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>The Cochrane Multiple Sclerosis Trials Register is updated regularly and contains trials identified from:</P>
<OL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (recent issue);</LI>
<LI>MEDLINE (PubMed) (1966 to date);</LI>
<LI>EMBASE (Embase.com) (1974 to date);</LI>
<LI>CINAHL (Ebsco host) (1981 to Feb 2011);</LI>
<LI>LILACS (Bireme) (1982 to date);</LI>
<LI>PEDro;</LI>
<LI>Clinical trials registries.</LI>
</OL>
<P>Information on the Cochrane Multiple Sclerosis Group's Trials Register and details of search strategies used to identify trials can be found in the 'Specialised Register' section within the Cochrane Multiple Sclerosis Group's <A HREF="http://mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">module</A>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-11-25 11:09:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>US Food and Drug Administration (FDA) regulatory reports (1995 to 2011)</LI>
<LI>European Medicines Agency (EMEA) regulatory reports (1995 to 2011)</LI>
<LI>Reference lists of all available review articles and primary studies</LI>
<LI>Abstract books of ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis), ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis), EFNS (European Federation of Neurological Societies), ENS (European Neurological Society), AAN (American Academy of Neurology), ANA (American Neurological Association) international meetings (1995 to 2011);</LI>
<LI>Contact with authors or sponsor companies to obtain missing data.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-28 09:42:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-11-20 16:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (LLM, LV) scrutinised all articles retrieved by the search and decided independently whether a trial met the criteria for inclusion in the review. Any disagreement about trial status was resolved by discussion among the two authors and a third reviewer (GF).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-11-25 11:34:11 +0100" MODIFIED_BY="[Empty name]">
<P>The two authors (LLM, LV) independently extracted trial data using an Excel sheet, focusing also on aspects of methodological quality in RCT. Study arms comparing different fixed doses of interferon within the therapeutic range were converted into a single arm by summing the number of events on the number of patients randomised. Other parameters were assessed, including patients' baseline characteristics, duration and completeness of follow-up. Disagreements on extractions were resolved by discussion among three authors (LLM, LV and GF).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-11-25 11:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (LLM, LV) independently judged trial quality according to the methods set out in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>Six recognised aspects of methodological quality in the RCTs were considered:</P>
<P>(i) random sequence generation (selection bias);</P>
<P>(ii) masking of patients' allocation to comparison groups (allocation concealment);</P>
<P>(iii) blinding of outcome assessment (detection bias);</P>
<P>(iv) blinding of participants and personnel (performance bias);</P>
<P>(v) how patients, withdrawn after randomisation or lost to follow-up, were treated in analysis (incomplete outcome data (attrition bias). We defined as "high risk of bias" lost to follow up more than 20%;</P>
<P>(vi) other bias, such as early study termination, were also reported.</P>
<P>Disagreements on trial quality were resolved by discussion among three authors (LLM, LV and GF). The results of trial quality assessment were included in the "Risk of Bias Tables" as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.1.0 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-11-25 11:35:13 +0100" MODIFIED_BY="[Empty name]">
<P>Binary outcomes were assessed by calculation of Risk Ratios (RRs) and 95% CI for each trial.</P>
<P>Continuous outcomes were assessed by mean-differences between intervention and control groups.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-05-05 18:05:02 +0200" MODIFIED_BY="[Empty name]">
<P>No cross-over studies were found. For each trial the analysis was performed taking into account the original randomisation. For RCTs comparing different dosages of the same treatment we considered together the outcomes in the treated arms, summing the number of events (numerator) and the number of randomised patients (denominator).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-11-25 11:35:29 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to retrieve missing data from the investigators and/or sponsor companies for further details. Idec-Biogen and Ares Serono International SA provided the required supplementary information on clinical outcomes (sustained progression and relapse rate).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-28 09:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity among trials were examined using the I-squared statistic.The I-squared estimate greater than the 50% was interpreted as indicating heterogeneity. In this case, we used random-effects estimates of the intervention effect (<LINK REF="REF-Der-Simonian-1986" TYPE="REFERENCE">Der Simonian 1986</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-24 11:16:20 +0100" MODIFIED_BY="[Empty name]">
<P>The possibility of publication biases was investigated using a funnel plot, i.e. trial effect against trial size (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>We have tried to avoid any possible publication bias, translating two Russian publications retrieved from the search.</P>
<P>We evaluated whether or not there was a selective under-reporting of data in the included published articles and we searched FDA trial registration reports. We checked duplicate papers and/or ancillary studies, in order to find possible other relevant data not reported in the primary included RCTs. </P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-20 16:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>Data were processed using the total number of randomised patients.</P>
<P>We calculated a weighted overall estimate of the RRs with 95% CI for binary outcomes, and weighted averages of differences between means for continuous outcomes.</P>
<P>We used a random effects model to combine the study findings, except for subgroup analysis where we used a fixed-effect model because we didn't find heterogeneity between the included studies.</P>
<P>When meta-analysis was not possible, we performed a qualitative description.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-24 11:22:20 +0100" MODIFIED_BY="[Empty name]">
<P>We performed two subgroup analyses regarding the outcome of sustained (3 or 6 months) disability progression.</P>
<P>The first analysis considered for each of the included studies: (i) the number of patients with pre-study relapses and (ii) the number of patients without pre-study relapses.</P>
<P>The second analysis considered each study according to baseline characteristics of the patients such as age, EDSS, disease duration, duration of progressive phase of the disease, and number of relapses, previous their comparison by statistical analysis (Anova test, post-hoc multiple comparison: mean difference significant at the 0.050 level).<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-11-25 11:38:55 +0100" MODIFIED_BY="[Empty name]">
<P>We performed a sensitivity analysis on primary outcomes, by including or excluding trials with high risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-29 12:25:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-11-25 11:40:01 +0100" MODIFIED_BY="[Empty name]">
<P>Out of 2389 references identified by the search strategy from 1995 to 15 February 2011, 123 articles were provisionally selected as potentially fulfilling inclusion criteria <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. A further sixty four articles were eliminated because they were non pertinent studies. Among the remaining 59 articles, 18 studies were excluded because they were performed in relapsing remitting (<LINK REF="STD-Buhse-2006" TYPE="STUDY">Buhse 2006</LINK>; <LINK REF="STD-Smith-2005" TYPE="STUDY">Smith 2005</LINK>) or primary progressive MS patients (<LINK REF="STD-Leary-2003" TYPE="STUDY">Leary 2003</LINK>; <LINK REF="STD-Montalban-2009" TYPE="STUDY">Montalban 2009</LINK>), or because evaluating the efficacy of treatments other than recombinant beta interferon (<LINK REF="STD-Goodkin-1997" TYPE="STUDY">Goodkin 1997</LINK>; <LINK REF="STD-Patti-1999" TYPE="STUDY">Patti 1999</LINK>; <LINK REF="STD-Arnason-1999" TYPE="STUDY">Arnason 1999</LINK>; <LINK REF="STD-Tubridy-1999" TYPE="STUDY">Tubridy 1999</LINK>; <LINK REF="STD-Goodkin-2000a" TYPE="STUDY">Goodkin 2000a</LINK>; <LINK REF="STD-Boiko2001" TYPE="STUDY">Boiko2001</LINK>; <LINK REF="STD-Skurkovich-2001" TYPE="STUDY">Skurkovich 2001</LINK>; <LINK REF="STD-Hoogervorst-2002" TYPE="STUDY">Hoogervorst 2002</LINK>; ,<LINK REF="STD-Zavalishin-2003" TYPE="STUDY">Zavalishin 2003</LINK>; <LINK REF="STD-Christodoulou-2006" TYPE="STUDY">Christodoulou 2006</LINK>;<LINK REF="STD-Bar_x002d_Or-2007" TYPE="STUDY">Bar-Or 2007</LINK>). Trials that included active treatment comparisons (<LINK REF="STD-Baum-2006" TYPE="STUDY">Baum 2006</LINK>) or add-on therapies (<LINK REF="STD-Fernandez-2002" TYPE="STUDY">Fernandez 2002</LINK>) were excluded (see table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). One observational study was also excluded (<LINK REF="STD-Rio-2007" TYPE="STUDY">Rio 2007</LINK>).</P>
<P>Five trials were eligible (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>; <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>; <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>;<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> ) to which 36 other references were correlated. The studies' methods, the characteristics of the participants, the interventions, the outcomes, along with risk of bias tables, are described in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>In all included studies, secondary progression was defined as a period of deterioration sustained for at least 6 months, after a period of relapsing-remitting phase; one study did not define for how long sustained progression was observed (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>. Deterioration was quantified in terms of: at least two relapses or at least 1.0-point EDSS increase independent of relapses in the two years before the study (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>); a history of at least one relapse and an increase in EDSS score of at least 1.0 point in the 2 years prior to screening (at least a 0.5-point increase for subjects with a screening EDSS score of 6.5 (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>), an increase of at least 1 EDSS point over the last 2 years (or 0.5 point between EDSS score of 6.0 and 6.5), with or without superimposed exacerbations (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>); not further defined in <LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK> and <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> studies.</P>
<P>Two studies (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>) compared the effect of IFN beta-1b <I>versus</I> placebo, the first comparing two different dosages: 250 ug and 160 ug/m<SUP>2 </SUP>(corresponding to a mean administered dose of 220 ug). Three RCTs reported the effect of IFN beta-1a for different dosages and preparations: 60 ug intramuscular injections (i.m.)/weekly (Avonex®) (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>, 22 mg subcutaneously/ weekly (Rebif®) (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK> and 22 or 44 ug (two arms) subcutaneously/ three times weekly (Rebif®) (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>).</P>
<P>Treatment duration and follow-up were two years for one study (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> and three years for the other four studies.</P>
<P>The primary outcome was time to disability progression defined by EDSS measure for all of the trials, except for <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>' study which used the MS Functional Composite (MSFC). Disability progression was defined as:</P>
<UL>
<LI>3 months' sustained increase in EDSS of &gt;1.0 point (0.5 for baseline EDSS &gt;6) (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>- <LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>);</LI>
<LI>3 months' sustained increase in EDSS of &gt;1.0 point (0.5 point for baseline EDSS &gt;5.5) (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>);</LI>
<LI>6 months' sustained increase in EDSS of &gt;1.0 point (0.5 for baseline EDSS&gt;6) (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>, <LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>);</LI>
<LI>6 months' sustained increase in EDSS of &gt;1.0 point (0.5 for baseline EDSS &gt; 5.5) <LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>.</LI>
</UL>
<P>Disability progression measured by EDSS was a secondary outcome in <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> defined as a 3 months' sustained increase in EDSS of &gt; 1.0 point (0.5 for baseline EDSS 6).</P>
<P>Results of 6 months' sustained increase in EDSS in the <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> were extracted from the <LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>.</P>
<P>The summary of baseline clinical characteristics of included patients are reported in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. The included patients were heterogeneous and significantly different for all the variables except for progression duration. Patients included in the <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> and <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK> studies were younger and their disease duration was lower than that reported in other trials. <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>' population had higher baseline EDSS. The number of relapses was different (0.8-1.7) and detected during a pre-study period of four years for Nordic (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>), three for Impact (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>) and two years in the other three trials.</P>
<P>Overall, 3122 (1829 IFN - 1293 placebo) patients were included in this review.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-25 11:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>To assess risk of bias in the included studies, data from FDA reports were also considered (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>). Risk of bias are reported in the corresponding table of each included study and summarized in the figures (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> ). Briefly, only one study was judged adequate for all aspects (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>). The major concern refers to incomplete outcome reporting since only a proportion of the randomised patients were included into the primary studies' analysis (74% in the <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> study, 72% in the <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> study, and 83% in the <LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK> study).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-29 12:25:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes  </HEADING>
<P>
<B>1.The number of patients who had a sustained disability progression</B>
</P>
<P>The number of patients who had 6 months's sustained progression assessed at 3 years was available for three trials (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>; <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>) and 2026 (65%) patients (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>): 1177 (64%) patients in the interferon groups and 849 (69%) controls. From these data the RR was 0·98 ([0.82,1.16], <I>p</I>=0.79). However, a high level of heterogeneity was found (I<SUP>2</SUP>= 57%). One study (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>) found a significant treatment effect while the other two studies did not confirm this.</P>
<P>The number of patients who had 3 months sustained progression assessed at 3 years was available for two trials (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>; <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>) and 1336 (43%) patients (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>): 773 (42%) patients in the interferon groups and 563 (43.5%) controls. From these data the RR was 0.88 ([0.80,0.97], <I>p</I>=0.01).</P>
<P>The first subgroup analysis (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) evaluating disability progression at 3 years for patients with (RR, (95% CI): 0.90 [0.75,1.09], <I>p</I>=0.28) or without pre-study relapses (RR, (95% CI):1.05 [0.83,1.33], <I>p</I>=0.70) did not show any treatment effect in both groups of patients. However, a high level of heterogeneity was found (I<SUP>2</SUP>= 51%) for subgroup of patients without pre-study relapses.</P>
<P>The second subgroup analysis was aimed to evaluate the role of baseline characteristics in the treatment response. We compared progression between <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK> and <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> studies versus the other included studies, because of their relative similarity in term of age and disease duration (see <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>). A slight non-significant effect in patients with lower age and disease duration (RR, (95% CI): 0.92 [0.83, 1.02] <I>p</I>=0.10) as compared with that in patients with higher age and disease duration ( 1.03 [0.90, 1.18] p=0.64) was found (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>2.<U>The number of patients who had progression of cognitive impairment. </U>
</P>
<P>Cognitive function was evaluated in two studies: <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> used the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> used the Paced Auditory Serial Addition Task (PASAT, within the MSFC).</P>
<P>It was not possible to give a synthesis due to differences in time-point reporting, used tests and type of measures.</P>
<P>In the first study (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>), BRB-N's score decrease over time appeared to be similar between treatment groups (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>), while no significant changes in mean PASAT's score were found at the end of 24 month follow-up (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>).</P>
<P>
<U>3. Safety </U>
</P>
<P>AEs were extracted and analysed as number of patients who had any event, while only "allergy/rash" was reported as number of events. If results provided by the primary studies were unclear, data extraction was not performed. For similar AEs (such as increase of liver enzymes), we extracted the results with higher values.</P>
<P>Details about AE risk are reported in "Analysis 2" sections (<LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>).</P>
<P>The risk of experiencing a Serious Adverse Event (SAE) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) was not significantly increased (RR, (95% CI): 1.00 [0.83, 1.19]) in treatment group, while the number of patients withdrew or dropped out due to AEs (including SAEs, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) were higher in the treated group (RR (95% CI): 2.62 [1.92, 3.57]).</P>
<P>Sixteen deaths occurred in the treated group (4 suicide, 3 pulmonary embolism, 3 cardiac arrest, 1 cancer, 1 intracerebral haemorrhage, 2 brainstem infarction and urosepsis, 2 unknown) and seven in the control groups (1 subarachnoid haemorrhage, 2 suicide, 1 "arteriosclerosis", 1 pneumonia, 2 unknown) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>The following AEs were significantly related to the IFN treatment (marked in the corresponding <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> table by an asterisk): injection site reactions (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>), cutaneous necrosis (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), and influenza like syndrome (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). Among haematological AEs, only leukopenia was significantly related to treatment (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<P>1. <U>Number of patients experiencing at least one relapse during follow-up</U>
</P>
<P>The number of patients who experienced at least one relapse at 3 years was available from four trials (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>; <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>), accounting for 1590 patients in the interferon groups and 1049 controls.</P>
<P>Results after two years were reported only by one study (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>).</P>
<P>IFN-beta significantly reduces the risk to have relapses during a three year follow-up: RR (95% CI): 0.91 [0.84,0.97] (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>2. <U>Relapse rate during follow-up</U>
</P>
<P>This outcome was available at three years only for three studies (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK> and <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>). We compared Betaseron® 250 ug versus placebo for <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> and <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> and Rebif® 44 ug versus placebo for <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>.</P>
<P>From these data the Mean Difference was -0.16 [-0.21, &#8211;0.10] (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>Results after two years were reported only for one study (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>).</P>
<P>3. <U>Quality of life (QOL) measured by validated questionnaires such as the "Multiple Sclerosis Quality of Life-54 instrument" (MSQOL-54) or activities of daily living (ADL) during follow-up</U>
</P>
<P>Comparison among studies was not allowed because of differences in the scales used (Sickness Impact Profile in <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>, Multiple Sclerosis Quality of Life Inventory (MSQLI) in <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> and <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>, General Health Questionnaire in <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>, Nottingham Health Profile Part I (NHP-I) in <LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>), the time-point of assessment and the availability of appropriate published results.</P>
<P>It may be described that a slight positive effect favouring the IFN group was found for the physical domain at 6 and 12 months and at last visit in <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>. To the contrary, no significant differences between treatment groups at any time point was found in health-related QOL measures in <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>. Significant benefit favouring IFNbeta-1a treatment was observed in MSQLI in the IMPACT study (<LINK REF="REF-Miller-2006" TYPE="REFERENCE">Miller 2006</LINK>).</P>
<P>4. <U>Psychological aspects measured by validated scales or other instruments for depression or anxiety during follow-up</U>
</P>
<P>This outcome was evaluated in three studies, with different scales: Montgomery Asberg Depression Rating Scale (MADRS) assessing mood changes and suicidal risk (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>), changes in Beck Depression Index (BDI) score between baseline and the end of follow-up (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>), the Center for Epidemiologic Studies Depression Rating Scale (CES-D) and Beck Hopelessness Scale (BHS) (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>).</P>
<P>Differences in scales, assessment time-points and availability of appropriate published results did not allow the comparison among studies.</P>
<P>It may be described that patients on interferon beta 1b had no increased incidence of new or worsened depression, according to studies results (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>; <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>). Depression was reported in 29% of patients receiving placebo, 32% receiving low-dose IFN, and 35% receiving high-dose IFN (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>).</P>
<P>5. <U>Change in MRI markers of disease activity.</U>
</P>
<P>All studies, expect for <LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>, provided MRI monitoring.</P>
<P>Baseline MRI characteristics of the included patients were similar in IFN and placebo-treated groups in all included studies in terms of total T2 lesion volume (TLV). Gadolinium enhancing lesions were absent in about 60% of the patients for <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> and in 50% of patients for the other three RCTs.</P>
<P>Different outcome measures were used at different time points: total lesion T2 volume or area, mean absolute or percentage change from baseline of total load volume (TLV) or area, number of new or enlarging T2-hyperintense lesions, number and/or percentage of patients with Gd-enhancing lesions, percentage of patients with new T2 or Gd-enhancing or enlarging lesions (the so called Combined Unique= CU), number of patients with enhancing lesions or number of enhancing lesions for patients. Furthermore, two studies have planned a " frequent MRI studies" (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>) performed in subgroups of patients, corresponding to respectively 20% and 46% of the original population. In particular, a subgroup of 125 patients also underwent monthly Gd-enhanced and proton density/T2-weighted brain MRI from months 0 to 6 and 18 to 24, in order to determine the effect of treatment on the patterns of lesion activity, defined as new enhancing lesions and new/enlarging T2 lesions not Gd-enhancing (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>, <LINK REF="REF-Miller-1999" TYPE="REFERENCE">Miller 1999</LINK>). In <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK> a cohort of 283 patients also had 11 monthly PD/T2 and Gd-enhanced scans at study start (<LINK REF="REF-Li-2001" TYPE="REFERENCE">Li 2001</LINK>). Furthermore atrophy was evaluated only in one RCT (<LINK REF="REF-Molyneux-2000b" TYPE="REFERENCE">Molyneux 2000b</LINK>).</P>
<P>On the basis of available data, we decided to verify the MRI effect using only two outcome measures: the number of patients with CU and the absolute change of TVL.</P>
<P>IFN reduces the risk to develop CU at 6 months (RR, (95% CI): 0.70 [0.52,0.95]) and until 24 months (RR, (95% CI): 0,52 [0.33,0.80]) as compared to placebo treatment (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The significance of these data is limited, because only single RCTs contributed to each analysis, involving subgroups of the original population (301 treated patients and 197 controls).</P>
<P>The decrease of TLV in IFN-treated patients was significant at 1 year (-1.74, (95% CI) [-3.25, -0.23]) and persisted at 3 years (-4.87, (95% CI) [-6.22, -3.52]), but the heterogeneity of the results suggests that these data should be considered with caution (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-28 09:42:49 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-11-25 10:44:09 +0100" MODIFIED_BY="[Empty name]">
<P>Our systematic review was planned to evaluate the benefit rIFNs versus placebo in SPMS.</P>
<P>The main result was the evidence of no effect of rIFNbs in reducing the risk of sustained 6 months progression in SPMS patients.</P>
<P>The main secondary results were a significant decrease of a) short -term (3 months) disability progression risk, reflecting relapse-related disability (<LINK REF="REF-Lublin-2003" TYPE="REFERENCE">Lublin 2003</LINK>) and b) risk of having relapses during the treatment, although of limited size (9% and 12% respectively).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-11-28 09:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>The five RCTs selected were of good methodological quality as far as the selection and detection bias were concerned (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), although only one was free of bias risks (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). RCTs accounted for 3122 (1829 IFN and 1293 placebo) treated patients.</P>
<P>The objectives of this review were only partially satisfied, but the results allow us to properly define the profile of therapeutic effects of IFN in SPMS (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>IFNs treatment is unable to prevent the risk of having sustained disability progression in these patients. On the contrary, significant results were detected on relapse-related outcomes. These findings suggest that IFNs have an anti-inflammatory effect on SPMS, the relapses-related outcomes might be independent from disability progression's evolution. It is known that the correlation between relapse rate and disability in MS patients changes over time; when milestones of disability are reached (EDSS 4), the clinical predictor of disability is no longer influent for prognosis (<LINK REF="REF-Confavreux-2006" TYPE="REFERENCE">Confavreux 2006</LINK>). A dissociation between the suppression of in&#64258;ammation and the disease progression in SPMS patients has been already showed in patients treated with immunosuppressive drugs (<LINK REF="REF-Esposito-2010" TYPE="REFERENCE">Esposito 2010</LINK>).</P>
<P>A trend for a better response was found in patients with pre-study relapse, younger age and shorter disease duration, mainly related to the results of one study (<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK> ) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; .<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>): these clinical baseline characteristics could be predictive factors of therapeutical response and should be taken into account in the selection of patients.</P>
<P>It may be noticed that the included population (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) seems to have a more marked progression of disability than that reported during natural evolution of the disease (<LINK REF="REF-Tremlett-2006" TYPE="REFERENCE">Tremlett 2006</LINK>; <LINK REF="REF-Koch-2010" TYPE="REFERENCE">Koch 2010 </LINK>; <LINK REF="REF-Weinshenker-1989a" TYPE="REFERENCE">Weinshenker 1989a</LINK>); the <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>'s cases show the more active disease. According to <LINK REF="REF-Kappos-2004" TYPE="REFERENCE">Kappos 2004</LINK>, a better response might be related to treatment in the early phase of disease. However, early treatment with interferon beta-1b after a first clinical event suggestive of MS reduced the risk of Clinically Defined MS,  but the risk for confirmed disability progression was not significantly lower in the early treatment group (0.76, 0.52-1.11; p=0.177) (<LINK REF="REF-Kappos-2009" TYPE="REFERENCE">Kappos 2009</LINK>). A 16 year follow-up study in RR patients treated with IFN beta-1b found a decrease in the incidence of developing SP compared to those who discontinued treatment (28.6% <I>vs.</I> 44.4%) (not significant ) (<LINK REF="REF-Ebers-2009" TYPE="REFERENCE">Ebers 2009</LINK>;<LINK REF="REF-Ebers-2010" TYPE="REFERENCE">Ebers 2010</LINK>). Other observational studies showed that IFN beta treatment reduces the risk to conversion to SP:  the percentage of patients that converted after 9 years of follow-up was 7.1% for treated <I>vs.</I> 21.7% for untreated (p = 0.022; RR = 0.32; 95% CI = 0.13-0.74) in  a study performed in Argentina (<LINK REF="REF-Patrucco-2009" TYPE="REFERENCE">Patrucco 2009</LINK> ). Similar results were reported in an Italian population, after 7 years of follow-up (<LINK REF="REF-Troiano-2007" TYPE="REFERENCE">Troiano 2007</LINK>).</P>
<P>Unfortunately, in this review the analysis of MRI outcome measures were only descriptive due to the limitation of available data. Lack of comparable data did not allow analysis of IFNs effect in the prevention of neurodegenerative aspects of the disease, such as cognitive functions and atrophy.</P>
<P>A comparative evaluation of different type of IFNs on disability progression was not the aim of our review. However, a possible role of different IFNs agents cannot be excluded, since different schedules of treatment have been adopted. Previous studies on RRMS have showed contradictory results. The annual relapse rates, the time to first relapse and the time to sustained progression were virtually equal in RRMS treated with different types of IFNs (<LINK REF="REF-Koch_x002d_Henriksen-2006" TYPE="REFERENCE">Koch-Henriksen 2006</LINK>). A recent meta-analysis of head-to-head and comparative trials of INFb agents in RRMS treatment has showed that high dose treatment demonstrated superior relapse reduction and MRI stability compared to low dose treatment; a trend favouring high dose treatment on disability progression (EDSS), was also suggested (<LINK REF="REF-Oliver-2011" TYPE="REFERENCE">Oliver 2011</LINK>).</P>
<P>We think that the results of this review are not related to IFN type or treatment schedules. Two RCTs analysed the role of the same interferon beta 1b (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>;<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>) but with contradictory results, which have been already discussed (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>; <LINK REF="REF-Kappos-2004" TYPE="REFERENCE">Kappos 2004</LINK>). Furthermore, the finding of relapse rate reduction was consistent for three out of four RCTs, using different types and dosages of IFNs.</P>
<P>Safety profile reflected what is already known, the risk of developing injection site reactions, influenza like syndrome and leukopenia seemed to be similar or inferior to what is reported in the relapsing form of the disease (<LINK REF="REF-Rice-2001" TYPE="REFERENCE">Rice 2001</LINK>;<LINK REF="REF-Filippini-2003" TYPE="REFERENCE">Filippini 2003</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-11-25 12:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of evidence has been described in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>The baseline characteristics of the studied population were heterogeneous in terms of age, percentage of patients with superimposed relapses, pre-study number of relapse and duration of the disease. Furthermore the adopted criteria for disability progression for patient inclusion and treatment effect were different (see section "<LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>"). We cannot exclude the fact that some patients classified as progressive might actually have experienced a prolonged relapse (transient treatment failure), since the adopted criterion was not able to capture permanent treatment failure, that is irreversible disability (<LINK REF="REF-Ebers-2008" TYPE="REFERENCE">Ebers 2008</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-11-25 11:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Study retrieval was not language restricted. Data collection was performed expanding the search to other sources, such as FDA reports, in particular for the <LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> study. </P>
<P>The pharmaceutical companies (Serono, Biogen) kindly collaborated in providing missing data from the primary studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-11-25 11:17:21 +0100" MODIFIED_BY="[Empty name]">
<P>The results of this review are partially in agreement with those of a recent Meta-Analysis of the Efficacy and Tolerability of Interferon-Beta in Multiple Sclerosis (<LINK REF="REF-Nikfar-2010" TYPE="REFERENCE">Nikfar 2010</LINK>), because of some differences in the inclusion of studies and selected outcomes. The review included all MS subtypes (2639 with SPMS) and adopted limited number of outcome measures. The key efficacy outcomes of interest were the number of patients with at least one relapse and the mean change in Expanded Disability Status Scale (EDSS) scores. Non significant results were found for the risk of at least one relapse (0.93 , 95% CI, 0.75 to 1.14) in patients with SPMS receiving IFN-beta-1b (3 trials) (RR 1.11 (95% CI, 0.79 to 1.55)). The pooled effect sizes for the mean change in EDSS score were not significant.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-11-28 09:48:03 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-11-25 10:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>This review defines the profile of therapeutic effects of IFN in SPMS; this therapy is able to prevent relapses, while the deterioration of the disease remains unresolved. The "window of therapeutic opportunity" for IFNs within the natural history of the disease is limited to the inflammatory phase, rIFNs not being useful in the secondary phase of the disease when the progression is established.</P>
<P>These data give further support to EMEA's indication for active MS (<LINK REF="REF-EMEA-2006" TYPE="REFERENCE">EMEA 2006</LINK>) and underline the need for careful clinical evaluation of responder patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-11-28 09:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>The conclusions of this review are based on data from well designed RCTs which include a high number of participants. We think that it gives conclusive evidence of the clinical efficacy of IFN-beta versus placebo in SPMS. </P>
<P>The licensure of Mitoxantrone has allowed a better control of refractory disease in selected patients, although at the expense of potentially life-threatening side effects. Studies focusing on innovative drugs aimed to evaluated motor , cognitive and degenerative MRI parameters of the disease are needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-11-29 12:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>Phil You (Biogen Idec Wellesley, MA) (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>, Peter Cornelisse and Elisabetta Verdun di Cantogno (MerkSerono-Ginevra) (<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>) for providing data from the primary studies.</P>
<P>Dr.Vasiliy Vlassov (Moscow Medical Academy) for his help in translation and analysis of Russian papers.</P>
<P>Deirdre Beecher Trials Search Coordinator for her support on papers retrieval and Liliana Coco Managing Editor for her precious technical assistance and support in drawing up the paper.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-11-21 09:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>Dr La Mantia has participated in clinical trials sponsored by SCHERING, and meetings sponsored by SCHERING, BAYER SERONO and BIOGEN.</P>
<P>Dr Fredrikson has received honoraria for lectures and educational activities sponsored by Bayer Schering Pharma, BiogenIdec, Merck Serono, Teva, Sanofi-Aventis.</P>
<P>Prof Ebers, Dr Vacchi, Dr Filippini, Dr. Di Pietrantonj, Dr. Rovaris have no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-11-29 12:09:10 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="15">
<TR>
<TD VALIGN="TOP">
<P>Conception of the study</P>
</TD>
<TD VALIGN="TOP">
<P>Fippini G, Ebers G, Fredrikson S.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Design</P>
</TD>
<TD VALIGN="TOP">
<P>Filippini G, La Mantia L, Ebers G, Fredrikson S.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Coordinator of the working group and contact Author</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Draft the protocol</P>
</TD>
<TD VALIGN="TOP">
<P>Filippini G, La Mantia L, Ebers G, Fredrikson S.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Check each draft version</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L , Vacchi L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Check references and tables</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Enter data into RevMan (text)</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Enter data into RevMan (references)</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Preparation of data sheet for data extraction</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Selection of studies </P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L, Filippini G.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Extract data from selected studies</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L, Filippini G, Rovaris M.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Enter data into data sheet</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L , Vacchi L.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Carry out the analysis</P>
</TD>
<TD VALIGN="TOP">
<P>La Mantia L, Vacchi L, Filippini G, Di Pietrantonj C.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Interpret the analysis</P>
</TD>
<TD VALIGN="TOP">
<P>All the authors</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Draft the final review</P>
</TD>
<TD VALIGN="TOP">
<P>All the authors</P>
</TD>
</TR>
</TABLE>
<P> </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-11-18 13:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroups analysis was revised taking into account baseline characteristics of the patients.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-25 12:35:48 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-11-25 12:26:34 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-25 12:26:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-2004-_x0028_Nordic_x0029_" MODIFIED="2011-11-15 10:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Andersen 2004 (Nordic)" YEAR="2004">
<REFERENCE MODIFIED="2010-12-17 11:11:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;non so come identiifarcla come primaria e come aggiungere le ref ancillari&lt;/p&gt;" NOTES_MODIFIED="2010-12-17 11:11:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM, et al</AU>
<TI>Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>5</NO>
<PG>706-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-09 11:12:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, et al</AU>
<TI>Health-related quality of life in secondary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>386-92</PG>
<IDENTIFIERS MODIFIED="2011-06-09 11:12:26 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-09 11:15:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu X, Dastidar P, Kuusisto H, Ukkonen M, Huhtala H, Elovaara I</AU>
<TI>Increased disability and MRI lesions after discontinuation of IFN-b-1in secondary progressive MS</TI>
<SO>Acta Neurol Scand</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>242&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 10:04:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu X, Kuusisto H, Dastidar P, Huhtala H, Nikkari ST, Ukkonen M, et al</AU>
<TI>Once-weekly 22lg subcutaneous IFN-b-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels</TI>
<SO>Acta Neurol Scand</SO>
<YR>2007</YR>
<VL>116</VL>
<PG>43&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" MODIFIED="2011-06-10 11:09:10 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 2002 (IMPACT)" YEAR="2002">
<REFERENCE MODIFIED="2010-12-18 23:20:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al</AU>
<TI>Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>10</NO>
<PG>1367-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:38:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cadavid D, Tang Y, O&#8217;Neill G</AU>
<TI>Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis</TI>
<SO>Rev Neurol</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>6</NO>
<PG>321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:36:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, et al</AU>
<TI>Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial</TI>
<SO>Archives of Neurology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>6</NO>
<PG>961-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:09:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al</AU>
<TI>Benefit of interferon beta-1a on MSFC progression in secondary progressive MS</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>5</NO>
<PG>679-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-10 11:09:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Masiello SA Director Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research</AU>
<TI>CBER 01-018 Warning Letter. Avonex (Interferon beta-1a) for SPMS. Biogen Inc; March 29, 2001</TI>
<SO>FDA 2001 Food and Drug Administration Center for Biologlcs Evaluation and Research</SO>
<YR>(accessed 18 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-03 18:37:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M</AU>
<TI>Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>180-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-North-American-SG-2004" MODIFIED="2011-11-25 10:42:18 +0100" MODIFIED_BY="[Empty name]" NAME="North American SG 2004" YEAR="">
<REFERENCE MODIFIED="2011-11-25 10:42:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>FDA 2001 - Unger, EF MD</AU>
<TI>Clinical Review of the June 28, 2000 Amendment to Supplemental BLA 98-0737 - - STN103471 Chiron Corp.; Interferon &#946;-1b (Betaseron ®.Information covered in this review: June 28, 2000 &#8211; major amendment to supplement June 14, 2001 &#8211; Responses to FDA Complete Review Letter; Combined analyses of North American and European SPMS Studies</TI>
<SO>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088275.pdf</SO>
<YR>(accessed 6 June 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 15:35:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al</AU>
<TI>Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1779-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:37:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The North American Study Group on Interferon beta-1b in Secondary Progressive MS</AU>
<TI>Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>1788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPECTRIMS-2001" MODIFIED="2011-11-15 09:41:32 +0100" MODIFIED_BY="[Empty name]" NAME="SPECTRIMS 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-03-25 10:14:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li DK, Zhao GJ, Paty DW, The University of British Columbia, MS/MRI Analysis Research Group, The SPECTRIMS Study Group</AU>
<TI>Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>11</NO>
<PG>1505-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 15:50:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patten SB, Metz LM</AU>
<TI>Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>5</NO>
<PG>744-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 15:50:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandberg-Wollheim M, Hommes OR, Hughes RA, Paty DW, Abdul-Ahad AK</AU>
<TI>Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis</TI>
<SO>Multiple sclerosis (Houndmills, Basingstoke, England)</SO>
<YR>1995</YR>
<VL>1 Suppl 1</VL>
<PG>S48-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 09:41:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group*</AU>
<TI>Randomized controlled trial of interferon-beta-1a in secondary progressive MS Clinical results</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>1496&#8211;504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:38:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sormani, MP, Stubinski B., Cornelisse P, Rocak S, Li D, De Stefano N</AU>
<TI>Magnetic Resonance Active Lesions As Individual-Level Surrogate for Relapses in Multiple Sclerosis</TI>
<SO>Multiple Sclerosis  </SO>
<YR>2010 Dec 9 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-The-European-SG-1998" MODIFIED="2011-11-25 12:26:34 +0100" MODIFIED_BY="[Empty name]" NAME="The European SG 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-11-15 10:05:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Interferon beta 1b and secondary progressive multiple sclerosis</TI>
<SO>Rev Prescr</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>205</NO>
<PG>243-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-25 12:26:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Placebo-controlled multicentre randomised trial of interferon beta-1 b in treatment of secondary progressive multiple sclerosis</TI>
<SO>Mezhdunarodnyi Meditsinskii Zhurnal</SO>
<YR>2000</YR>
<VL>nr</VL>
<PG>306 -16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:37:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, et al</AU>
<TI>T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>(Pt 7)</NO>
<PG>1396-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:39:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, et al</AU>
<TI>The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>12</NO>
<PG>2185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 10:05:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brex PA, Molyneux PD, Smiddy P, Moseley IF, Thompson AJ, Miller DH, et al</AU>
<TI>The effect of interferon beta-1b on the evolution of new enhancing lesions to hypointense T1 lesions in secondary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>1999</YR>
<VL>5 Suppl 1</VL>
<PG>S9 [Abstract no: 31]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 09:48:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>FDA</AU>
<TI>Clinical Review of the June 28, 2000 Amendment to Supplemental BLA 98-0737 - - STN103471 Chiron Corp.; Interferon &#946;-1b (Betaseron ®.Information covered in this review: June 28, 2000 &#8211; major amendment to supplement June 14, 2001 &#8211; Responses to FDA Complete Review Letter; Combined analyses of North American and European SPMS Studies</TI>
<SO>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088275.pdf</SO>
<YR>December 13, 2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:54:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, et al</AU>
<TI>Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>10</NO>
<PG>1870-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-09 11:19:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodin SD</AU>
<TI>Interferon b treatment for multiple sclerosis</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>496</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:39:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin DE</AU>
<TI>Interferon b therapy for multiple sclerosis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1486&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:55:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inglese M, van Waesberghe JH, Rovaris M, Beckmann K, Barkhof F, Hahn D, et al</AU>
<TI>The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>5</NO>
<PG>853-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:40:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Panitch HS</AU>
<TI>Interferon b treatment for multiple sclerosis</TI>
<SO>The Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>494</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-24 12:26:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F</AU>
<TI>Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1969-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 09:49:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al</AU>
<TI>Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1779-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-24 11:54:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K</AU>
<TI>Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>6</NO>
<PG>850-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-24 11:53:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DH, Molyneux PD, MacManus DG, Barker GJ, Wagner K</AU>
<TI>A double-blind, placebo-controlled trial of interferon A-1b in secondary progressive multiple sclerosis: magnetic resonance imaging results</TI>
<SO>Annals of Neurology</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>3</NO>
<PG>503-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 23:57:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DH, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, et al</AU>
<TI>MRI protocol for the European trial of Beta interferon-1b in secondary progressive multiple sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>150</VL>
<PG>S251</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 10:05:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molineux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, et al</AU>
<TI>The effect of interferon beta 1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<PG>2256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 00:04:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, et al</AU>
<TI>Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>12</NO>
<PG>2191-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 00:04:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Brex PA, Fogg C, Lewis S, Middleditch C, Barkhof F, et al</AU>
<TI>The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>4</NO>
<PG>237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 00:06:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, et al</AU>
<TI>Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-03 16:02:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, et al</AU>
<TI>Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial</TI>
<SO>Multiple Sclerosis</SO>
<YR>1995</YR>
<VL>1 Suppl 1</VL>
<PG>S51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 00:07:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, et al</AU>
<TI>Interferon beta-1b treatment does not induce autoantibodies</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>6</NO>
<PG>996-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:41:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Rovaris M, Comi G, Filippi M</AU>
<TI>A reassessment of the plateauing relationship between T2 lesion load and disability in MS</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>73</VL>
<PG>1538-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-19 18:15:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The European Study Group on Interferon beta</AU>
<TI>Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9139</NO>
<PG>1491-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-09 11:19:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AJ, Kappos L, Polman CH, Pozzilli C, Dahlke E, The European Study Group on Interferon beta</AU>
<TI>Interferon beta-1b delays progression of disability in secondary progressive multiple sclerosis: final results of the European multicentre study</TI>
<SO>Multiple Sclerosis</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>4</NO>
<PG>392</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-08 10:42:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann C, Walther EU, Goebels N, Lienert C, Kappos L, Hartung HP, et al</AU>
<TI>Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis</TI>
<SO>Nervenarzt</SO>
<YR>1999</YR>
<VL>70</VL>
<NO>8</NO>
<PG>759-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-15 10:07:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arnason-1999" MODIFIED="2011-06-08 10:42:43 +0200" MODIFIED_BY="[Empty name]" NAME="Arnason 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-06-08 10:42:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnason, BGW, Jacobs G, Hanlon M, Harding B, Noronha A.B.C, Auty A ,et al</AU>
<TI>TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bar_x002d_Or-2007" MODIFIED="2011-06-08 10:43:10 +0200" MODIFIED_BY="[Empty name]" NAME="Bar-Or 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-08 10:43:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, et al</AU>
<TI>Induction of Antigen-Specific Tolerance in Multiple Sclerosis after Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial</TI>
<SO>Archives of Neurology</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>10</NO>
<PG>1407-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baum-2006" MODIFIED="2011-01-13 18:15:07 +0100" MODIFIED_BY="[Empty name]" NAME="Baum 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-13 18:15:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baum K, Mannitol Formulation Study Group</AU>
<TI>Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis</TI>
<SO>The Journal of international medical research</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boiko2001" MODIFIED="2011-11-15 09:50:57 +0100" MODIFIED_BY="[Empty name]" NAME="Boiko2001" YEAR="2001">
<REFERENCE MODIFIED="2011-06-08 10:43:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boiko A, Skurkovich S, Buglak A, Alekseeva,T, Smirnova N, Skurkovich B, et al</AU>
<TI>Randomized, placebo-controlled trial comparing short course of anti-ifn? And anti-tnfa showed only anti-ifn? Effective in secondary progressive ms </TI>
<SO>Journal of Neurosurgery </SO>
<YR>2001</YR>
<VL>187 </VL>
<NO>suppl 1</NO>
<PG>S456 </PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buhse-2006" MODIFIED="2011-01-13 18:23:16 +0100" MODIFIED_BY="[Empty name]" NAME="Buhse 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-13 18:23:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00567490&lt;br&gt;PUBMED 16924997&lt;br&gt;Controlled Clinical Trial&lt;br&gt;Journal Article&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/490/CN-00567490/frame.html&lt;/p&gt;" NOTES_MODIFIED="2011-01-13 18:23:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhse M</AU>
<TI>Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis</TI>
<SO>The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>4</NO>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christodoulou-2006" MODIFIED="2011-01-16 11:15:50 +0100" MODIFIED_BY="[Empty name]" NAME="Christodoulou 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-16 11:15:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00564385&lt;br&gt;PUBMED 16626752&lt;br&gt;Clinical Trial&lt;br&gt;Comparative Study&lt;br&gt;Journal Article&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, N.I.H., Extramural&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/385/CN-00564385/frame.html&lt;/p&gt;" NOTES_MODIFIED="2011-01-16 11:15:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE, Krupp LB</AU>
<TI>Effects of donepezil on memory and cognition in multiple sclerosis</TI>
<SO>Journal of the neurological sciences.</SO>
<YR>2006</YR>
<VL>245</VL>
<NO>1-2</NO>
<PG>127-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2002" MODIFIED="2011-06-08 10:44:25 +0200" MODIFIED_BY="[Empty name]" NAME="Fernandez 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-08 10:44:25 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20020826&lt;br&gt;IS - 0340-5354 (Print)&lt;br&gt;IS - 0340-5354 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;RN - 0 (Adjuvants, Immunologic)&lt;br&gt;RN - 0 (Immunosuppressive Agents)&lt;br&gt;RN - 145155-23-3 (interferon beta-1b)&lt;br&gt;RN - 145258-61-3 (interferon beta 1a)&lt;br&gt;RN - 446-86-6 (Azathioprine)&lt;br&gt;RN - 77238-31-4 (Interferon-beta)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-06-08 10:44:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez O, Guerrero M, Mayorga C, Munoz L, Lean A, Luque G, et al</AU>
<TI>Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study</TI>
<SO>Journal of Neurology</SO>
<YR>2002</YR>
<VL>249</VL>
<NO>8</NO>
<PG>1058-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodkin-1997" MODIFIED="2011-01-13 23:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Goodkin 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-01-13 23:24:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin DE, Kinkel RP, Weinstock-Guttman B, Medendorp VanderBurg, Gogol DM, Perryman JE, et al</AU>
<TI>A randomized, double-masked, dose-comparison, phase II study of bimonthly intravenous methyprednisolone (IVMP) to modify progression of disability in patients with secondary progressive multiple sclerosis (SPMS)</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48 Suppl 2</VL>
<NO>3</NO>
<PG>A339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodkin-2000a" MODIFIED="2011-06-08 10:44:59 +0200" MODIFIED_BY="[Empty name]" NAME="Goodkin 2000a" YEAR="">
<REFERENCE MODIFIED="2011-06-08 10:44:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, et al</AU>
<TI>A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54 </VL>
<NO>7</NO>
<PG>1414</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoogervorst-2002" MODIFIED="2011-06-08 10:45:11 +0200" MODIFIED_BY="[Empty name]" NAME="Hoogervorst 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-08 10:45:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;DA - 20021001&lt;br&gt;IS - 1352-4585&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;CY - England&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-06-08 10:45:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoogervorst EL, Polman CH, Barkhof F</AU>
<TI>Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone</TI>
<SO>Multiple Sclerosis</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>5</NO>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leary-2003" MODIFIED="2011-01-13 18:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Leary 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-01-13 18:30:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00412728&lt;br&gt;PUBMED 12525716&lt;br&gt;Clinical Trial&lt;br&gt;Journal Article&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/728/CN-00412728/frame.html&lt;/p&gt;" NOTES_MODIFIED="2011-01-13 18:30:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ</AU>
<TI>Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montalban-2009" MODIFIED="2011-06-08 10:45:26 +0200" MODIFIED_BY="[Empty name]" NAME="Montalban 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-08 10:45:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, et al</AU>
<TI>progressive and transitional multiple sclerosisA single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary</TI>
<SO>Multiple Sclerosis</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>10</NO>
<PG>1195&#8211;205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patti-1999" MODIFIED="2011-01-05 11:50:50 +0100" MODIFIED_BY="[Empty name]" NAME="Patti 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-01-05 11:50:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patti F, L'Episcopo MR, Cataldi ML, Reggio A</AU>
<TI>Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>5</NO>
<PG>283-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rio-2007" MODIFIED="2011-11-15 10:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="Rio 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-15 10:07:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Río J, Tintoré M, Nos C, Téllez N, Galán I, Pelayo R, et al</AU>
<TI>Interferon beta in secondary progressive multiple sclerosis. Daily clinical practice</TI>
<SO>Journal of Neurology</SO>
<YR>2007</YR>
<VL>254</VL>
<PG>849&#8211;53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skurkovich-2001" MODIFIED="2011-01-13 18:36:35 +0100" MODIFIED_BY="[Empty name]" NAME="Skurkovich 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-13 18:36:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, et al</AU>
<TI>Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>5</NO>
<PG>277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2005" MODIFIED="2011-06-08 10:46:24 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-08 10:46:24 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20050930&lt;br&gt;IS - 1352-4585&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;br&gt;2012&lt;/p&gt;" NOTES_MODIFIED="2011-06-08 10:46:24 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, et al</AU>
<TI>A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta</TI>
<SO>Multiple Sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>5</NO>
<PG>573-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tubridy-1999" MODIFIED="2011-01-13 23:28:32 +0100" MODIFIED_BY="[Empty name]" NAME="Tubridy 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-01-13 23:28:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al</AU>
<TI>The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>466-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavalishin-2003" MODIFIED="2011-06-08 10:46:44 +0200" MODIFIED_BY="[Empty name]" NAME="Zavalishin 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-06-08 10:46:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cochrane ID: CN-00457526&lt;br&gt;Rezul'taty multitsentrovogo issledovaniia &amp;#8218;ffektivnosti preparata Rebif-22 mkg v Rossii&lt;br&gt;PUBMED 12938639&lt;br&gt;Clinical Trial&lt;br&gt;English Abstract&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/526/CN-00457526/frame.html&lt;/p&gt;" NOTES_MODIFIED="2011-06-08 10:46:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavalishin IA, Gusev EI, Iakhno NN, Skoromets AA, Ko AN, Demina TL, et al</AU>
<TI>Results of a multicenter study of Rebif-22 mcg administration in Russia</TI>
<SO>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov (ZH NEVROL PSIKHIATR)</SO>
<YR>2003</YR>
<VL>Spec No 2</VL>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-25 12:35:48 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-25 12:35:48 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-2006" MODIFIED="2009-11-25 15:20:30 +0100" MODIFIED_BY="[Empty name]" NAME="Amato 2006" TYPE="JOURNAL_ARTICLE">
<AU>Amato MP, Valentina Zipolia, Portaccio E</AU>
<TI>Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2006</YR>
<VL>245</VL>
<NO>1-2</NO>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calabrese-2009" MODIFIED="2010-04-14 17:11:07 +0200" MODIFIED_BY="[Empty name]" NAME="Calabrese 2009" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al</AU>
<TI>Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1144-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Compston-2002" NAME="Compston 2002" TYPE="JOURNAL_ARTICLE">
<AU>Compston A, Coles A</AU>
<TI>Multiple Sclerosis</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9313</NO>
<PG>1221-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11955556"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Confavreux-2000" NAME="Confavreux 2000" TYPE="JOURNAL_ARTICLE">
<AU>Confavreux C, Vukusic S, Moreau T, Adeleine P</AU>
<TI>Relapses and progression of disability in multiple sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>20</NO>
<PG>1430-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Confavreux-2003" MODIFIED="2011-06-08 09:43:43 +0200" MODIFIED_BY="[Empty name]" NAME="Confavreux 2003" TYPE="JOURNAL_ARTICLE">
<AU>Confavreux C, Vukusic S, Adeleine P</AU>
<TI>Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process</TI>
<SO>Brain</SO>
<YR>2003</YR>
<VL>126</VL>
<PG>770-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Confavreux-2006" MODIFIED="2011-11-25 12:35:48 +0100" MODIFIED_BY="[Empty name]" NAME="Confavreux 2006" TYPE="JOURNAL_ARTICLE">
<AU>Confavreux C, Vukusic S</AU>
<TI>Natural history of multiple sclerosis: a unifying concept</TI>
<SO>Brain</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>3</NO>
<PG>606-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cottrell-1999" MODIFIED="2011-06-08 09:59:41 +0200" MODIFIED_BY="[Empty name]" NAME="Cottrell 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cottrell DA, Rice GPA, Hader W, BaskervilleJ, Koopman WJ, Ebers GC</AU>
<TI>The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis</TI>
<SO>Brain</SO>
<YR>1999</YR>
<VL>122</VL>
<PG>625-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Der-Simonian-1986" MODIFIED="2011-06-08 09:49:54 +0200" MODIFIED_BY="[Empty name]" NAME="Der Simonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>Der Simonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duque-2008" MODIFIED="2009-11-25 16:55:37 +0100" MODIFIED_BY="[Empty name]" NAME="Duque 2008" TYPE="JOURNAL_ARTICLE">
<AU>Duque B, Sepulcre J, Bejarano B, Samaranch L, Pastor P, Villoslada P</AU>
<TI>Memory decline evolves independently of disease activity in MS</TI>
<SO>Multiple Sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>7</NO>
<PG>947-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebers-2000" MODIFIED="2011-06-08 10:01:01 +0200" MODIFIED_BY="[Empty name]" NAME="Ebers 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, et al</AU>
<TI>The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<NO>Pt 3</NO>
<PG>641-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebers-2008" MODIFIED="2009-11-30 16:06:55 +0100" MODIFIED_BY="[Empty name]" NAME="Ebers 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH</AU>
<TI>Disability as an outcome in MS clinical trials</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>71</VL>
<NO>9</NO>
<PG>624-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebers-2009" MODIFIED="2011-06-08 10:01:27 +0200" MODIFIED_BY="[Empty name]" NAME="Ebers 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, et al</AU>
<TI>Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: Design and lessons from a 16-year observational study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>8</NO>
<PG>1724-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebers-2010" MODIFIED="2011-11-15 10:07:49 +0100" MODIFIED_BY="[Empty name]" NAME="Ebers 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, et al</AU>
<TI>Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial</TI>
<SO>Journal of Neurology Neurosurgery &amp; Psychiatry</SO>
<YR>2010</YR>
<VL>81</VL>
<PG>907-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2000" MODIFIED="2011-11-25 10:25:50 +0100" MODIFIED_BY="[Empty name]" NAME="EMEA 2000" TYPE="CORRESPONDENCE">
<AU>The European Agency for the Evaluation of Medical Products</AU>
<SO>PRESS RELEASE. CPMP/4305/00</SO>
<YR>18 December 2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2006" MODIFIED="2011-11-25 10:26:30 +0100" MODIFIED_BY="[Empty name]" NAME="EMEA 2006" TYPE="CORRESPONDENCE">
<AU>European Medicines Agency</AU>
<TI>Press Release</TI>
<SO>Doc. Ref. EMEA/152608/2006</SO>
<YR>28 April 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2008" MODIFIED="2011-11-25 10:27:53 +0100" MODIFIED_BY="[Empty name]" NAME="EMEA 2008" TYPE="OTHER">
<TI>Committee for medicinal products for human use summary of positive opinion for Extavia. International Nonproprietary Name (INN): interferon beta-1b. Novartis Europharm Ltd.; London, 20 March 2008. Doc. Ref. EMEA/CHMP/138637/2008</TI>
<SO>http://data.ellispub.com/pdf/EN/2008/EMEA/Extavia_13863908en.pdf (17/02/2011)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esposito-2010" MODIFIED="2011-06-08 09:49:09 +0200" MODIFIED_BY="[Empty name]" NAME="Esposito 2010" TYPE="JOURNAL_ARTICLE">
<AU>Esposito F, Radaelli M, Martinelli V, Sormani MP, Martinelli Boneschi F, Moiola L, et al</AU>
<TI>Comparative study of mitoxantrone efficacy profile in patients with relapsing&#8211;remitting and secondary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1490-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2000" MODIFIED="2011-06-10 11:10:29 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2000" TYPE="OTHER">
<AU>Center for Drug Evaluation and Research</AU>
<TI>Approval letter for Novantrone (mitoxantrone hydrochloride) injection for Multiple Sclerosis: Immunex Corporation. FDA U.S. Food &amp; Drug Administration; 1 March 2000. Application Number NDA 21-120</TI>
<SO>http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120.pdf_Novantrone_Approv.pdf</SO>
<YR>(accessed 31 May 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2001" MODIFIED="2011-06-10 11:10:41 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2001" TYPE="OTHER">
<AU>Unger, EF</AU>
<TI>Interferon 1b (Betaseron) treatment of secondary progressive forms of Multiple Sclerosis. Clinical Review of the June 28, 2000 Amendment to Supplemental BLA 98-0737 -- STN103471: Chiron Corp. FDA U.S. Food &amp; Drug Administraion; 13 December 2001</TI>
<SO>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088275.pdf</SO>
<YR>(accessed 6 June 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009" MODIFIED="2011-11-15 09:52:43 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2009" TYPE="OTHER">
<AU>Center for Drug Evaluation and Research</AU>
<TI>Approval letter for Interferon Beta 1b, label product with the proprietary name Extavia: Novartis Pharmaceuticals Corporation. FDA U.S. Food &amp; Drug Administration; 14 August 2009. Application Number 125290</TI>
<SO>http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/0125290s000approv.pdf</SO>
<YR>(accessed 26 May 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filippini-2003" MODIFIED="2008-07-10 15:53:23 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Filippini 2003" TYPE="JOURNAL_ARTICLE">
<AU>Filippini, Munari L, Ebers GC, D'Amico R, Rice GPA</AU>
<TI>Interferons in relapsing remitting multiple sclerosis</TI>
<SO>The Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9371</NO>
<PG>545-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frisher-2009" MODIFIED="2009-11-30 16:30:51 +0100" MODIFIED_BY="[Empty name]" NAME="Frisher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Frisher JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al</AU>
<TI>The relation between inflammation and neurodegeneration in multiple sclerosis brains</TI>
<SO>Brain</SO>
<YR>2009</YR>
<VL>132</VL>
<PG>1175-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glass-2010" MODIFIED="2011-03-25 12:12:40 +0100" MODIFIED_BY="[Empty name]" NAME="Glass 2010" TYPE="JOURNAL_ARTICLE">
<AU>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH</AU>
<TI>Mechanisms underlying inflammation in neurodegeneration</TI>
<SO>Cell</SO>
<YR>2010</YR>
<VL>140</VL>
<NO>6</NO>
<PG>918-34</PG>
<IDENTIFIERS MODIFIED="2010-04-14 12:35:32 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2011-06-08 10:04:27 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kappos-2001" MODIFIED="2011-11-25 10:24:36 +0100" MODIFIED_BY="[Empty name]" NAME="Kappos 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F</AU>
<TI>Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1969-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kappos-2004" MODIFIED="2011-06-08 12:32:17 +0200" MODIFIED_BY="[Empty name]" NAME="Kappos 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al</AU>
<TI>Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1779-87</PG>
<IDENTIFIERS MODIFIED="2011-06-08 12:32:13 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15557490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kappos-2009" MODIFIED="2011-11-15 09:53:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kappos 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al</AU>
<TI>Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial</TI>
<SO>Lancet Neurology</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>11</NO>
<PG>987-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koch-2010" MODIFIED="2011-11-15 09:54:45 +0100" MODIFIED_BY="[Empty name]" NAME="Koch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Koch M, Kingwell E,Rieckmann P, Tremlett H, UBC MS Clinic Neurologists</AU>
<TI>The natural history of secondary progressive multiple sclerosis </TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>2010</YR>
<VL>81</VL>
<PG>1039-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koch_x002d_Henriksen-2006" MODIFIED="2011-06-08 09:42:54 +0200" MODIFIED_BY="[Empty name]" NAME="Koch-Henriksen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al</AU>
<TI>A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>7</NO>
<PG>1056-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremenchutzky-2006" MODIFIED="2009-11-25 16:57:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kremenchutzky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kremenchutzky M, Rice GPA, Baskerville DM, Wingerchuk DM, Ebers GC</AU>
<TI>The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease</TI>
<SO>Brain</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>3</NO>
<PG>584-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="84040263"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lassmann-2009" MODIFIED="2009-11-25 17:11:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lassmann 2009" TYPE="OTHER">
<AU>Lassmann H</AU>
<TI>Axonal and neuronal pathology in multiple sclerosis:what have we learnt from animal models</TI>
<SO>Experimental Neurology</SO>
<YR>2009 Oct 17 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2009-11-25 17:09:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-25 17:09:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" doi:10.1016/j.expneurol.2009.10.009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2001" MODIFIED="2011-02-24 12:00:06 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2001" TYPE="JOURNAL_ARTICLE">
<AU>Li DK, Zhao GJ, Paty DW, The University of British Columbia, MS/MRI Analysis Research Group, The SPECTRIMS Study Group</AU>
<TI>Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>11</NO>
<PG>1505-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lublin-1996" NAME="Lublin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lublin FD, Reingold SC</AU>
<TI>Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>4</NO>
<PG>907-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lublin-2003" MODIFIED="2011-06-08 09:51:14 +0200" MODIFIED_BY="[Empty name]" NAME="Lublin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lublin FD, Baier M, Cutter G</AU>
<TI>Effect of relapses on development of residual deficit in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1528-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2001" NAME="McDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al</AU>
<TI>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>1</NO>
<PG>121-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11456302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-1999" MODIFIED="2011-02-24 11:54:48 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1999" TYPE="JOURNAL_ARTICLE">
<AU>Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K</AU>
<TI>Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>6</NO>
<PG>850-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2006" MODIFIED="2011-03-25 12:14:24 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2006" TYPE="JOURNAL_ARTICLE">
<AU>Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M</AU>
<TI>Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>180-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molyneux-2000b" MODIFIED="2011-11-15 10:16:30 +0100" MODIFIED_BY="[Empty name]" NAME="Molyneux 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Kappos L, Polamn C, Pozzilli C, Barkhof F, Filippi M, et al</AU>
<TI>The effect of interferon beta 1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<PG>2256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nikfar-2010" MODIFIED="2011-06-08 10:06:03 +0200" MODIFIED_BY="[Empty name]" NAME="Nikfar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nikfar S, Rahimi R, Abdollahi M</AU>
<TI>A Meta-Analysis of the Efficacy and Tolerability of Interferon-Beta in Multiple Sclerosis, Overall and by Drug and Disease Type</TI>
<SO>Clinical Therapy</SO>
<YR>2010</YR>
<VL>32</VL>
<PG>1871-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noseworthy-2000" NAME="Noseworthy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG</AU>
<TI>Multiple Sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>13</NO>
<PG>938-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2011" MODIFIED="2011-06-08 10:06:21 +0200" MODIFIED_BY="[Empty name]" NAME="Oliver 2011" TYPE="JOURNAL_ARTICLE">
<AU>Oliver BJ, Kohli E, Kasper LH</AU>
<TI>Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of the comparative trials</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2011</YR>
<VL>302</VL>
<NO>1-2</NO>
<PG>96-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrucco-2009" MODIFIED="2011-11-15 09:55:52 +0100" MODIFIED_BY="[Empty name]" NAME="Patrucco 2009" TYPE="JOURNAL_ARTICLE">
<AU>Patrucco L, Rojas JI, Cristiano E</AU>
<TI>Long Term Effect of Interferon-Beta on Disease Severity in Relapsing-Remitting Multiple Sclerosis Patients</TI>
<SO>Rev Neurol </SO>
<YR>2010</YR>
<VL>50</VL>
<PG>529-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paty-1998" MODIFIED="2011-06-09 11:22:17 +0200" MODIFIED_BY="[Empty name]" NAME="Paty 1998" TYPE="BOOK">
<AU>Paty DW, Ebers GC</AU>
<SO>Multiple Sclerosis</SO>
<YR>1998</YR>
<PB>FA Davis Co</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polman-1995" MODIFIED="2011-06-08 09:50:04 +0200" MODIFIED_BY="[Empty name]" NAME="Polman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, et al</AU>
<TI>Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial</TI>
<SO>Multiple Sclerosis</SO>
<YR>1995</YR>
<VL>1 Suppl 1</VL>
<PG>S51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polman-2005" MODIFIED="2009-11-25 17:15:13 +0100" MODIFIED_BY="[Empty name]" NAME="Polman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al</AU>
<TI>Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"</TI>
<SO>Annals of neurology</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>6</NO>
<PG>840-6</PG>
<IDENTIFIERS MODIFIED="2009-11-25 17:15:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16283615"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al</AU>
<TI>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83202737"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rice-2001" MODIFIED="2011-06-08 10:15:27 +0200" MODIFIED_BY="[Empty name]" NAME="Rice 2001" TYPE="COCHRANE_REVIEW">
<AU>Rice GPA, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al</AU>
<TI>Interferon in relapsing-remitting multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-06-08 10:15:27 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-08 10:15:27 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seewann-2009" MODIFIED="2010-04-14 17:10:21 +0200" MODIFIED_BY="[Empty name]" NAME="Seewann 2009" TYPE="JOURNAL_ARTICLE">
<AU>Seewann A , Vrenken H ,van der Valk P, Blezer EL, Castelijns JA, Polman CH, et al</AU>
<TI>Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis</TI>
<SO>Archives of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>5</NO>
<PG>601-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tekok_x002d_Kilic-2007" MODIFIED="2011-06-10 11:29:04 +0200" MODIFIED_BY="[Empty name]" NAME="Tekok-Kilic 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, Dwyer MG, Carone D, Srinivasaraghavan B, et al</AU>
<TI>Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis</TI>
<SO>Neuroimage</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>4</NO>
<PG>1294-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17524670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tremlett-2006" MODIFIED="2011-11-15 09:56:26 +0100" MODIFIED_BY="[Empty name]" NAME="Tremlett 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tremlett H, Paty D and Devonshire V</AU>
<TI>Disability progression in multiple sclerosis is slower than previously reported</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<PG>172-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tremlett-2009" MODIFIED="2009-11-25 16:54:27 +0100" MODIFIED_BY="[Empty name]" NAME="Tremlett 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y on behalf of the UBC Neurologists</AU>
<TI>Impact of multiple sclerosis relapses on progression diminishes with time</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>20</NO>
<PG>1616-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Troiano-2007" MODIFIED="2011-11-15 09:56:54 +0100" MODIFIED_BY="[Empty name]" NAME="Troiano 2007" TYPE="JOURNAL_ARTICLE">
<AU>Trojano M , Pellegrini F, Fuiani A,Paolicelli D, Zipoli V, Zimatore GB, et al</AU>
<TI>New Natural History of Interferon-beta &#8211;Treated Relapsing Multiple Sclerosis</TI>
<SO>Ann Neurol</SO>
<YR>2007</YR>
<VL>61</VL>
<PG>300&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukkonen-2009" MODIFIED="2010-04-14 17:09:47 +0200" MODIFIED_BY="[Empty name]" NAME="Ukkonen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ukkonen M, Vahvelainen T, Hämäläinen P, Dastidar P, Elovaara I</AU>
<TI>Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>1055-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinshenker-1989" MODIFIED="2008-07-10 15:55:30 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Weinshenker 1989" TYPE="JOURNAL_ARTICLE">
<AU>Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al</AU>
<TI>The natural history of multiple sclerosis:a geographically based study. 2. Predictive value of the early clinical course</TI>
<SO>Brain</SO>
<YR>1989</YR>
<VL>112</VL>
<NO>Pt 6</NO>
<PG>1419-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinshenker-1989a" MODIFIED="2011-11-25 10:31:37 +0100" MODIFIED_BY="[Empty name]" NAME="Weinshenker 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Weinshenker BG, Bass B , Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al</AU>
<TI>The natural history of multiple sclerosis: a geographically based study I Clinical course and disability</TI>
<SO>Brian</SO>
<YR>1989</YR>
<VL>112</VL>
<PG>133-46</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-12-18 23:11:55 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2011-01-16 11:17:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anon-2000" MODIFIED="2010-10-28 09:52:09 +0200" MODIFIED_BY="[Empty name]" NAME="Anon 2000" NOTES="&lt;p&gt;Need to check citation for this DB 28/10/10&lt;/p&gt;" NOTES_MODIFIED="2010-10-28 09:52:09 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>[Kontrolirovannoe po platsebo randomizirovannoe issledovanie po primeneniiu interferona betta-1 b v lechenii vtoroi progressiruiushchei fazy rasseiannogo skleroza; placebo-controlled multicentre randimised trial of interferon beta-1 b in treatment of secondary progressive multiple sclerosis]</TI>
<SO>Mezhdunarodnyi Meditsinskii Zhurnal</SO>
<YR>2000</YR>
<PG>306-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anon-2001" MODIFIED="2010-10-28 09:52:32 +0200" MODIFIED_BY="[Empty name]" NAME="Anon 2001" NOTES="&lt;p&gt;&lt;br&gt;Need to check citation for this DB 28/10/10&lt;/p&gt;" NOTES_MODIFIED="2010-10-28 09:52:32 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Anon 2001</AU>
<TI>Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>11</NO>
<PG>1496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anon-2003" MODIFIED="2010-10-28 09:54:30 +0200" MODIFIED_BY="[Empty name]" NAME="Anon 2003" NOTES="&lt;p&gt;Need to check citation DB 28/10/10&lt;/p&gt;" NOTES_MODIFIED="2010-10-28 09:54:30 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>BETASERON approved for secondary-progressive MS with relapses</TI>
<SO>Multiple Sclerosis Quarterly Report</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>3</NO>
<PG>19-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anon-2007" MODIFIED="2010-10-28 09:55:30 +0200" MODIFIED_BY="[Empty name]" NAME="Anon 2007" NOTES="&lt;p&gt;need to check citation DB 28/10/10&lt;/p&gt;" NOTES_MODIFIED="2010-10-28 09:55:30 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Anon 2007</AU>
<TI>Multiple sclerosis: Interferon beta for some serious forms</TI>
<SO>Prescrire International</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>92</NO>
<PG>250-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2000" MODIFIED="2010-10-28 09:16:32 +0200" MODIFIED_BY="[Empty name]" NAME="Anonymous 2000" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Interferon beta-1b and secondary progressive multiple sclerosis. Useful, but further assessment required</TI>
<SO>Prescrire International</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>110-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Applebee-2009" MODIFIED="2010-10-28 09:16:36 +0200" MODIFIED_BY="[Empty name]" NAME="Applebee 2009" TYPE="JOURNAL_ARTICLE">
<AU>Applebee A, Panitch H</AU>
<TI>Early stage and long term treatment of multiple sclerosis with interferon-beta</TI>
<SO>Biologics</SO>
<YR>2009</YR>
<VL>3</VL>
<PG>257-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baum-2006a" MODIFIED="2011-01-12 16:18:40 +0100" MODIFIED_BY="[Empty name]" NAME="Baum 2006a" NOTES="&lt;p&gt;Cochrane ID: CN-00564062&lt;br&gt;PUBMED 16604818&lt;br&gt;Clinical Trial, Phase IV&lt;br&gt;Comparative Study&lt;br&gt;Journal Article&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/062/CN-00564062/frame.html&lt;/p&gt;" NOTES_MODIFIED="2011-01-12 16:18:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Baum K, Mannitol Formulation Study Group</AU>
<TI>Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis</TI>
<SO>The Journal of international medical research.</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bayas-2003" MODIFIED="2010-10-28 09:17:57 +0200" MODIFIED_BY="[Empty name]" NAME="Bayas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bayas A, Gold R</AU>
<TI>Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment</TI>
<SO>Journal of Neurology</SO>
<YR>2003</YR>
<VL>250 Suppl 4</VL>
<PG>IV3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-2007" MODIFIED="2010-10-28 09:18:13 +0200" MODIFIED_BY="[Empty name]" NAME="Bell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K</AU>
<TI>Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2007</YR>
<VL>13(3)</VL>
<PG>245-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beutler-2000" MODIFIED="2010-10-28 09:18:18 +0200" MODIFIED_BY="[Empty name]" NAME="Beutler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Beutler E, Koziol JA</AU>
<TI>The cladribine trial in secondary progressive multiple sclerosis: A reanalysis</TI>
<SO>Neuroepidemiology</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boiko-2001" MODIFIED="2010-10-28 09:18:27 +0200" MODIFIED_BY="[Empty name]" NAME="Boiko 2001" TYPE="JOURNAL_ARTICLE">
<AU>Boiko A, Skurkovich S, Buglak A, Alekseeva T, Smirnova N, Skurkovich B, et al</AU>
<TI>Randomized, placebo-controlled trial comparing short course of anti-ifn? And anti-tnfa showed only anti-ifn? Effective in secondary progressive ms</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2001</YR>
<VL>187</VL>
<NO>Suppl 1</NO>
<PG>S456</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cendrowski-2004" MODIFIED="2010-10-28 09:19:22 +0200" MODIFIED_BY="[Empty name]" NAME="Cendrowski 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cendrowski W</AU>
<TI>Selected issues of immunomodulating treatment in multiple sclerosis</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>4</NO>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cendrowski-2005" MODIFIED="2010-10-28 09:19:26 +0200" MODIFIED_BY="[Empty name]" NAME="Cendrowski 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cendrowski W</AU>
<TI>Secondary progressive multiple sclerosis: the outcomes of interferon beta treatment</TI>
<SO>Neurologica</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clegg-2000" MODIFIED="2010-10-28 09:19:29 +0200" MODIFIED_BY="[Empty name]" NAME="Clegg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Clegg A, Bryant J, Milne R</AU>
<TI>Disease-modifying drugs for multiple sclerosis: a rapid and systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>2000</YR>
<VL>4(9)</VL>
<PG>1-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2004" MODIFIED="2010-10-28 09:19:45 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Antel JP</AU>
<TI>Does interferon beta help in secondary progressive MS?</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1768-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coles-2006" MODIFIED="2010-10-28 09:19:56 +0200" MODIFIED_BY="[Empty name]" NAME="Coles 2006" TYPE="JOURNAL_ARTICLE">
<AU>Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al</AU>
<TI>The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy</TI>
<SO>Journal of Neurology</SO>
<YR>2006</YR>
<VL>253</VL>
<NO>1</NO>
<PG>98-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danish-1999" MODIFIED="2010-10-28 09:20:01 +0200" MODIFIED_BY="[Empty name]" NAME="Danish 1999" TYPE="JOURNAL_ARTICLE">
<AU>Danish Centre for Evaluation and Health Technology Assessment</AU>
<TI>Interferon beta treatment for multiple sclerosis (funded by DIHTA)</TI>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Haan-1999" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="de Haan 1999" TYPE="JOURNAL_ARTICLE">
<AU>de Haan RJ, Vermeulen M</AU>
<TI>[Interferon beta-1b now also for the secondary progressive form of multiple sclerosis? [Dutch]</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1999</YR>
<VL>143</VL>
<NO>14</NO>
<PG>709-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deomina-1997" MODIFIED="2010-10-28 09:20:05 +0200" MODIFIED_BY="[Empty name]" NAME="Deomina 1997" TYPE="JOURNAL_ARTICLE">
<AU>Deomina T, Buglak AB, Beliaeva IA, Alekseeva TG, Pashenkov MV, Smirnova NF, et al</AU>
<TI>A three month pilot clinical trial of antibodies to cytokines (interferon-Ó, interferon-y, TNF-Ó) in multiple sclerosis</TI>
<SO>European Journal of Neurology</SO>
<YR>1997</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>S62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Exton-2002" MODIFIED="2010-10-28 09:20:15 +0200" MODIFIED_BY="[Empty name]" NAME="Exton 2002" TYPE="JOURNAL_ARTICLE">
<AU>Exton MS, Baase J, Pithan V, Goebel MU, Limmroth V, Schedlowski M</AU>
<TI>Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males</TI>
<SO>Neuropsychobiology</SO>
<YR>2002</YR>
<VL>45</VL>
<PG>199-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fan-2009" MODIFIED="2010-10-28 09:40:30 +0200" MODIFIED_BY="[Empty name]" NAME="Fan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fan X, Yang L</AU>
<TI>[A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis]</TI>
<SO>Zhonghua Yi.Xue.Za Zhi</SO>
<YR>2009</YR>
<VL>89</VL>
<NO>21</NO>
<PG>1484-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fergusson-2005" MODIFIED="2010-10-28 09:40:37 +0200" MODIFIED_BY="[Empty name]" NAME="Fergusson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron DW, et al</AU>
<TI>Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review</TI>
<SO>Transfusion</SO>
<YR>2005</YR>
<VL>45(10)</VL>
<PG>1640-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galetta-2002" MODIFIED="2010-10-28 09:52:43 +0200" MODIFIED_BY="[Empty name]" NAME="Galetta 2002" TYPE="JOURNAL_ARTICLE">
<AU>Galetta SL, Markowitz C, Lee AG</AU>
<TI>Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162(19)</VL>
<PG>2161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gold-1996" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Gold 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gold R, Hartung HP, Toyka KV</AU>
<TI>Immunomodulating therapy of multiple sclerosis. Application of beta interferon and copolymer-1 in relapsing-remitting multiple sclerosis</TI>
<SO>Therapiewoche</SO>
<YR>1996</YR>
<VL>46</VL>
<PG>532-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodin-2008" MODIFIED="2010-10-28 09:52:47 +0200" MODIFIED_BY="[Empty name]" NAME="Goodin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC</AU>
<TI>Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>71</VL>
<NO>10</NO>
<PG>766-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodkin-1997a" MODIFIED="2011-01-12 16:18:40 +0100" MODIFIED_BY="[Empty name]" NAME="Goodkin 1997a" NOTES="&lt;p&gt;to be scanned 12/01/2011 DB&lt;/p&gt;" NOTES_MODIFIED="2011-01-12 16:18:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin DE, Kinkel RP, Weinstock-Guttman B, Medendorp VanderBurg, Gogol DM, Perryman JE, et al</AU>
<TI>A randomized, double-masked, dose-comparison, phase II study of bimonthly intravenous methyprednisolone (IVMP) to modify progression of disability in patients with secondary progressive multiple sclerosis (SPMS)</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48 Suppl 2</VL>
<NO>3</NO>
<PG>A339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodkin-2000" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Goodkin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin DE</AU>
<TI>Interferon Beta-1b in secondary progressive MS: Clinical and MRI results of a 3-Year randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<PG>2352</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guo-2009" MODIFIED="2010-10-28 09:52:54 +0200" MODIFIED_BY="[Empty name]" NAME="Guo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, et al</AU>
<TI>Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications</TI>
<SO>Pharmacoeconomics</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>1</NO>
<PG>39-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartung-2009" MODIFIED="2010-10-28 09:53:07 +0200" MODIFIED_BY="[Empty name]" NAME="Hartung 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hartung HP</AU>
<TI>High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>2</NO>
<PG>291-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2003" MODIFIED="2010-10-28 09:53:13 +0200" MODIFIED_BY="[Empty name]" NAME="Hughes 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RA</AU>
<TI>Interferon beta 1a for secondary progressive multiple sclerosis</TI>
<SO>Journal of the neurological sciences.</SO>
<YR>2003</YR>
<VL>206</VL>
<NO>2</NO>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSI-2001" MODIFIED="2010-10-28 09:46:22 +0200" MODIFIED_BY="[Empty name]" NAME="ICSI 2001" TYPE="OTHER">
<AU>Institute for Clinical Systems Improvement</AU>
<TI>Interferon beta-1a, interferon beta-1b, glatiramer acetate, and mitoxantrone (for treatment of multiple sclerosis)</TI>
<SO>Bloomington MN: Institute for Clinical Systems Improvement (ICSI)</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-2000" MODIFIED="2010-10-28 09:46:36 +0200" MODIFIED_BY="[Empty name]" NAME="Jacobs 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs L, Rudick R, Simon J</AU>
<TI>Extended observations on MS patients treated with IM interferon-beta1a (Avonex (TM)): implications for modern MS trials and therapeutics</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>2</NO>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2010" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Jankovic 2010" TYPE="OTHER">
<AU>Jankovic SM</AU>
<TI>Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis</TI>
<SO>Journal of Inflammation Research</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>1</NO>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jarius-2003" MODIFIED="2010-10-28 09:46:53 +0200" MODIFIED_BY="[Empty name]" NAME="Jarius 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jarius S, Hohlfeld R, Voltz R</AU>
<TI>[Diagnosis and treatment of multiple sclerosis. Update, 2003]</TI>
<SO>MMW Fortschritte der Medizin</SO>
<YR>2003</YR>
<VL>145 Suppl 2</VL>
<PG>88-91, 93, 95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kappos-2006" MODIFIED="2010-10-28 09:44:16 +0200" MODIFIED_BY="[Empty name]" NAME="Kappos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kappos L, Traboulsee A, Constantinescu C, Er&#8222;linna JP, Forrestal F, Jongen P, et al</AU>
<TI>Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>6</NO>
<PG>944-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobelt-2003" MODIFIED="2010-10-28 09:44:13 +0200" MODIFIED_BY="[Empty name]" NAME="Kobelt 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kobelt G, Jonsson L, Fredrikson S</AU>
<TI>Cost-utility of interferon beta 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis</TI>
<SO>European Journal of Health Economics</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>50-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Komori-2009" MODIFIED="2010-10-28 09:43:36 +0200" MODIFIED_BY="[Empty name]" NAME="Komori 2009" TYPE="JOURNAL_ARTICLE">
<AU>Komori M, Kondo T, Tanaka M</AU>
<TI>Mitoxantrone for the treatment of patients with multiple sclerosis</TI>
<SO>Brain and Nerve</SO>
<YR>2009</YR>
<VL>61</VL>
<NO>5</NO>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lam-2008" MODIFIED="2010-10-28 09:46:39 +0200" MODIFIED_BY="[Empty name]" NAME="Lam 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lam S, Wang S, Gottesman M</AU>
<TI>Interferon-beta1b for the treatment of multiple sclerosis</TI>
<SO>Expert opinion on drug metabolism &amp; toxicology</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>8</NO>
<PG>1111-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lim-2010" MODIFIED="2010-10-28 09:47:39 +0200" MODIFIED_BY="[Empty name]" NAME="Lim 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lim SY, Constantinescu CS</AU>
<TI>Current and future disease-modifying therapies in multiple sclerosis</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>5</NO>
<PG>637-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2003" MODIFIED="2010-10-28 09:49:05 +0200" MODIFIED_BY="[Empty name]" NAME="Lin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS</AU>
<TI>Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>8</NO>
<PG>1090-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopatinskaya-2006" MODIFIED="2010-10-28 09:43:40 +0200" MODIFIED_BY="[Empty name]" NAME="Lopatinskaya 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lopatinskaya L, Zwemmer J, Uitdehaag B, Lucas K, Polman C, Nagelkerken L</AU>
<TI>Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years</TI>
<SO>Multiple Sclerosis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>6</NO>
<PG>704-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lyseng_x002d_Williamson-2002" MODIFIED="2010-10-28 09:43:44 +0200" MODIFIED_BY="[Empty name]" NAME="Lyseng-Williamson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lyseng-Williamson K, Plosker G</AU>
<TI>Management of relapsing-remitting multiple sclerosis: defining the role of subcutaneous recombinant interferon-[beta]-1a (rebif)</TI>
<SO>Disease Management &amp; Health Outcomes</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>5</NO>
<PG>307-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manfredonia-2008" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Manfredonia 2008" TYPE="JOURNAL_ARTICLE">
<AU>Manfredonia F, Pasquali L, Dardano A, Ludice A, Murri L, Monzani F</AU>
<TI>Review of the clinical evidence for interferon (beta) la (Rebif(registered trademark)) in the treatment of multiple sclerosis</TI>
<SO>Neuropsychiatric Disease and Treatment</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>2</NO>
<PG>321-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinelli-2005" MODIFIED="2010-10-28 09:43:48 +0200" MODIFIED_BY="[Empty name]" NAME="Martinelli 2005" TYPE="COCHRANE_REVIEW">
<AU>Martinelli Boneschi Filippo AU: Rovaris Marco AU: Capra Ruggero AU: Comi Giancarlo</AU>
<TI>Mitoxantrone for multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCormack-2004" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="McCormack 2004" TYPE="JOURNAL_ARTICLE">
<AU>McCormack PL, Scott LJ</AU>
<TI>Interferon-(beta)-1b: A review of its use in relapsing-remitting and secondary progressive multiple sclerosis</TI>
<SO>CNS Drugs</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>8</NO>
<PG>521-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNamee-1998" MODIFIED="2010-10-28 09:43:53 +0200" MODIFIED_BY="[Empty name]" NAME="McNamee 1998" TYPE="JOURNAL_ARTICLE">
<AU>McNamee P, Parkin D</AU>
<TI>Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness</TI>
<SO>Health Technology Assessment</SO>
<YR>1998</YR>
<VL>2(4) Update 1999</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Menge-2008" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Menge 2008" TYPE="JOURNAL_ARTICLE">
<AU>Menge T, Weber MS, Hemmer B, Kieseier BC, Von Budingen HC, Warnke C, et al</AU>
<TI>Disease-modifying agents for multiple sclerosis: Recent advances and future prospects</TI>
<SO>Drugs</SO>
<YR>2008</YR>
<VL>68</VL>
<NO>17</NO>
<PG>2445-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohr-1999" MODIFIED="2010-10-28 09:44:00 +0200" MODIFIED_BY="[Empty name]" NAME="Mohr 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al</AU>
<TI>Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>192-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molyneux-2000" MODIFIED="2010-12-19 00:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Molyneux 2000" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Brex PA, Fogg C, Lewis S, Middleditch C, Barkhof F, et al</AU>
<TI>The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>4</NO>
<PG>237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molyneux-2000a" MODIFIED="2010-10-28 09:44:04 +0200" MODIFIED_BY="[Empty name]" NAME="Molyneux 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, et al</AU>
<TI>The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<NO>(Pt 11)</NO>
<PG>2256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neuhaus-2004" MODIFIED="2010-10-28 09:50:48 +0200" MODIFIED_BY="[Empty name]" NAME="Neuhaus 2004" TYPE="JOURNAL_ARTICLE">
<AU>Neuhaus O, Stuve O, Zamvil SS, Hartung HP</AU>
<TI>Are statins a treatment option for multiple sclerosis?</TI>
<SO>Lancet neurology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>6</NO>
<PG>369-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Reference" MODIFIED="2011-01-12 16:18:40 +0100" MODIFIED_BY="[Empty name]" NAME="New Reference" TYPE="OTHER">
<SO>Journal of Neurosurgery</SO>
<VL>187</VL>
<NO>Suppl 1</NO>
<PG>S456</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nguyen-2003" MODIFIED="2010-10-28 10:05:14 +0200" MODIFIED_BY="[Empty name]" NAME="Nguyen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD</AU>
<TI>Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients</TI>
<SO>Journal of the neurological sciences</SO>
<YR>2003</YR>
<VL>209</VL>
<NO>1-2</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-1999" MODIFIED="2010-10-28 10:05:05 +0200" MODIFIED_BY="[Empty name]" NAME="Nicholson 1999" TYPE="OTHER">
<AU>Nicholson T, Milne R</AU>
<TI>Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis</TI>
<SO>Southampton: Wessex Institute for Health Research and Development (WIHRD)</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panitch-2004" MODIFIED="2010-10-28 10:04:55 +0200" MODIFIED_BY="[Empty name]" NAME="Panitch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Panitch H, Miller A, Paty D, Weinshenker B</AU>
<TI>Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pascual-2009" MODIFIED="2010-10-28 10:04:46 +0200" MODIFIED_BY="[Empty name]" NAME="Pascual 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pascual AM, Tellez N, Bosca I, Mallada J, Belenguer A, Abellan I, et al</AU>
<TI>Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required</TI>
<SO>Multiple Sclerosis</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrucco-2010" MODIFIED="2010-10-28 10:04:29 +0200" MODIFIED_BY="[Empty name]" NAME="Patrucco 2010" TYPE="JOURNAL_ARTICLE">
<AU>Patrucco L, Rojas JI, Cristiano E</AU>
<TI>[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]</TI>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petereit-2006" MODIFIED="2010-10-28 10:03:30 +0200" MODIFIED_BY="[Empty name]" NAME="Petereit 2006" TYPE="JOURNAL_ARTICLE">
<AU>Petereit HF, Reske D, Pukrop R, Maas-Enriquez M, Japp G, Jongen PJ, et al</AU>
<TI>No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Portaccio-2009" MODIFIED="2010-10-13 12:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Portaccio 2009" TYPE="JOURNAL_ARTICLE">
<AU>Portaccio E, Amato MP</AU>
<TI>Improving compliance with interferon-(beta) therapy in patients with multiple sclerosis</TI>
<SO>CNS Drugs</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>6</NO>
<PG>453-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rice-2009" MODIFIED="2010-10-28 10:02:57 +0200" MODIFIED_BY="[Empty name]" NAME="Rice 2009" TYPE="COCHRANE_PROTOCOL">
<AU>Rice GPA, Ebers G, Fredrikson S, Tesser F, Filippini G</AU>
<TI>Interferon beta for secondary progressive multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rieckmann-2005" MODIFIED="2010-10-28 10:01:17 +0200" MODIFIED_BY="[Empty name]" NAME="Rieckmann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rieckmann P, Kruse N, Nagelkerken L, Beckmann K, Miller D, Polman C, et al</AU>
<TI>Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2005</YR>
<VL>252</VL>
<NO>5</NO>
<PG>526-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandberg_x002d_Wollheim-2005" MODIFIED="2010-10-28 10:01:00 +0200" MODIFIED_BY="[Empty name]" NAME="Sandberg-Wollheim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sandberg-Wollheim M</AU>
<TI>Interferon-beta1a treatment for multiple sclerosis</TI>
<SO>Expert Review of Neurotherapeutics</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>25-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shapiro-2003" MODIFIED="2010-10-28 10:00:53 +0200" MODIFIED_BY="[Empty name]" NAME="Shapiro 2003" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro S, Galboiz Y, Lahat N, Kinarty A, Miller A</AU>
<TI>The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta</TI>
<SO>Journal of neuroimmunology</SO>
<YR>2003</YR>
<VL>144</VL>
<NO>1-2</NO>
<PG>116-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simo-2009" MODIFIED="2010-10-28 10:00:48 +0200" MODIFIED_BY="[Empty name]" NAME="Simo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Simo M</AU>
<TI>[Therapy of multiple sclerosis]</TI>
<SO>Neuropsychopharmacol.Hung</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>1</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-2003" MODIFIED="2010-10-28 10:00:03 +0200" MODIFIED_BY="[Empty name]" NAME="Sorensen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen PS</AU>
<TI>The role of intravenous immunoglobulin in the treatment of multiple sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2003</YR>
<VL>206</VL>
<NO>2</NO>
<PG>123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sormani-2003" MODIFIED="2010-10-28 09:59:58 +0200" MODIFIED_BY="[Empty name]" NAME="Sormani 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, et al</AU>
<TI>MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>9</NO>
<PG>1462-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sormani-2005" MODIFIED="2010-10-28 09:59:52 +0200" MODIFIED_BY="[Empty name]" NAME="Sormani 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Bruzzi P, Beckmann K, Kappos L, Miller DH, Polman C, et al</AU>
<TI>The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2005</YR>
<VL>252</VL>
<NO>12</NO>
<PG>1455-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2003" MODIFIED="2010-10-28 09:58:21 +0200" MODIFIED_BY="[Empty name]" NAME="Turner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD</AU>
<TI>Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years</TI>
<SO>Multiple Sclerosis</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twork-2007a" MODIFIED="2010-10-28 09:58:14 +0200" MODIFIED_BY="[Empty name]" NAME="Twork 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Twork S, Nippert I, Scherer P, Haas J, Pohlau D, Kugler J</AU>
<TI>Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population</TI>
<SO>Curr.Med Res Opin</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vamvakas-1995" MODIFIED="2010-10-28 09:58:02 +0200" MODIFIED_BY="[Empty name]" NAME="Vamvakas 1995" TYPE="JOURNAL_ARTICLE">
<AU>Vamvakas EC, Pineda AA, Weinshenker BG</AU>
<TI>Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>4</NO>
<PG>163-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Oosten-1998" MODIFIED="2010-10-28 09:57:48 +0200" MODIFIED_BY="[Empty name]" NAME="van Oosten 1998" TYPE="JOURNAL_ARTICLE">
<AU>van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Ader HJ, Polman, et al</AU>
<TI>Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>6</NO>
<PG>793-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vudattu-2009" MODIFIED="2010-10-28 09:57:36 +0200" MODIFIED_BY="[Empty name]" NAME="Vudattu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Vudattu NK, Kuhlmann-Berenzon S, Khademi M, Seyfert V, Olsson T, Maeurer MJ</AU>
<TI>Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system</TI>
<SO>PLoS ONE</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>8</NO>
<PG>e6534</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2009" MODIFIED="2010-10-28 09:57:33 +0200" MODIFIED_BY="[Empty name]" NAME="Wright 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wright BR, Warrington AE, Edberg DE, Rodriguez M</AU>
<TI>Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies</TI>
<SO>Archives of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>12</NO>
<PG>1456-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-25 12:12:43 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-25 12:09:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-07-02 19:40:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<CHAR_METHODS MODIFIED="2011-07-02 19:39:25 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo controlled two arm trial.</P>
<P>It was a multicentre study (32): Denmark (4 centres, 48 patients), Finland (6 centres, 123 patients), Norway (12 centres, 120 patients) and Sweden (10 centres, 80 patients).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-02 19:39:36 +0200" MODIFIED_BY="[Empty name]">
<P>371 patients with SP MS: 188 IFN and 183 placebo-treated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-02 19:39:47 +0200" MODIFIED_BY="[Empty name]">
<P>IFN beta-1a (Rebif; Serono), 22 ug subcutaneously once weekly <I>versus</I> placebo (unspecified) for 36 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-02 19:40:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<U>Primary:</U> The time to progression on the EDSS, defined as an increase from baseline by at least 1.0 point (or 0.5 points if<BR/>the baseline EDSS score was 5.5 or higher) and confirmed at two consecutive scheduled visits separated by 6 months.</P>
<P>
<U>Secondary</U>:Time to progression on the RFSS (Regional Functional System Score).</P>
<P>
<U>Tertiary</U>: The proportion of progression free patients, time to first exacerbation, proportion of exacerbation free patients, MS related hospitalisation rate, ambulation index and arm index.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-02 19:40:12 +0200" MODIFIED_BY="[Empty name]">
<P>Serono personnel were involved in the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-25 09:54:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<CHAR_METHODS MODIFIED="2011-07-02 19:40:27 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, two-arm trial.</P>
<P>It was a multicentre study (42): 31 in the United States, four in Canada, and seven in Europe.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-02 19:40:47 +0200" MODIFIED_BY="[Empty name]">
<P>436 patients with SPMS: 217 IFN beta 1a (Avonex) and 219 placebo (unspecified) patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-02 19:41:00 +0200" MODIFIED_BY="[Empty name]">
<P>Weekly IM injections of IFNb-1a (60 ug) versus placebo (unspecified) for 24 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-25 09:54:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>Primary</U>: Baseline to month 24 change in the MS Functional Composite (MSFC), MSFC Z-score change.</P>
<P>
<U>Others </U>:</P>
<P>Clinical outcomes: number of patients with EDSS worsening or stable, time to EDSS worsening, defined as a 1.0 step increase for baseline EDSS 3.5 to 5.5 and 0.5 step increase for baseline EDSS 6.0 to 6.5 sustained for 3 months. Relapse rate, Quality of life (The MS Quality of Life Inventory (MSQLI), and depression (The Beck Depression Inventory).</P>
<P>MRI Outcome: Total volumes of T2-hyperintense lesions and Gd-enhancing lesions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-28 15:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>Biogen, Inc. supported this study </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-25 12:06:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-North-American-SG-2004">
<CHAR_METHODS MODIFIED="2011-07-02 19:42:54 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, four-arm trial.</P>
<P>It was a multicentre study, performed in United States (31 centers) and Canada (4).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-02 19:43:20 +0200" MODIFIED_BY="[Empty name]">
<P>939 patients with SPMS: 631 treated with IFN beta-1b (Betaferon, 2 arms with different dosages) and 308 placebo-treated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-02 19:43:54 +0200" MODIFIED_BY="[Empty name]">
<P>Subcutaneous injection every other day of IFN-1b 250 ug (8.0 million international units [MIU]), IFN-1b 160ug (5 MIU)/m<SUP>2</SUP> body surface area (mean administered dose 220 ug) or one of two placebo treatments, for 36 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-25 12:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>Primary:</U> The time to progression on the EDSS, defined as an increase from baseline by more than 1.0 point (or 0.5 points if the baseline EDSS score was 6.0 to 6.5 ) and confirmed at two consecutive scheduled visits s<U>eparated by 6 months.</U>
</P>
<P>
<U>Secondary </U>:</P>
<P>Clinical : Mean EDSS change, annual relapse rate, change in composite neuropsychological test score (Rao Brief Repeatable Battery).</P>
<P>MRI: absolute change in T2-weighted lesion area (assessed annually)from baseline to end point,annual new active lesion rate (new, recurrent, and newly enlarging or enhancing lesions per year on study) (Monthly scanning for Frequent MRI substudy population, n=163).</P>
<P>
<U>Tertiary </U>:</P>
<P>Clinical: proportion of subjects with confirmed disease progression, relapse-related endpoints, social handicap (Environmental Status Scale), Quality of Life (MSQLI), depression (Beck Depression Inventory).<BR/>MRI : Absolute and % change in annual T2 lesion area, other measures of disease activity (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-28 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by Berlex Laboratories, Montville, NJ.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-25 09:54:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SPECTRIMS-2001">
<CHAR_METHODS MODIFIED="2011-11-25 09:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, three-arm trial.</P>
<P>It was a multicentre study (22) performed in Europe, Canada and Australia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-02 19:46:37 +0200" MODIFIED_BY="[Empty name]">
<P>618 patients with SPMS: 413 treated with IFN beta-1a (2 arms with different dosages= 204 Rebif 44ug and 209 Rebif 22ug) and 205 placebo (unspecified) patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-02 19:47:01 +0200" MODIFIED_BY="[Empty name]">
<P>Subcutaneous injection, three times weekly of IFN-1a (Rebif) at 2 different dosages (22 and 44 ug) or placebo (unspecified) treatments, for 36 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-02 19:48:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<U>Primary:</U> The time to progression on the EDSS, defined as an increase from baseline by more than 1.0 point (or 0.5 points if baseline EDSS was <U>&lt; </U>5.5), confirmed at two consecutive scheduled visits separated by 3 months.</P>
<P>
<I>
<U>Secondary</U>
</I>
<U> </U>:<I> </I>
</P>
<P>Clinical : proportion of patients progressing, exacerbation count, time to first exacerbation, time between first and second exacerbations, number of moderate and severe exacerbations, number of steroid courses, number of hospitalizations, and Integrated Disability Status Score (IDSS, defined by area under an EDSS time-curve adjusted for baseline)<I>. </I>
</P>
<P>MRI: lesion burden, T2 activity (New T2, recurrent T2, newly enlarging T2, and persistently enlarging T2 lesions) enhancing lesions and Combined Unique (CU) activity analysis: (Monthly scanning for Frequent MRI substudy population, n=283).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-28 15:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by Serono International SA, Geneva, Switzerland.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-25 09:55:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-The-European-SG-1998">
<CHAR_METHODS MODIFIED="2011-07-02 19:38:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, two-arm trial. It was a multicentre study (32) performed in European countries.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-02 19:38:26 +0200" MODIFIED_BY="[Empty name]">
<P>718 patients with SP MS: 360 treated with IFN beta 1b (Betaferon) and 358 placebo-treated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-02 19:38:11 +0200" MODIFIED_BY="[Empty name]">
<P>Subcutaneous injection every other day of IFN-1b 250 ug (8.0 million international units [MIU]), or placebo (unspecified) treatments, for 36 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-25 09:55:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>Primary:</U> The time to progression on the EDSS, defined as an increase from baseline by more than 1.0 point (or 0.5 points if baseline EDSS was 6), confirmed at two consecutive scheduled visits separated by 3 months, not obtained during relapses.</P>
<P>
<U>
<I>Secondary </I>
</U>
<I>: </I>
</P>
<P>Clinical :<I> </I>proportion of patients with confirmed progression,Time to becoming wheelchair-bound,Proportion of patients becoming wheelchair bound,Change in EDSS from baseline,Annual relapse rate,Time to first relapse, Proportion of patients with moderate or severe relapse.</P>
<P>
<U>
<I>Tertiary</I>
</U> :</P>
<P>MS-related steroid use and hospital admissions. Montgomery Asberg Depression RatingScale (MADRS) to assess mood changes and suicidal risk.</P>
<P>MRI :Percentage change in annual T2 lesion volume. (Monthly scanning for Frequent MRI substudy population, n=125)T1-weighted gadolinium-enhanced scans in months 0&#8211;6 and 18&#8211;24.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-02 19:37:10 +0200" MODIFIED_BY="[Empty name]">
<P>This study was funded by Schering AG, Berlin.</P>
<P>The cognitive function evaluation was included in the protocol <LINK REF="REF-Polman-1995" TYPE="REFERENCE">Polman 1995</LINK> but results were not retrieved in the primary study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-25 12:12:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-01-16 11:30:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnason-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-16 11:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment is Lenercept</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-16 11:17:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bar_x002d_Or-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-16 11:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment is BHT-3009, a tolerizing DNA vaccine encoding full-length human myelin basic protein</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:09:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:09:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, parallel group, comparative trial evaluating the safety and tolerability of two formulations of IFNb (IFNbeta-1b-G or the refrigeration-free formulation (IFNbeta-1b-M) in patients with relapsing-remitting or secondary progressive MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:11:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boiko2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:11:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with secondary progressive MS in a randomized, double-blind, placebo-controlled study evaluating short course of antibodies (AB) to IFN-gamma or AB to tumour necrosis factor (TNF)-alpha</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:11:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buhse-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:11:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapsing remitting MS patients randomised to receive EMLA cream or placebo cream 2 hr before IFN&#946;-1a injection once weekly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:11:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christodoulou-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:11:36 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment is donepezil</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernandez-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective open label evaluating combination therapy with interferon beta 1 b and azathioprine in secondary progressive MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:11:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodkin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>A randomized, double-masked, dose-comparison, phase II study of intravenous methyprednisolone in patients with secondary progressive multiple sclerosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodkin-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment is complex of human leukocyte antigen-DR2 with myelin basic protein84-102 (AG284).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoogervorst-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:05 +0100" MODIFIED_BY="[Empty name]">
<P>MS patients suffered from an acute relapse , treated with intravenous methylprednisolone, participating in a double-blind, placebo-controlled,<BR/>randomized, parallel-group, multicentre, phase II study evaluating the safety, tolerability and MRI effects of oral interferon beta-1a.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:11:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leary-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:11:22 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial of two doses of interferon -1a in primary progressive MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montalban-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:07 +0100" MODIFIED_BY="[Empty name]">
<P>study on the effect of interferon beta in primary progressive MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patti-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:17 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment is natural interferon beta derived from human fibroblasts (Ares-Serono@).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rio-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label, non-randomised, observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skurkovich-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:33 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, study. In secondary progressive MS randomized to three groups (antibodies to TNF-a, to IFN-g; and placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:38 +0100" MODIFIED_BY="[Empty name]">
<P>Combination therapy with pulse cyclophosphamide given with methylprednisolone<BR/>and interferon beta (IFNb)-1a in remitting-relapsing MS patients during IFNb monotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tubridy-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>A double-blind, placebo-controlled trial in patients with relapsing-remitting and secondary progressive MS randomized to infusions of anti-4 integrin antibody (natalizumab; Antegren) or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-25 12:12:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zavalishin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-25 12:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>Multicenter study evaluating the effect of Rebif 22 in relapsing remitting and secondary progressive MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-25 12:09:14 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-25 09:54:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 09:54:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 09:54:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>The contract research organization computer generated two minimization schemes, one for North America and one for Europe and Israel (page 680).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-20 17:44:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>Each block allocated 2 subjects to fixed-dose Betaseron, 2 to Body Surface Area (BSA)-adjusted Betaseron, 1 to fixed placebo, and 1 to BSA-adjusted placebo. Each site received an adequate number of blocks, based on projected subject recruitment, to ensure sequential subject numbering within each site. The randomisation schedule was generated by the Biostatistics and Data Management Group of Berlex Laboratories (Richmond, CA) using an SAS program (Cary, NC).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-20 17:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION>
<P>Computer generated randomisation list provided by Serono, stratified by center; treatments were equally allocated with a block size of six.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-16 17:14:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>Central randomisation schedule assigned placebo or interferon -1b to blocks of six patients in a 1/1 ratio.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-25 09:55:01 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-20 17:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>"equal allocation (page 707)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 09:54:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>Not reported any comments on this aspect.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-20 17:44:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>The biostatistician and supporting programmers were the only individuals with access to the randomisation codes.The active study drug was indistinguishable from placebo in appearance, smell and colour, and labels and packages for active study agent and placebo were indistinguishable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 09:55:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION>
<P>The block size was not revealed to the investigators.The manufacturer labelled containers of study medication with patient identification numbers based on the randomisation list, and patients received the medication labelled with their numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-16 17:14:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>Access to the code was strictly limited according to study protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-26 10:25:04 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-20 17:43:41 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-11-20 17:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>Only 83% of randomised patients completed about 3 years.</P>
<P>Lost to follow-up:</P>
<P>- 21% for treated patients</P>
<P>- 16% for placebo</P>
<P>More AE and patients' decision in the treated group</P>
<P>The median time on treatment was 35.2 months (mean 32.0) for placebo and 35.0 months (mean 31.1) for IFN.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-16 17:08:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>Lost to follow-up 52 patients (P 23; T 29 ) /436 (12 %). </P>
<P>Reasons for withdrawal were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-16 17:11:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>Only 72% of randomised patients were included in analysis (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK> page 26).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-01-14 16:50:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION>
<P>Lost to follow-up 47/618 patients (44 ug = 14, 22 ug =14, Placebo= 19) (8 %).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-17 11:33:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>1/4 of randomised patients were lost to follow-up.</P>
<P>Due to early study termination, at 33 months primary outcome was not available for 187/718 patients (26%) of the randomised patients; placebo= 97/358 (27%), treated= 90/360 (25%).</P>
<P>Is not clear which data were used for analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-05-26 10:25:04 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-25 12:09:14 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-17 11:15:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>The study was terminated during the third year by the Steering Committee based on negative results from the SPECTRIMS study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 12:05:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>In FDA&#8217;s letters of July 23, 1998, December 6, 1999, and March 8,2000, Biogen was informed that the proposed primary endpoint, the Multiple Sclerosis Functional Composite (MSFC) had not been validated as a clinical efficacy outcome measurement and therefore, was not appropriate for use as a primary efficacy endpoint in a Phase 3 study (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>; <LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 12:06:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>The Independent Data and Safety Monitoring Board recommended early termination of the trial based on the results of a planned interim analysis indicating that continuing the trial was unlikely to change the results.The study initiated in August 2, 1995, interrupted November 22, 1999. The last patient enrolled on April 1, 1997. The final patient visit occurred on November 15, 1999.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-14 16:51:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 12:09:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>In November 20, 1997, a planned interim analysis was done after all patients had been in the study for at least 2 years.The results gave evidence of efficacy and led to a recommendation to the early termination of the study. The study has been initiated in September 1994 and stopped in March 1998. EDSS information at month 33 was available for three-fourths of patients in both treatment groups in the final data set, compared with 40% in the interim analysis (<LINK REF="REF-Kappos-2001" TYPE="REFERENCE">Kappos 2001</LINK>, page 1971).<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-11-20 17:36:33 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-20 17:36:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>"Patients were instructed to cover injection sites."</P>
<P>No blinding questionnaire was conducted at study termination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-16 17:07:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>Patients were instructed to cover injection sites.</P>
<P>No blinding questionnaire was conducted at study termination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-16 17:10:52 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>Patients and treating physicians were more likely to guess treatment allocation correctly due to side effects. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-16 17:13:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION>
<P>Patients were instructed to cover injection sites and to discuss only neurologic matters during neurologic evaluations. </P>
<P>Blinding questionnaire was conducted at study termination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-28 11:40:56 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>54·3% of 304 patients guessed correctly that they were on placebo and 65·6% of 308 that they were on active treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-11-25 12:07:05 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-20 17:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_">
<DESCRIPTION>
<P>"double blind" is reported, without any other comments</P>
<P>Placebo is not described.</P>
<P>No blinding questionnaire was conducted at study termination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-28 11:23:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_">
<DESCRIPTION>
<P>The examining technician administered the MSFC, and the examining neurologist determined the EDSS during all scheduled study visits.Neither the examining technician nor the examining neurologist was involved with any other aspect of subject care, and neither had access to the results of prior examinations or to clinical information that might compromise blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-25 12:07:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-North-American-SG-2004">
<DESCRIPTION>
<P>Separate treating and examining physicians were employed.</P>
<P>A questionnaire to evaluate the success of blinding was made: results suggest a substantial maintenance of blinding for the critical evaluation physicians (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-09 16:13:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPECTRIMS-2001">
<DESCRIPTION>
<P>Solutions of IFNb-1a and placebo were physically indistinguishable, and packaging and labelling were prepared to preserve blinding neurologic assessments. Separate treating and examining physicians were employed. Patients were instructed to cover injection sites and to discuss only neurologic matters during neurologic evaluations.</P>
<P>Evaluating physicians guessed treatment assignments correctly for 29% of patients on active treatment and 26% of patients on placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-25 10:24:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-The-European-SG-1998">
<DESCRIPTION>
<P>Interferon beta-1b was indistinguishable from placebo.</P>
<P>Separate treating and examining physicians were employed. Separate designated EDSS raters performed only the standardized neurologic tests EDSS physicians received no potentially unmasking information from the treating physicians, and were allowed to speak to patients only as necessary to carry out neurological tests. During EDSS assessments all potential injection sites were covered.</P>
<P>Blinding questionnaire was conducted at study termination; EDSS physicians guessed correctly for only 54 (18.6%) of 291 of patients on placebo and 65 (20.8%) of 312 patients on interferon -1b. "The data at study termination were collected under double-blind conditions and comprise the data collected after database lock for the interim analysis until the beginning of the open-label extension phase" (<LINK REF="REF-Kappos-2001" TYPE="REFERENCE">Kappos 2001</LINK> page 1970). It is unclear if the 3 years evaluation was double blind or open for the early study termination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-11-25 12:14:58 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-11-25 12:14:58 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-06-05 08:10:18 +0200" MODIFIED_BY="Grade Profiler">INTERFERONS for secondary progressive multiple sclerosis</TITLE>
<TABLE COLS="7" ROWS="23">
<TR>
<TD COLSPAN="7">
<P>
<B>INTERFERONS for secondary progressive multiple sclerosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with secondary progressive multiple sclerosis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> INTERFERONS<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INTERFERONS</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sustained (6 months) EDSS increase after 3 years</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.82 to 1.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2026<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>HIGH</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>RCTs low risk of bias</P>
<P>Heterogeneity probably due to different clinical characteristics of patients</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>410 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>402 per 1000</B>
<BR/>(336 to 475)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>372 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>365 per 1000</B>
<BR/>(305 to 432)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sustained (3 months) EDSS increase after 3 years</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.8 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1336<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>HIGH</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>579 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>510 per 1000</B>
<BR/>(463 to 562)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>594 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>523 per 1000</B>
<BR/>(475 to 576)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sustained (3 or 6 months) EDSS increase at 3 years in patients with pre study relapses</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.9 </B>
<BR/>(0.75 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1106<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>HIGH</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>465 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>419 per 1000</B>
<BR/>(349 to 507)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>388 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>349 per 1000</B>
<BR/>(291 to 423)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of patients with at least one relapse during follow-up - after 3 years</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.84 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2639<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>HIGH</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>530 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>482 per 1000</B>
<BR/>(445 to 514)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>509 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>463 per 1000</B>
<BR/>(428 to 494)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-11-20 17:37:39 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-11-20 17:37:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-03-09 12:32:47 +0100" MODIFIED_BY="[Empty name]">Summary of baseline characteristics of included studies</TITLE>
<TABLE COLS="11" ROWS="13">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Study Name</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Number of patients</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>% of female</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Age - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Baseline EDSS - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Disease duration - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Pre-study change* in EDSS - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Pre-study progression duration* - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Pre-study number of relapses* - mean (SD)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Pre-study % of patients without relapse*</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Rebif 22µg weekly</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>188</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> 45.1 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.7 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> 14.2 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> 4.8 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.7 (0.4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>40</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>183</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>46.4 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.0 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>.14.4 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>6.1 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.6 (0.4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>34</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Avonex 60µg weekly</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>217</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>64</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>47.2 (8.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.2 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>16.2 (9.0)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.5 (2.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>37</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>219</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>64</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>47.9 (7.7)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.2 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>16.7 (9.0)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>nr</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.3 (2.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>44</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Betaferon 250µg, every other day  </P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>317</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>66</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>46.1 (8.0)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.2 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>14.6 (7.8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.7 (0.9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.0 (3.3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.8 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>54</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Betaferon 160µg/m<SUP>2, </SUP>every other day</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>314</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>61</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>46.8 (8.3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.1 (1.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>14.5 (8.7)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.7 (0.9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.1 (3.5)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.9 (1.6)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>55</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo </P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>308</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>47.6 (8.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.1 <U>+</U>1.1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>14.9 (8.3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.7 (0.9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.1 (3.5)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.8 (1.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>56</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Rebif 44µg, three times weekly</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>204</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>67</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>42.6 (7.3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.3 <U>+</U> 1.1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>12.9 (6.9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.5 (0.8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>3.7 (2.7)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.9 (1.3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>52</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Rebif 22µg, three times weekly</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>209</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>62</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>43.1 (7.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.5 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>13.3 (7.4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.6 (0.9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.2 (3.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.9 (1.4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>54</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo </P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>205</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>42.7 (6.8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5.4 (1.1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>13.7 (7.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.7 (1.0)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4.1 (3.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.9 (1.2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>52</P>
</TD>
</TR>
<TR>
<TD VALIGN="MIDDLE">
<P>
<LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Betaferon 250µg, every other day  </P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>360</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>58·1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> 41·1 (7·2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5·1 (1·1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>12.8 (6.6)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.5 (nr)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>3·8 (2·7)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.7 (0.85)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>32</P>
</TD>
</TR>
<TR>
<TD VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>358</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>64·2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>40·9 (7·2)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>5·2 (1·1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>13.4 (7.5)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>3·8 (3·4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>28</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Pre-study length of observation: 4 years (<LINK REF="STD-Andersen-2004-_x0028_Nordic_x0029_" TYPE="STUDY">Andersen 2004 (Nordic)</LINK>) ; 3 years (<LINK REF="STD-Cohen-2002-_x0028_IMPACT_x0029_" TYPE="STUDY">Cohen 2002 (IMPACT)</LINK> ; 2 years (<LINK REF="STD-North-American-SG-2004" TYPE="STUDY">North American SG 2004</LINK> ; <LINK REF="STD-SPECTRIMS-2001" TYPE="STUDY">SPECTRIMS 2001</LINK> ; <LINK REF="STD-The-European-SG-1998" TYPE="STUDY">The European SG 1998</LINK>)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-24 12:35:05 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-24 12:35:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Disability progression</NAME>
<DICH_OUTCOME CHI2="4.683698774553863" CI_END="1.1632372379603213" CI_START="0.8201224015245889" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.976727657609248" ESTIMABLE="YES" EVENTS_1="451" EVENTS_2="348" I2="57.29870565404783" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.0656682965254736" LOG_CI_START="-0.08612132525088571" LOG_EFFECT_SIZE="-0.010226514362706081" METHOD="MH" MODIFIED="2011-06-30 16:57:03 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09614985037693002" P_Q="1.0" P_Z="0.7917050948985418" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01357714337670198" TOTALS="YES" TOTAL_1="1177" TOTAL_2="849" WEIGHT="100.0" Z="0.2640971049762138">
<NAME>Sustained (6 months) EDSS increase after 3 years</NAME>
<GROUP_LABEL_1>treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4368754767000973" CI_START="0.8638150836087681" EFFECT_SIZE="1.114089184060721" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="68" LOG_CI_END="0.15741913269560737" LOG_CI_START="-0.06357921673808999" LOG_EFFECT_SIZE="0.04691995797875868" MODIFIED="2011-04-30 15:07:40 +0200" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.12981552441682664" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="186" TOTAL_2="183" VAR="0.016852070379615718" WEIGHT="26.125741813830018"/>
<DICH_DATA CI_END="1.259006569338807" CI_START="0.867870051878034" EFFECT_SIZE="1.0453009598421195" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="106" LOG_CI_END="0.10002799620806138" LOG_CI_START="-0.06154529783873656" LOG_EFFECT_SIZE="0.019241349184662443" MODIFIED="2011-01-20 18:31:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.09490895272379368" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.009007709307127305" WEIGHT="35.199954293463655"/>
<DICH_DATA CI_END="0.9895942988400875" CI_START="0.7132471419513363" EFFECT_SIZE="0.8401340996168583" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="174" LOG_CI_END="-0.004542815389265811" LOG_CI_START="-0.14675995992640725" LOG_EFFECT_SIZE="-0.07565138765783651" MODIFIED="2011-04-26 10:41:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.08353905468733609" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.00697877365805373" WEIGHT="38.67430389270632">
<FOOTNOTE>&#8727;kappos 2001</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.588231528178191" CI_END="1.1037509763484983" CI_START="0.8259873286889708" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9548216171054882" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="369" I2="47.85274025448963" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.04287110075104079" LOG_CI_START="-0.08302661505573046" LOG_EFFECT_SIZE="-0.020077757152344847" METHOD="MH" MODIFIED="2011-11-24 12:35:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0877796066154577" P_Q="0.334291532214976" P_Z="0.5318809333298085" Q="0.9322020454162775" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01695804094963289" TOTALS="SUB" TOTAL_1="1166" TOTAL_2="843" WEIGHT="200.00000000000003" Z="0.6251373292480478">
<NAME>Sustained (3 or 6 months) EDSS increase at 3 years in patients with or without pre-study relapses</NAME>
<GROUP_LABEL_1>treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9947898852925676" CI_END="1.0851872330528467" CI_START="0.7524638915697959" DF="2" EFFECT_SIZE="0.9036394239212918" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="215" I2="33.21735158042263" ID="CMP-001.02.01" LOG_CI_END="0.035504675757348045" LOG_CI_START="-0.12351433569191296" LOG_EFFECT_SIZE="-0.04400482996728243" MODIFIED="2011-05-19 17:53:37 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22371225178054" P_Z="0.27803271621234027" STUDIES="3" TAU2="0.009051507695031316" TOTAL_1="644" TOTAL_2="462" WEIGHT="100.00000000000001" Z="1.0847493151371035">
<NAME>In patients with pre study relapses</NAME>
<DICH_DATA CI_END="1.7636897135993685" CI_START="0.8199063622267123" EFFECT_SIZE="1.2025225225225225" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="25" LOG_CI_END="0.24642218197226953" LOG_CI_START="-0.08623574358007423" LOG_EFFECT_SIZE="0.08009321919609769" MODIFIED="2011-01-20 18:54:59 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.1954049121527356" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="111" TOTAL_2="71" VAR="0.03818307969341832" WEIGHT="18.47196838765778"/>
<DICH_DATA CI_END="1.144750358687872" CI_START="0.6716751748496588" EFFECT_SIZE="0.8768696581196581" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="52" LOG_CI_END="0.058710788278476284" LOG_CI_START="-0.17284070295193138" LOG_EFFECT_SIZE="-0.05706495733672753" MODIFIED="2011-01-20 18:50:47 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.13601449214710867" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="288" TOTAL_2="134" VAR="0.018499942074035887" WEIGHT="31.668598652949974"/>
<DICH_DATA CI_END="0.992089756334861" CI_START="0.6919551334363475" EFFECT_SIZE="0.828541851523218" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="138" LOG_CI_END="-0.0034490345821490648" LOG_CI_START="-0.15992206440555254" LOG_EFFECT_SIZE="-0.08168554949385079" MODIFIED="2011-05-19 17:53:37 +0200" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.09191303227225667" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="245" TOTAL_2="257" VAR="0.008448005501480896" WEIGHT="49.85943295939225">
<FOOTNOTE>Sustained 3 months' EDSS increase</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.052763179896627" CI_END="1.327868132004283" CI_START="0.8261638853203858" DF="2" EFFECT_SIZE="1.0473951952963034" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="154" I2="50.650953159049045" ID="CMP-001.02.02" LOG_CI_END="0.12315494823497407" LOG_CI_START="-0.08293379356286876" LOG_EFFECT_SIZE="0.020110577336052694" MODIFIED="2011-06-02 17:03:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13181184770819288" P_Z="0.7020794795215163" STUDIES="3" TAU2="0.022188574007098918" TOTAL_1="522" TOTAL_2="381" WEIGHT="100.00000000000001" Z="0.38251490055322607">
<NAME>In patients without pre-study relapses</NAME>
<DICH_DATA CI_END="1.542649835834844" CI_START="0.7348748301131197" EFFECT_SIZE="1.0647321428571428" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="42" LOG_CI_END="0.1882673572861119" LOG_CI_START="-0.1337866272021722" LOG_EFFECT_SIZE="0.027240365041969892" MODIFIED="2011-04-30 14:19:33 +0200" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.18917610468135213" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="64" TOTAL_2="106" VAR="0.0357875985824099" WEIGHT="25.2775046236174"/>
<DICH_DATA CI_END="1.5968308726869007" CI_START="0.9722046544495567" EFFECT_SIZE="1.2459720730397421" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="57" LOG_CI_END="0.203258920553986" LOG_CI_START="-0.012242304062834363" LOG_EFFECT_SIZE="0.09550830824557582" MODIFIED="2011-04-30 14:19:33 +0200" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.1265864860881864" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="343" TOTAL_2="174" VAR="0.016024138460154606" WEIGHT="38.35092763819913"/>
<DICH_DATA CI_END="1.1224932700708548" CI_START="0.6624078365012929" EFFECT_SIZE="0.8622924901185771" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="55" LOG_CI_END="0.050183745862574035" LOG_CI_START="-0.17887453834706293" LOG_EFFECT_SIZE="-0.06434539624224443" MODIFIED="2011-06-02 17:03:14 +0200" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.1345499700015342" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="115" TOTAL_2="101" VAR="0.018103694427413754" WEIGHT="36.37156773818348">
<FOOTNOTE>sustained 3 months' EDSS increase</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1694939192206595" CI_END="0.973488925030783" CI_START="0.8288687307931593" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8982730819363686" ESTIMABLE="YES" EVENTS_1="669" EVENTS_2="495" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.011668984899345114" LOG_CI_START="-0.08151424388431829" LOG_EFFECT_SIZE="-0.04659161439183174" METHOD="MH" MODIFIED="2011-11-24 12:33:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7603298903204467" P_Q="0.5037439289644554" P_Z="0.008926329307101829" Q="0.4470401471094039" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1403" TOTAL_2="987" WEIGHT="200.0" Z="2.6148628415627972">
<NAME>Sustained (3 months) EDSS increase</NAME>
<GROUP_LABEL_1>treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.002598644405978366" CI_END="1.0792133032536007" CI_START="0.8105720797908963" DF="1" EFFECT_SIZE="0.9352968361735616" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="169" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.03310729016090189" LOG_CI_START="-0.09120835963895735" LOG_EFFECT_SIZE="-0.029050534739027772" MODIFIED="2011-11-24 12:33:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9593439454683876" P_Z="0.3596548035196949" STUDIES="2" TAU2="0.0" TOTAL_1="630" TOTAL_2="424" WEIGHT="99.99999999999999" Z="0.916023073712616">
<NAME>After 2 years</NAME>
<DICH_DATA CI_END="1.2869003316127998" CI_START="0.6894414695373517" EFFECT_SIZE="0.9419354838709677" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.10954491278882189" LOG_CI_START="-0.16150259756053073" LOG_EFFECT_SIZE="-0.025978842385854406" MODIFIED="2011-01-20 18:37:30 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.15921464928602472" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.02534930454727185" WEIGHT="21.035883827922547"/>
<DICH_DATA CI_END="1.0966803888339218" CI_START="0.7946616737860264" EFFECT_SIZE="0.9335362196503543" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="109" LOG_CI_END="0.04008007735575388" LOG_CI_START="-0.09981773232678602" LOG_EFFECT_SIZE="-0.029868827485516076" MODIFIED="2011-11-24 12:33:57 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.08217666591285044" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.006753004420552236" WEIGHT="78.96411617207744">
<FOOTNOTE>.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7388590771022026" CI_END="0.9717012164279388" CI_START="0.8000217838112905" DF="1" EFFECT_SIZE="0.8816927699024647" ESTIMABLE="YES" EVENTS_1="408" EVENTS_2="326" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.01246725359658773" LOG_CI_START="-0.09689818743276163" LOG_EFFECT_SIZE="-0.05468272051467466" MODIFIED="2011-11-24 12:32:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39002663105130586" P_Z="0.011123688997789656" STUDIES="2" TAU2="0.0" TOTAL_1="773" TOTAL_2="563" WEIGHT="100.0" Z="2.5387889939341868">
<NAME>After 3 years</NAME>
<DICH_DATA CI_END="1.039781860661901" CI_START="0.8040707591452867" EFFECT_SIZE="0.9143621766280107" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="133" LOG_CI_END="0.01694223675292037" LOG_CI_START="-0.0947057311593205" LOG_EFFECT_SIZE="-0.03888174720320006" MODIFIED="2011-11-24 12:32:50 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.06558256901800472" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.004301073359001353" WEIGHT="57.18755638363161">
<FOOTNOTE>Data at 3 years were provided by Serono manufacturer</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9743829297626961" CI_START="0.7239223343131265" EFFECT_SIZE="0.8398675877950489" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="193" LOG_CI_END="-0.011270333059726335" LOG_CI_START="-0.14030802439473142" LOG_EFFECT_SIZE="-0.07578917872722887" MODIFIED="2011-01-21 16:55:14 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.0757973786370557" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.005745242608249188" WEIGHT="42.81244361636839"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.470472655300446" CI_END="1.0512122675305913" CI_START="0.8897292243126572" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9671061344950421" ESTIMABLE="YES" EVENTS_1="765" EVENTS_2="537" I2="10.524002528963617" I2_Q="47.24391225218443" ID="CMP-001.04" LOG_CI_END="0.021690420413722388" LOG_CI_START="-0.050742144230790584" LOG_EFFECT_SIZE="-0.014525861908534091" METHOD="MH" MODIFIED="2011-11-07 22:37:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3460631431995299" P_Q="0.16858132478621468" P_Z="0.4318000690402317" Q="1.8955158403333388" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1807" TOTAL_2="1268" WEIGHT="200.0" Z="0.7861150940838817">
<NAME>Sustained (3 or 6 months') EDSS increase according to pre-study clinical characteristics of patients</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.566469116774731" CI_END="1.0156688761485912" CI_START="0.8260764185259541" DF="1" EFFECT_SIZE="0.915980407878416" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="303" I2="61.03596207474747" ID="CMP-001.04.01" LOG_CI_END="0.006752144266480792" LOG_CI_START="-0.0829797751868716" LOG_EFFECT_SIZE="-0.03811381546019538" MODIFIED="2011-11-07 22:37:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10915147451151186" P_Z="0.09591327755657145" STUDIES="2" TAU2="0.0" TOTAL_1="773" TOTAL_2="563" WEIGHT="100.0" Z="1.6649973848876136">
<NAME>low age and disease duration</NAME>
<DICH_DATA CI_END="1.1293688901772003" CI_START="0.8726333159216024" EFFECT_SIZE="0.9927360774818402" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="129" LOG_CI_END="0.05283582040240179" LOG_CI_START="-0.059168210275732776" LOG_EFFECT_SIZE="-0.003166194936665511" MODIFIED="2011-11-07 22:31:48 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.06579172204922981" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.004328550690203111" WEIGHT="49.70204798306376"/>
<DICH_DATA CI_END="0.9895942988400875" CI_START="0.7132471419513363" EFFECT_SIZE="0.8401340996168583" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="174" LOG_CI_END="-0.004542815389265811" LOG_CI_START="-0.14675995992640725" LOG_EFFECT_SIZE="-0.07565138765783651" MODIFIED="2011-05-10 11:41:40 +0200" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.08353905468733609" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.00697877365805373" WEIGHT="50.297952016936236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48945822462189703" CI_END="1.182076406152804" CI_START="0.901653301755555" DF="2" EFFECT_SIZE="1.0323870856103423" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="234" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.07264554904786076" LOG_CI_START="-0.04496042263400326" LOG_EFFECT_SIZE="0.013842563206928773" MODIFIED="2011-11-07 22:37:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7829166004097455" P_Z="0.6445210743888901" STUDIES="3" TAU2="0.0" TOTAL_1="1034" TOTAL_2="705" WEIGHT="100.0" Z="0.4613868658420094">
<NAME>high age and disease duration</NAME>
<DICH_DATA CI_END="1.3959943308974554" CI_START="0.8411899715226157" EFFECT_SIZE="1.0836495888678053" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="68" LOG_CI_END="0.14488365463030015" LOG_CI_START="-0.07510591351585362" LOG_EFFECT_SIZE="0.034888870557223256" MODIFIED="2011-05-19 18:21:57 +0200" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.12922296129497562" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="186" TOTAL_2="178" VAR="0.01669857372584277" WEIGHT="25.579405730084137"/>
<DICH_DATA CI_END="1.2869003316127998" CI_START="0.6894414695373517" EFFECT_SIZE="0.9419354838709677" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.10954491278882189" LOG_CI_START="-0.16150259756053073" LOG_EFFECT_SIZE="-0.025978842385854406" MODIFIED="2011-11-07 22:35:42 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.15921464928602472" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.02534930454727185" WEIGHT="21.983380261823523"/>
<DICH_DATA CI_END="1.259006569338807" CI_START="0.867870051878034" EFFECT_SIZE="1.0453009598421195" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="106" LOG_CI_END="0.10002799620806138" LOG_CI_START="-0.06154529783873656" LOG_EFFECT_SIZE="0.019241349184662443" MODIFIED="2011-05-10 11:41:55 +0200" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.09490895272379368" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.009007709307127305" WEIGHT="52.43721400809233"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-07-13 10:24:00 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Adverse Events</NAME>
<DICH_OUTCOME CHI2="0.38931825098868983" CI_END="1.190947714799432" CI_START="0.8332248465437694" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9961562261540153" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="146" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.07589269542691539" LOG_CI_START="-0.07923778798501707" LOG_EFFECT_SIZE="-0.001672546279050815" METHOD="MH" MODIFIED="2011-07-13 10:24:00 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9833420739115809" P_Q="1.0" P_Z="0.9662891366370905" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1809" TOTAL_2="1273" WEIGHT="99.99999999999997" Z="0.04226287957488509">
<NAME>Total number of patients with Serious AEs</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4164502849190586" CI_START="0.7246584103503457" EFFECT_SIZE="1.0131350412505429" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.15120133610021183" LOG_CI_START="-0.13986666302786707" LOG_EFFECT_SIZE="0.005667336536172367" MODIFIED="2011-04-30 13:03:34 +0200" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.17097478349766632" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.029232376592073867" WEIGHT="28.40569180540193"/>
<DICH_DATA CI_END="22.09663064810862" CI_START="0.18437528172909262" EFFECT_SIZE="2.0184331797235022" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3443260563778003" LOG_CI_START="-0.7342973030666603" LOG_EFFECT_SIZE="0.30501437665557" MODIFIED="2011-07-13 10:24:00 +0200" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="1.22099365068925" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="1.4908254950234623" WEIGHT="0.5569839548530311"/>
<DICH_DATA CI_END="1.2299991313768128" CI_START="0.7929384980565658" EFFECT_SIZE="0.9875796999963145" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="86" LOG_CI_END="0.08990480474151968" LOG_CI_START="-0.10076049615083577" LOG_EFFECT_SIZE="-0.005427845704658052" MODIFIED="2011-01-21 17:33:53 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.11199774155263052" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.012543494112889821" WEIGHT="66.19892932070685"/>
<DICH_DATA CI_END="2.631789360053422" CI_START="0.30332031770443835" EFFECT_SIZE="0.8934624697336562" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.4202511268008683" LOG_CI_START="-0.5180984977955496" LOG_EFFECT_SIZE="-0.04892368549734065" MODIFIED="2011-01-21 17:34:10 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.5511912143934897" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.30381175482457" WEIGHT="2.733159158681579"/>
<DICH_DATA CI_END="3.405379685528798" CI_START="0.29039926363830926" EFFECT_SIZE="0.9944444444444445" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5321655409586734" LOG_CI_START="-0.537004489205499" LOG_EFFECT_SIZE="-0.0024194741234128915" MODIFIED="2011-01-21 17:33:32 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.6280357681954403" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.39442892613283675" WEIGHT="2.10523576035659"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9506756042906797" CI_END="3.5715638798740375" CI_START="1.9152550109902649" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6154264696222267" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5528584221852424" LOG_CI_START="0.28222660728247334" LOG_EFFECT_SIZE="0.41754251473385795" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9171806968762106" P_Q="1.0" P_Z="1.4680512326931224E-9" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1809" TOTAL_2="1273" WEIGHT="100.0" Z="6.047835072063977">
<NAME>Patients who had discontinuated for AEs (including SAEs) *</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.486956323545425" CI_START="1.038682875620784" EFFECT_SIZE="2.595744680851064" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.8120409738502101" LOG_CI_START="0.01648297162785144" LOG_EFFECT_SIZE="0.41426197273903076" MODIFIED="2011-01-21 17:42:13 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.46731470858103696" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.2183830368561795" WEIGHT="11.572148630163444"/>
<DICH_DATA CI_END="4.1829169079781305" CI_START="0.8687650642990119" EFFECT_SIZE="1.9062980030721965" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6214792375748911" LOG_CI_START="-0.06109765171381531" LOG_EFFECT_SIZE="0.2801907929305379" MODIFIED="2011-02-25 17:59:04 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.4009490435782808" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.16076013554633814" WEIGHT="15.720072343915955"/>
<DICH_DATA CI_END="4.608710978756578" CI_START="1.3800160197583244" EFFECT_SIZE="2.521922873745378" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="12" LOG_CI_END="0.6635794735254965" LOG_CI_START="0.1398841278883815" LOG_EFFECT_SIZE="0.40173180070693904" MODIFIED="2011-04-30 15:47:31 +0200" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.3076212383610109" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.09463082629076187" WEIGHT="26.705472834414838">
<FOOTNOTE>FDA</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.953238686898975" CI_START="1.2756248814697337" EFFECT_SIZE="2.9782082324455206" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="6" LOG_CI_END="0.8421871378602179" LOG_CI_START="0.10572298170577593" LOG_EFFECT_SIZE="0.4739550597829969" MODIFIED="2011-01-21 17:42:03 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.43260269088148695" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.18714508815790334" WEIGHT="13.503752546654512"/>
<DICH_DATA CI_END="5.153079776325889" CI_START="1.7271764001533882" EFFECT_SIZE="2.9833333333333334" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="16" LOG_CI_END="0.7120668659522319" LOG_CI_START="0.23733669524026704" LOG_EFFECT_SIZE="0.47470178059624957" MODIFIED="2011-04-30 15:55:33 +0200" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.2788588522284528" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.07776225946617008" WEIGHT="32.49855364485125"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7586362020070574" CI_END="3.4216954642154658" CI_START="0.5827426684688943" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4120792985894357" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.5342413540957374" LOG_CI_START="-0.23452318166587108" LOG_EFFECT_SIZE="0.14985908621493316" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7800407959443323" P_Q="1.0" P_Z="0.44478917882943014" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1809" TOTAL_2="1273" WEIGHT="100.0" Z="0.7641310130061284">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.8374288863515" CI_START="0.13857779876362677" EFFECT_SIZE="0.973404255319149" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.834892822423646" LOG_CI_START="-0.8583063414901467" LOG_EFFECT_SIZE="-0.011706759533250363" MODIFIED="2011-02-25 16:28:00 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.9945935703539979" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.9892163701895128" WEIGHT="20.614394847653358"/>
<DICH_DATA CI_END="104.49622759109123" CI_START="0.2436530043548107" EFFECT_SIZE="5.045871559633028" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0191006123040594" LOG_CI_START="-0.6132282291968189" LOG_EFFECT_SIZE="0.7029361915536202" MODIFIED="2011-02-25 16:26:42 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="1.5462429917355303" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="2.390867389491243" WEIGHT="8.529162652215657"/>
<DICH_DATA CI_END="7.213112916056788" CI_START="0.2972778101359827" EFFECT_SIZE="1.4643423137876386" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.8581227308087471" LOG_CI_START="-0.5268375068568024" LOG_EFFECT_SIZE="0.16564261197597235" MODIFIED="2011-02-25 16:28:18 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.8135324992684869" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.6618351273660307" WEIGHT="30.8114453308114"/>
<DICH_DATA CI_END="4.421011092301516" CI_START="0.12539162550467642" EFFECT_SIZE="0.7445520581113801" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6455216045505916" LOG_CI_START="-0.9017314676405225" LOG_EFFECT_SIZE="-0.12810493154496547" MODIFIED="2011-02-25 16:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.9088641136312909" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.8260339770467922" WEIGHT="24.68675310155421"/>
<DICH_DATA CI_END="28.544938980940515" CI_START="0.3117988020125214" EFFECT_SIZE="2.9833333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.455529118974541" LOG_CI_START="-0.5061255577820419" LOG_EFFECT_SIZE="0.47470178059624957" MODIFIED="2011-02-25 16:26:20 +0100" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="1.1522856674740731" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="1.32776225946617" WEIGHT="15.358244067765373"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.276633699331953" CI_END="1.950857993409056" CI_START="0.3556186351816809" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8329234400888242" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.2902256574399199" LOG_CI_START="-0.44901548914018113" LOG_EFFECT_SIZE="-0.07939491585013062" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5170121598194566" P_Q="1.0" P_Z="0.6737532767762338" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1351" TOTAL_2="1090" WEIGHT="100.0" Z="0.4210024735277177">
<NAME>Patients who done or attempted suicide</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.212379177087431" CI_START="0.013779100630234044" EFFECT_SIZE="0.3363914373088685" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9144689931480245" LOG_CI_START="-1.8607791281521469" LOG_EFFECT_SIZE="-0.47315506750206104" MODIFIED="2011-02-25 16:30:44 +0100" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.63019448415148" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="2.6575340561579095" WEIGHT="7.095265143193352"/>
<DICH_DATA CI_END="115.22691434377934" CI_START="0.3098431974412336" EFFECT_SIZE="5.975138121546961" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0615539320886698" LOG_CI_START="-0.5088580342768183" LOG_EFFECT_SIZE="0.7763479489059257" MODIFIED="2011-02-25 16:30:50 +0100" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="1.509872712787527" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="361" TOTAL_2="308" VAR="2.2797156088203665" WEIGHT="8.271167106349465"/>
<DICH_DATA CI_END="2.9334654886235088" CI_START="0.25721881489470033" EFFECT_SIZE="0.8686440677966102" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.4673809832329238" LOG_CI_START="-0.5896972670616284" LOG_EFFECT_SIZE="-0.061158141914352274" MODIFIED="2011-02-25 16:31:51 +0100" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.6209329968447496" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.38555778657060175" WEIGHT="48.90553222442479"/>
<DICH_DATA CI_END="2.47802834391001" CI_START="0.1436670859661643" EFFECT_SIZE="0.5966666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39410626956761263" LOG_CI_START="-0.8426427170471511" LOG_EFFECT_SIZE="-0.22426822373976926" MODIFIED="2011-02-25 16:29:58 +0100" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.7264724767437305" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.5277622594661701" WEIGHT="35.72803552603241"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.379850129581169" CI_END="2.4755256861558355" CI_START="0.9899553729210601" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5654583845679397" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="103" I2="77.16816853512687" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3936674369482002" LOG_CI_START="-0.0043843829084842375" LOG_EFFECT_SIZE="0.194641527019858" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0363662284376044" P_Q="1.0" P_Z="0.055264929452276" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08489707918049576" TOTALS="YES" TOTAL_1="991" TOTAL_2="666" WEIGHT="100.0" Z="1.9167875327998962">
<NAME>Allergy/Rash (number of events)</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6228343046772211" CI_START="0.9807546707897533" EFFECT_SIZE="1.2615872241862733" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="65" LOG_CI_END="0.21027417956874006" LOG_CI_START="-0.008439614890105621" LOG_EFFECT_SIZE="0.10091728233931724" MODIFIED="2011-02-25 17:23:38 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.1284735655158693" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.016505457036360364" WEIGHT="53.914504007639735"/>
<DICH_DATA CI_END="2.888158534091319" CI_START="1.4058995127883414" EFFECT_SIZE="2.0150584795321635" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="38" LOG_CI_END="0.4606210284375533" LOG_CI_START="0.14795428042696432" LOG_EFFECT_SIZE="0.30428765443225875" MODIFIED="2011-02-25 17:24:16 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.18366199550678403" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.033731728593533954" WEIGHT="46.085495992360265"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26015130906002476" CI_END="82.3397138953645" CI_START="6.724986306523278" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="23.53154156508601" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.9156093536272152" LOG_CI_START="0.8276914043610727" LOG_EFFECT_SIZE="1.3716503789941439" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.967340012151253" P_Q="0.6646129791243595" P_Z="7.722311317122237E-7" Q="0.1879683222209247" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1817" TOTAL_2="1076" WEIGHT="200.0" Z="4.9422575370186586">
<NAME>Cutaneous necrosis *</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.002719133087576714" CI_END="238.79091900033427" CI_START="4.566070641343868" DF="1" EFFECT_SIZE="33.02023931874129" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="0" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="2.3780178069504885" LOG_CI_START="0.6595426261442553" LOG_EFFECT_SIZE="1.5187802165473718" MODIFIED="2011-04-30 21:33:31 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9584129324248453" P_Z="5.313885065907287E-4" STUDIES="2" TAU2="0.0" TOTAL_1="773" TOTAL_2="563" WEIGHT="99.99999999999999" Z="3.4644137525084657">
<NAME>Number of events</NAME>
<DICH_DATA CI_END="509.72013763153814" CI_START="1.9278936181415458" EFFECT_SIZE="31.347826086956523" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="0" LOG_CI_END="2.7073317917003323" LOG_CI_START="0.2850830657033404" LOG_EFFECT_SIZE="1.496207428701836" MODIFIED="2011-04-30 20:38:16 +0200" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.422840891975204" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="2.0244762038767945" WEIGHT="50.33256418959142"/>
<DICH_DATA CI_END="576.5834265420727" CI_START="2.1011082464322595" EFFECT_SIZE="34.80609418282548" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.760862154762612" LOG_CI_START="0.3224484272832615" LOG_EFFECT_SIZE="1.5416552910229369" MODIFIED="2011-04-30 20:42:22 +0200" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.4323362938639896" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="2.0515872587200294" WEIGHT="49.66743581040856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06830633136584319" CI_END="94.61271414744351" CI_START="3.719974501877131" DF="1" EFFECT_SIZE="18.760513963691928" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="1" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="1.9759495012332473" LOG_CI_START="0.5705399630722168" LOG_EFFECT_SIZE="1.273244732152732" MODIFIED="2011-04-30 21:33:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7938189151396386" P_Z="3.83336581494305E-4" STUDIES="2" TAU2="0.0" TOTAL_1="1044" TOTAL_2="513" WEIGHT="100.00000000000001" Z="3.5512976833643335">
<NAME>Number of patients</NAME>
<DICH_DATA CI_END="117.2220628901088" CI_START="2.213406772145403" EFFECT_SIZE="16.107765451664026" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="1" LOG_CI_END="2.0690093598873327" LOG_CI_START="0.3450612343810624" LOG_EFFECT_SIZE="1.2070352971341975" MODIFIED="2011-04-30 20:39:44 +0200" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="1.0126556626032337" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="1.0254714910023943" WEIGHT="66.45955151654172"/>
<DICH_DATA CI_END="414.7569645587282" CI_START="1.5526745099333574" EFFECT_SIZE="25.3768115942029" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="0" LOG_CI_END="2.617793687388452" LOG_CI_START="0.19108042330392894" LOG_EFFECT_SIZE="1.404437055346191" MODIFIED="2011-04-30 20:39:40 +0200" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="1.4254633837476403" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="2.0319458584052725" WEIGHT="33.54044848345829"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="65.8453132434819" CI_END="4.314576695716061" CI_START="2.8883209589624084" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5301391331344822" ESTIMABLE="YES" EVENTS_1="866" EVENTS_2="226" I2="93.92515609241791" I2_Q="84.12202477016784" ID="CMP-002.07" LOG_CI_END="0.6349381933924524" LOG_CI_START="0.4606454516958169" LOG_EFFECT_SIZE="0.5477918225441346" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.7008616737257398E-13" P_Q="0.012087308388906925" P_Z="7.060427361165975E-35" Q="6.298032246083626" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3727782554172097" TOTALS="SUB" TOTAL_1="1809" TOTAL_2="1273" WEIGHT="200.0" Z="12.3201027508168">
<NAME>Injection site reactions *</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5552107000682341" CI_END="4.739463573250764" CI_START="3.1077594979931944" DF="1" EFFECT_SIZE="3.8378526463587455" ESTIMABLE="YES" EVENTS_1="495" EVENTS_2="83" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.6757291896992741" LOG_CI_START="0.49244740242750784" LOG_EFFECT_SIZE="0.584088296063391" MODIFIED="2011-04-30 21:33:45 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.456196487909292" P_Z="8.239379648847552E-36" STUDIES="2" TAU2="0.0" TOTAL_1="991" TOTAL_2="666" WEIGHT="100.0" Z="12.492152560452086">
<NAME>Number of events</NAME>
<DICH_DATA CI_END="4.727754042183252" CI_START="2.720856122318902" EFFECT_SIZE="3.586577551161028" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="46" LOG_CI_END="0.6746548746200025" LOG_CI_START="0.43470557708477864" LOG_EFFECT_SIZE="0.5546802258523906" MODIFIED="2011-04-30 19:56:37 +0200" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.14094740514036944" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.01986617101580344" WEIGHT="58.34446431380716"/>
<DICH_DATA CI_END="5.851495603797872" CI_START="3.042916431411746" EFFECT_SIZE="4.21966966966967" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="37" LOG_CI_END="0.7672668830841192" LOG_CI_START="0.48329002535353255" LOG_EFFECT_SIZE="0.6252784542188259" MODIFIED="2011-04-30 19:53:15 +0200" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.16680941193906335" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.02782537991145613" WEIGHT="41.655535686192835"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="19.388791806892954" CI_END="3.0653520256472597" CI_START="0.837579941693208" DF="2" EFFECT_SIZE="1.6023349746263387" ESTIMABLE="YES" EVENTS_1="371" EVENTS_2="143" I2="89.68476210421233" ID="CMP-002.07.02" LOG_CI_END="0.4864803561846823" LOG_CI_START="-0.07697373165904095" LOG_EFFECT_SIZE="0.20475331226282073" MODIFIED="2011-04-30 21:33:51 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.162817228339001E-5" P_Z="0.15431313777241246" STUDIES="3" TAU2="0.2887530271360299" TOTAL_1="818" TOTAL_2="607" WEIGHT="100.0" Z="1.4244607552185051">
<NAME>Number of patients</NAME>
<DICH_DATA CI_END="5.670807700241579" CI_START="1.9315208236269759" EFFECT_SIZE="3.3095744680851062" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="15" LOG_CI_END="0.7536449204053869" LOG_CI_START="0.2858993946126224" LOG_EFFECT_SIZE="0.5197721575090047" MODIFIED="2011-04-30 19:45:51 +0200" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.2747560372283645" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.07549087999343441" WEIGHT="30.074608061199434"/>
<DICH_DATA CI_END="1.1707029715736772" CI_START="0.5194868067390518" EFFECT_SIZE="0.7798491830749895" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="44" LOG_CI_END="0.06844672071739313" LOG_CI_START="-0.28442547762208015" LOG_EFFECT_SIZE="-0.10798937845234348" MODIFIED="2011-04-30 19:41:17 +0200" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.20727887605015954" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.0429645324566174" WEIGHT="33.02355401098091"/>
<DICH_DATA CI_END="2.0160798212390922" CI_START="1.4166853083457396" EFFECT_SIZE="1.690014989046466" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="84" LOG_CI_END="0.3045077228317295" LOG_CI_START="0.15127339010129975" LOG_EFFECT_SIZE="0.2278905564665146" MODIFIED="2011-04-30 19:41:30 +0200" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.09001060556803472" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.008101909114724325" WEIGHT="36.90183792781965"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9767780100799524" CI_END="1.1844922240023816" CI_START="0.9367344265062469" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0533539975487727" ESTIMABLE="YES" EVENTS_1="510" EVENTS_2="278" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.0735322139959372" LOG_CI_START="-0.028383518451536277" LOG_EFFECT_SIZE="0.022574347772200437" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.39521960652335086" P_Q="1.0" P_Z="0.3852495351434858" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1809" TOTAL_2="1273" WEIGHT="99.99999999999999" Z="0.8682645465124504">
<NAME>Patients with psychiatric disorders</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.243330758311126" CI_START="0.9022225284932308" EFFECT_SIZE="1.4226677577741407" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.3508933109967763" LOG_CI_START="-0.04468633277129269" LOG_EFFECT_SIZE="0.1531034891127418" MODIFIED="2011-02-25 17:31:28 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.23236544090018102" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.05399369812473552" WEIGHT="6.637653689697924"/>
<DICH_DATA CI_END="1.3184973053105775" CI_START="0.69330977559194" EFFECT_SIZE="0.9560999272374484" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="57" LOG_CI_END="0.12007924653753617" LOG_CI_START="-0.15907267625340438" LOG_EFFECT_SIZE="-0.019496714857934087" MODIFIED="2011-02-25 17:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.16397522127170205" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.026887873191103646" WEIGHT="13.32911186507184"/>
<DICH_DATA CI_END="1.1710686793171403" CI_START="0.8623798386345728" EFFECT_SIZE="1.004940803579752" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="136" LOG_CI_END="0.06858236575879251" LOG_CI_START="-0.0643014053021692" LOG_EFFECT_SIZE="0.0021404802283116514" MODIFIED="2011-04-30 20:51:58 +0200" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.07805658490648426" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.006092830447263186" WEIGHT="58.82183538179222"/>
<DICH_DATA CI_END="1.4978714921475214" CI_START="0.8998854151402548" EFFECT_SIZE="1.1609964295974062" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="59" LOG_CI_END="0.17547455525581973" LOG_CI_START="-0.04581278693892858" LOG_EFFECT_SIZE="0.06483088415844557" MODIFIED="2011-02-25 17:30:15 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.12998528019520522" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.01689617306742601" WEIGHT="21.21139906343801"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-25 17:28:57 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.0" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.734267452524536" CI_END="1.6007094724304165" CI_START="0.9682193583868614" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2449248565115685" ESTIMABLE="YES" EVENTS_1="537" EVENTS_2="290" I2="77.10168584977411" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.20431251494871344" LOG_CI_START="-0.014026238410120337" LOG_EFFECT_SIZE="0.09514313826929659" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.012687596301180992" P_Q="1.0" P_Z="0.08760944177871499" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.036461099425312955" TOTALS="YES" TOTAL_1="1036" TOTAL_2="710" WEIGHT="99.99999999999997" Z="1.7081449950157568">
<NAME>Patients with headache</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5254994123560612" CI_START="1.2672245747525486" EFFECT_SIZE="1.7889591719378954" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="37" LOG_CI_END="0.40234727179489393" LOG_CI_START="0.10285358641708804" LOG_EFFECT_SIZE="0.25260042910599095" MODIFIED="2011-02-25 17:32:41 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.1759240733085755" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.030949279569481056" WEIGHT="24.40113837751776"/>
<DICH_DATA CI_END="1.2115173988401993" CI_START="0.8250557239700858" EFFECT_SIZE="0.9997846591153796" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="107" LOG_CI_END="0.08332965550698074" LOG_CI_START="-0.08351671836468194" LOG_EFFECT_SIZE="-9.353142885058556E-5" MODIFIED="2011-02-25 17:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.0980063859150853" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.00960525168013663" WEIGHT="35.7069736686459"/>
<DICH_DATA CI_END="1.3895670885407412" CI_START="1.0599142561608326" EFFECT_SIZE="1.2135987669061936" ESTIMABLE="YES" EVENTS_1="363" EVENTS_2="146" LOG_CI_END="0.1428795194327009" LOG_CI_START="0.025270733583269724" LOG_EFFECT_SIZE="0.08407512650798535" MODIFIED="2011-02-25 17:33:21 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.06908398298083497" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.004772596704496296" WEIGHT="39.891887953836324"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.18313718168611" CI_END="2.067571102974132" CI_START="1.0126944051677034" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4470030021628568" ESTIMABLE="YES" EVENTS_1="715" EVENTS_2="326" I2="91.70884496571946" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.31546045370140996" LOG_CI_START="0.005478410639512257" LOG_EFFECT_SIZE="0.16046943217046106" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="6.849643663375815E-8" P_Q="1.0" P_Z="0.04243363635224339" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1194814944897722" TOTALS="YES" TOTAL_1="1449" TOTAL_2="915" WEIGHT="100.0" Z="2.0292421107173237">
<NAME>Patients with influenza like syndrome *</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.371569757733032" CI_START="1.223563955319261" EFFECT_SIZE="1.7034574468085106" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="40" LOG_CI_END="0.3750359035832791" LOG_CI_START="0.08762667472280902" LOG_EFFECT_SIZE="0.23133128915304405" MODIFIED="2011-02-25 17:36:01 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.168825603731268" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.028502084475227132" WEIGHT="22.404473896137194"/>
<DICH_DATA CI_END="2.6077167441471736" CI_START="1.717897501671359" EFFECT_SIZE="2.1165514592933947" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="72" LOG_CI_END="0.41626041561250354" LOG_CI_START="0.23499724809447614" LOG_EFFECT_SIZE="0.3256288318534898" MODIFIED="2011-04-30 21:32:42 +0200" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.10647488186723947" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.011336900468642601" WEIGHT="25.34425095975402"/>
<DICH_DATA CI_END="1.5496217817153615" CI_START="1.0907850246514266" EFFECT_SIZE="1.3001170075684643" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="107" LOG_CI_END="0.19022571226210255" LOG_CI_START="0.037739166897118474" LOG_EFFECT_SIZE="0.11398243957961052" MODIFIED="2011-04-30 21:32:42 +0200" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.08957135156796482" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.008023027021711954" WEIGHT="26.00295419076305"/>
<DICH_DATA CI_END="1.1400362581043988" CI_START="0.8245442579466034" EFFECT_SIZE="0.9695413093163766" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="107" LOG_CI_END="0.056918664006872045" LOG_CI_START="-0.08378602835647679" LOG_EFFECT_SIZE="-0.013433682174802373" MODIFIED="2011-04-30 21:32:43 +0200" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.0826506327936913" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.006831127101197599" WEIGHT="26.248320953345743"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.664760951232399" CI_END="1.8344874387206118" CI_START="0.9275937504726973" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3044765553577056" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="139" I2="64.69400885195536" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.26351474235906897" LOG_CI_START="-0.032642186019782346" LOG_EFFECT_SIZE="0.11543627816964334" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.05887259988345106" P_Q="1.0" P_Z="0.1265342452663446" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.056260077283882194" TOTALS="YES" TOTAL_1="1036" TOTAL_2="710" WEIGHT="100.0" Z="1.5279125763515642">
<NAME>Patients with myalgia</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2883389887049366" CI_START="1.004022496142316" EFFECT_SIZE="1.8170212765957447" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.5169765817802258" LOG_CI_START="0.00174344372634948" LOG_EFFECT_SIZE="0.2593600127532876" MODIFIED="2011-02-25 17:37:22 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.30265049573801334" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.09159732257046523" WEIGHT="20.468024756706807"/>
<DICH_DATA CI_END="1.301880201982539" CI_START="0.7363339879372903" EFFECT_SIZE="0.9790907215076691" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="67" LOG_CI_END="0.11457102262570344" LOG_CI_START="-0.13292515275846745" LOG_EFFECT_SIZE="-0.009177065066382013" MODIFIED="2011-02-25 17:37:36 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.14538047854648872" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.021135483542406068" WEIGHT="39.10235791783483"/>
<DICH_DATA CI_END="1.9018103737882412" CI_START="1.1143551741431112" EFFECT_SIZE="1.4557789084438513" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="57" LOG_CI_END="0.27916721201100464" LOG_CI_START="0.0470236339131803" LOG_EFFECT_SIZE="0.16309542296209248" MODIFIED="2011-02-25 17:38:03 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.13636228690390648" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.018594673289663303" WEIGHT="40.42961732545837"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2499956524666067" CI_END="1.2187933860794442" CI_START="0.97982134676018" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0927944806644847" ESTIMABLE="YES" EVENTS_1="543" EVENTS_2="305" I2="11.11093935637358" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.085930088808763" LOG_CI_START="-0.00885310307200953" LOG_EFFECT_SIZE="0.03853849286837671" METHOD="MH" MODIFIED="2011-06-07 22:21:58 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.32465349635563145" P_Q="1.0" P_Z="0.11097453848511492" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0014277026370223547" TOTALS="YES" TOTAL_1="1036" TOTAL_2="710" WEIGHT="100.0" Z="1.5938281153368654">
<NAME>Patients with fatigue/asthenia</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3471749886830926" CI_START="0.9082879034985547" EFFECT_SIZE="1.4601063829787233" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.3705454687151279" LOG_CI_START="-0.041776469670266256" LOG_EFFECT_SIZE="0.16438449952243084" MODIFIED="2011-02-25 17:39:28 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.2421999476340928" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.0586608146339573" WEIGHT="5.158772498012305"/>
<DICH_DATA CI_END="1.399633196667475" CI_START="0.938134391388315" EFFECT_SIZE="1.14588133640553" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="96" LOG_CI_END="0.14601423458146548" LOG_CI_START="-0.027734942796177296" LOG_EFFECT_SIZE="0.059139645892644074" MODIFIED="2011-02-25 17:39:16 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.10206112686392646" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.010416473616734492" WEIGHT="26.17176439311632"/>
<DICH_DATA CI_END="1.1709052298092868" CI_START="0.9417674068441086" EFFECT_SIZE="1.0501049385360004" ESTIMABLE="YES" EVENTS_1="398" EVENTS_2="185" LOG_CI_END="0.06852174576711009" LOG_CI_START="-0.026056343913142075" LOG_EFFECT_SIZE="0.021232700926984014" MODIFIED="2011-02-25 17:39:41 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.0555556380472746" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.003086428918839785" WEIGHT="68.66946310887137"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.377693262064255" CI_END="4.752031362490004" CI_START="1.0629335361262424" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2474637927927352" ESTIMABLE="YES" EVENTS_1="326" EVENTS_2="112" I2="91.06252831076876" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.6768792982423714" LOG_CI_START="0.026506109494094075" LOG_EFFECT_SIZE="0.35169270386823276" METHOD="MH" MODIFIED="2011-06-07 22:21:59 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.3827638056684854E-5" P_Q="1.0" P_Z="0.0340295341849824" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3880949092157275" TOTALS="YES" TOTAL_1="1230" TOTAL_2="691" WEIGHT="100.0" Z="2.119721554124636">
<NAME>Patients with leucopenia *</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5772836462565083" CI_START="1.0254627252580224" EFFECT_SIZE="1.2717883418222977" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="76" LOG_CI_END="0.19790980044808493" LOG_CI_START="0.010919878737572863" LOG_EFFECT_SIZE="0.1044148395928289" MODIFIED="2011-04-30 21:16:26 +0200" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.10983880562779537" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="186" TOTAL_2="178" VAR="0.012064563221740612" WEIGHT="36.47265352529664"/>
<DICH_DATA CI_END="4.415843173731968" CI_START="2.0177930691123467" EFFECT_SIZE="2.985005485797879" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="26" LOG_CI_END="0.6450136412627565" LOG_CI_START="0.3048766259491306" LOG_EFFECT_SIZE="0.4749451336059435" MODIFIED="2011-02-25 17:42:52 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.1997981665006041" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.03991930733700312" WEIGHT="34.099049117166885"/>
<DICH_DATA CI_END="6.2357628117272235" CI_START="1.7210991979268155" EFFECT_SIZE="3.276029055690073" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="10" LOG_CI_END="0.794889587671857" LOG_CI_START="0.2358059022105868" LOG_EFFECT_SIZE="0.5153477449412219" MODIFIED="2011-02-25 17:43:07 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.328408524348827" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.10785215886497408" WEIGHT="29.42829735753646"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3955201945099898" CI_END="2.948060358667264" CI_START="0.9740733588904555" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6945875768985275" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="61" I2="28.342133353997728" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.4695363710349713" LOG_CI_START="-0.011408334536573691" LOG_EFFECT_SIZE="0.2290640182491988" METHOD="MH" MODIFIED="2011-06-07 22:21:59 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.2374752896973532" P_Q="1.0" P_Z="0.06190429216010838" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07887208164146509" TOTALS="YES" TOTAL_1="819" TOTAL_2="491" WEIGHT="100.0" Z="1.866980635077056">
<NAME>Patients with liver dysfunction</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9385638614846608" CI_START="1.150880932107548" EFFECT_SIZE="1.4936720469552458" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="58" LOG_CI_END="0.28748011240206905" LOG_CI_START="0.06103039469538114" LOG_EFFECT_SIZE="0.17425525354872512" MODIFIED="2011-02-25 17:55:00 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.13301768512508946" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="188" TOTAL_2="183" VAR="0.01769370455603745" WEIGHT="82.64987855725364"/>
<DICH_DATA CI_END="10.366961615743481" CI_START="0.9218407801959172" EFFECT_SIZE="3.0913893291072374" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.015651490538778" LOG_CI_START="-0.03534408355982476" LOG_EFFECT_SIZE="0.4901537034894765" MODIFIED="2011-02-25 17:55:14 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.617360002737516" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.3811333729800658" WEIGHT="17.35012144274635"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-06-30 17:07:49 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Relapses' outcomes</NAME>
<DICH_OUTCOME CHI2="4.30287824726733" CI_END="0.9573559136971023" CI_START="0.8324684642900531" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8927309825778578" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="636" I2="7.038968566207554" I2_Q="58.123541914440146" ID="CMP-003.01" LOG_CI_END="-0.018926575683103665" LOG_CI_START="-0.07963220952641441" LOG_EFFECT_SIZE="-0.049279392604759005" METHOD="MH" MODIFIED="2011-06-30 17:06:50 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3665648910067013" P_Q="0.1222719845089828" P_Z="0.001462090644860395" Q="2.387976552259627" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="5.437173683069099E-4" TOTALS="SUB" TOTAL_1="1807" TOTAL_2="1268" WEIGHT="200.0" Z="3.1821044792856625">
<NAME>Number of patients with at least one relapse during follow</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9544117515341247" CI_START="0.5417547417992641" DF="0" EFFECT_SIZE="0.7190668202764977" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="80" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.020264221899529266" LOG_CI_START="-0.26619727875619736" LOG_EFFECT_SIZE="-0.14323075032786334" MODIFIED="2011-05-31 11:32:53 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.022432989878270165" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="2.2829554978033784">
<NAME>After 2 years</NAME>
<DICH_DATA CI_END="0.9544117515341247" CI_START="0.5417547417992641" EFFECT_SIZE="0.7190668202764977" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="80" LOG_CI_END="-0.020264221899529266" LOG_CI_START="-0.26619727875619736" LOG_EFFECT_SIZE="-0.14323075032786334" MODIFIED="2011-05-31 11:32:53 +0200" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.1444622949858721" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" VAR="0.02086935467258513" WEIGHT="100.0">
<FOOTNOTE>Results at 2 years of follow-up</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7968028742552162" CI_END="0.9730572728351025" CI_START="0.842353449643416" DF="3" EFFECT_SIZE="0.9053497393125285" ESTIMABLE="YES" EVENTS_1="742" EVENTS_2="556" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.011861596993487872" LOG_CI_START="-0.0745056412546583" LOG_EFFECT_SIZE="-0.04318361912407305" MODIFIED="2011-05-31 11:32:53 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6156310551432642" P_Z="0.00688825128229455" STUDIES="4" TAU2="0.0" TOTAL_1="1590" TOTAL_2="1049" WEIGHT="99.99999999999999" Z="2.702199042335489">
<NAME>After 3 years</NAME>
<DICH_DATA CI_END="1.3141856777170269" CI_START="0.7812761265672505" EFFECT_SIZE="1.0132827324478177" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="68" LOG_CI_END="0.11865672984402835" LOG_CI_START="-0.10719544621200881" LOG_EFFECT_SIZE="0.00573064181600977" MODIFIED="2011-04-30 15:13:21 +0200" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.13266668620161834" STUDY_ID="STD-Andersen-2004-_x0028_Nordic_x0029_" TOTAL_1="186" TOTAL_2="178" VAR="0.017600449627718673" WEIGHT="7.693270750587721"/>
<DICH_DATA CI_END="0.9921603854821557" CI_START="0.6855781946084196" EFFECT_SIZE="0.8247445215585552" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="116" LOG_CI_END="-0.0034181172614966442" LOG_CI_START="-0.16394300396676834" LOG_EFFECT_SIZE="-0.08368056061413245" MODIFIED="2011-04-30 15:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.09429311306168107" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="631" TOTAL_2="308" VAR="0.00889119117086297" WEIGHT="15.229120791132235"/>
<DICH_DATA CI_END="1.0316102744589721" CI_START="0.8210876093362689" EFFECT_SIZE="0.9203490718321227" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="144" LOG_CI_END="0.013515658900773313" LOG_CI_START="-0.08561050156341565" LOG_EFFECT_SIZE="-0.03604742133132116" MODIFIED="2011-05-13 10:36:29 +0200" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.05822719733907254" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="413" TOTAL_2="205" VAR="0.0033904065099632967" WEIGHT="39.9376959430114"/>
<DICH_DATA CI_END="1.0162768394465709" CI_START="0.8020843089290853" EFFECT_SIZE="0.9028508771929824" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="228" LOG_CI_END="0.007012028289331193" LOG_CI_START="-0.09577997962322911" LOG_EFFECT_SIZE="-0.04438397566694896" MODIFIED="2011-01-21 16:47:59 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.06038053427648338" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" VAR="0.003645808919513584" WEIGHT="37.13991251526864"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.1821827339165285" CI_END="-0.10043569119925741" CI_START="-0.19342077292596974" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14692823206261357" ESTIMABLE="YES" I2="5.72508712258343" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-06-30 17:07:49 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36438011511809554" P_Q="0.4556513319192027" P_Z="5.866227305271853E-10" Q="0.5565559785652797" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.1190913164423244E-4" TOTALS="SUB" TOTAL_1="1098" TOTAL_2="1090" UNITS="" WEIGHT="200.0" Z="6.19398376185194">
<NAME>Relapse rate</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.032349838504122E-31" CI_END="-0.03534455699204067" CI_START="-0.2046554430079593" DF="0" EFFECT_SIZE="-0.11999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-003.02.01" MODIFIED="2011-05-31 11:36:01 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.005464918605832193" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="2.7782700058954672">
<NAME>After 2 years</NAME>
<CONT_DATA CI_END="-0.035344556992040685" CI_START="-0.2046554430079593" EFFECT_SIZE="-0.12" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.31" MODIFIED="2011-05-31 11:36:01 +0200" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="0.37" SD_2="0.52" SE="0.04319234622457894" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6432513680916196" CI_END="-0.10292447344502234" CI_START="-0.21419154492859213" DF="2" EFFECT_SIZE="-0.15855800918680724" ESTIMABLE="YES" I2="24.33561090166145" ID="CMP-003.02.02" MODIFIED="2011-05-31 11:35:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26670153833086463" P_Z="2.323819065242917E-8" STUDIES="3" TAU2="6.026226917628717E-4" TOTAL_1="881" TOTAL_2="871" WEIGHT="100.0" Z="5.585983046429018">
<NAME>After 3 years</NAME>
<CONT_DATA CI_END="-0.051846517311876575" CI_START="-0.18815348268812349" EFFECT_SIZE="-0.12000000000000002" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.28" MODIFIED="2011-05-26 10:46:03 +0200" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="0.34" SD_2="0.51" SE="0.03477282400376202" STUDY_ID="STD-North-American-SG-2004" TOTAL_1="317" TOTAL_2="308" WEIGHT="44.470662871595835">
<FOOTNOTE>Betaseron 250 ug vs. Placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.1254286396374774" CI_START="-0.2945713603625225" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.71" MODIFIED="2011-05-26 10:56:00 +0200" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.4" SD_2="0.47" SE="0.043149446127383285" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="204" TOTAL_2="205" WEIGHT="32.692548670891206">
<FOOTNOTE>Rebif 44 ug vs. Placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.053989911341808694" CI_START="-0.26601008865819115" EFFECT_SIZE="-0.15999999999999992" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.69" MODIFIED="2011-05-26 10:34:07 +0200" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="0.64" SD_2="0.8" SE="0.05408777380318479" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="360" TOTAL_2="358" WEIGHT="22.836788457512952"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-11-12 22:42:59 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>MRI: role of treatment</NAME>
<DICH_OUTCOME CHI2="3.178693947855643" CI_END="0.6448396633988882" CI_START="0.4760462716618108" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5540519087420399" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="145" I2="37.08107691999708" I2_Q="36.71583038223892" ID="CMP-004.01" LOG_CI_END="-0.19054825739171294" LOG_CI_START="-0.322350831836819" LOG_EFFECT_SIZE="-0.256449544614266" METHOD="MH" MODIFIED="2011-06-30 17:09:24 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20405894988689077" P_Q="0.2059393782989134" P_Z="2.4020175496408788E-14" Q="3.160348017648142" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013389808598859382" TOTALS="SUB" TOTAL_1="301" TOTAL_2="197" WEIGHT="300.0" Z="7.627041784453132">
<NAME>Number of patients with combined lesions at different times (6, 9 and 24 months)</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9533772548552762" CI_START="0.5191104150937452" DF="0" EFFECT_SIZE="0.7034970238095238" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="42" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.02073521344178118" LOG_CI_START="-0.2847402576317146" LOG_EFFECT_SIZE="-0.1527377355367479" MODIFIED="2011-01-21 17:09:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.023339024620041473" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="61" WEIGHT="100.0" Z="2.2678389471745115">
<NAME>6 months</NAME>
<DICH_DATA CI_END="0.9533772548552762" CI_START="0.5191104150937452" EFFECT_SIZE="0.7034970238095238" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="42" LOG_CI_END="-0.02073521344178118" LOG_CI_START="-0.2847402576317146" LOG_EFFECT_SIZE="-0.1527377355367479" MODIFIED="2011-01-21 17:09:41 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.15507786980321214" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="64" TOTAL_2="61" VAR="0.02404914570270202" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6187364022993324" CI_START="0.42197477726973603" DF="0" EFFECT_SIZE="0.5109707971586425" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="70" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-0.2084943322543447" LOG_CI_START="-0.3747135073794293" LOG_EFFECT_SIZE="-0.29160391981688705" MODIFIED="2011-01-21 17:10:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.1185245412644116E-12" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="83" WEIGHT="100.0" Z="6.876862193085839">
<NAME>9 months</NAME>
<DICH_DATA CI_END="0.6187364022993324" CI_START="0.42197477726973603" EFFECT_SIZE="0.5109707971586425" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="70" LOG_CI_END="-0.2084943322543447" LOG_CI_START="-0.3747135073794293" LOG_EFFECT_SIZE="-0.29160391981688705" MODIFIED="2011-01-21 17:10:57 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.0976379662666615" STUDY_ID="STD-SPECTRIMS-2001" TOTAL_1="181" TOTAL_2="83" VAR="0.00953317245668973" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7971213449539637" CI_START="0.33432463336594" DF="0" EFFECT_SIZE="0.5162337662337663" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.09847556137362555" LOG_CI_START="-0.4758316229863599" LOG_EFFECT_SIZE="-0.28715359217999276" MODIFIED="2011-01-21 17:11:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0028551643374896117" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="99.99999999999999" Z="2.9829159033447765">
<NAME>24 months</NAME>
<DICH_DATA CI_END="0.7971213449539637" CI_START="0.33432463336594" EFFECT_SIZE="0.5162337662337663" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" LOG_CI_END="-0.09847556137362555" LOG_CI_START="-0.4758316229863599" LOG_EFFECT_SIZE="-0.28715359217999276" MODIFIED="2011-01-21 17:11:17 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.22166081853395092" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="56" TOTAL_2="53" VAR="0.049133518473141125" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="46.41895257497671" CI_END="-2.412926792271544" CI_START="-4.284328780872318" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.348627786571931" ESTIMABLE="YES" I2="91.3828301197897" I2_Q="79.11338455679706" ID="CMP-004.02" MODIFIED="2011-11-12 22:42:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.014839406427882E-9" P_Q="0.008331178664036987" P_Z="2.312755475693649E-12" Q="9.575510237350843" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.0680196473118397" TOTALS="SUB" TOTAL_1="1283" TOTAL_2="1262" UNITS="" WEIGHT="300.0" Z="7.014195666446083">
<NAME>Mean absolute change of T2 lesion load</NAME>
<GROUP_LABEL_1>Treated</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.137067844270852" CI_END="-0.23325747827759336" CI_START="-3.250778853909414" DF="1" EFFECT_SIZE="-1.7420181660935035" ESTIMABLE="YES" I2="91.76077770322395" ID="CMP-004.02.01" MODIFIED="2011-05-09 17:56:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.942978407940224E-4" P_Z="0.023637020072121914" STUDIES="2" TAU2="1.0880993020048295" TOTAL_1="512" TOTAL_2="510" WEIGHT="100.0" Z="2.2629784123685837">
<NAME>1 year</NAME>
<CONT_DATA CI_END="-0.4714101452842784" CI_START="-1.5085898547157215" EFFECT_SIZE="-0.99" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="1.42" MODIFIED="2011-05-09 17:56:05 +0200" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="2.6" SD_2="2.5" SE="0.26459152250056234" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="183" TOTAL_2="189" WEIGHT="51.16765155236991"/>
<CONT_DATA CI_END="-1.8359603910518025" CI_START="-3.224039608948198" EFFECT_SIZE="-2.5300000000000002" ESTIMABLE="YES" MEAN_1="-1.22" MEAN_2="1.31" MODIFIED="2011-02-02 10:57:47 +0100" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="4.2" SD_2="4.8" SE="0.3541083481240949" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="329" TOTAL_2="321" WEIGHT="48.83234844763009"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.309937704642888" CI_END="-0.04636866249254146" CI_START="-5.0828884155357414" DF="1" EFFECT_SIZE="-2.5646285390141412" ESTIMABLE="YES" I2="89.25878956739638" ID="CMP-004.02.02" MODIFIED="2011-02-02 10:58:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0022791538200342965" P_Z="0.04592818055171945" STUDIES="2" TAU2="2.947726896068483" TOTAL_1="478" TOTAL_2="478" WEIGHT="100.0" Z="1.996052757324778">
<NAME>2 years</NAME>
<CONT_DATA CI_END="-0.012427191287785577" CI_START="-2.507572808712214" EFFECT_SIZE="-1.2599999999999998" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.76" MODIFIED="2011-02-02 10:56:39 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="7.2" SD_2="4.2" SE="0.6365284354982588" STUDY_ID="STD-Cohen-2002-_x0028_IMPACT_x0029_" TOTAL_1="170" TOTAL_2="176" WEIGHT="49.236243618126814"/>
<CONT_DATA CI_END="-2.7488568642564584" CI_START="-4.911143135743542" EFFECT_SIZE="-3.83" ESTIMABLE="YES" MEAN_1="-1.53" MEAN_2="2.3" MODIFIED="2011-02-02 10:58:21 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="5.9" SD_2="7.6" SE="0.5516137767180728" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="308" TOTAL_2="302" WEIGHT="50.76375638187319"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.5156413856676787" CI_START="-6.2243586143323215" DF="0" EFFECT_SIZE="-4.87" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" MODIFIED="2011-05-01 19:46:42 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.8198478793717902E-12" STUDIES="1" TAU2="0.0" TOTAL_1="293" TOTAL_2="274" WEIGHT="100.0" Z="7.0476345804583085">
<NAME>3 years</NAME>
<CONT_DATA CI_END="-3.5156413856676787" CI_START="-6.2243586143323215" EFFECT_SIZE="-4.87" ESTIMABLE="YES" MEAN_1="-0.61" MEAN_2="4.26" MODIFIED="2011-05-01 19:46:42 +0200" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="7.3" SD_2="9.0" SE="0.6910119905341777" STUDY_ID="STD-The-European-SG-1998" TOTAL_1="293" TOTAL_2="274" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-11-28 07:31:43 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-06-10 11:18:26 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUAAAALzCAYAAABgJt7sAABEpElEQVR42u2dD4QWXd/Hb5JkJZEkSZYkSRJJkqybJLdkRW65JYkkyUo88sh65CFJblmRJFmJJEkSKytJlpWVJJEktySSZCXz+p73/V3v7OzMnDOzc+31Zz4fxu78ueaaszPz2XPO/M5vfoti/Pbbb0w1mgDqzm9x+UHNTj7nHBAgNwISBKjt9c8NwEXANQAIEBAgAAIEBAiAAAEBAiBAQIAACBAQIAACBAQI0LUCTI4amDt3brRgwYJo//790adPn9r+huamRoAAlQkwPu3duxcBIkCA7hdgnLGxMbds3rx5U5bfuHEjWrVqlaslrlu3Lrp37960/V29ejVatmyZ++zBgwejnz9/Tll/69ataO3atW4fq1evju7cuZN6PM+ePYuWLFkSbdmypbHu0qVLbpkm/Z489pcvX0Zbt251+54/f360ffv26P3795x9BAhc++ECfPr0qVsm2Rn3799PrSVq27jckuvPnDnTWP/gwYPUfYyMjGTWSPfs2eOWX79+3TvYX2JNrtu0aRNnHwEC137xJvDFixcb223bts0tk8TE48ePpzWTN2/e7JapZvjq1Sv3e29vb2O9amRadvjwYVcz1E/Na9/J4zlx4oSbf/funfu5YcMGt/z48eNuXj+TApwzZ46bp9aHAAFKC3DNmjXRzZs3p2ynJm3atnpgYqjpmXeT2T4mJyfdvH5qXs3V5PEkJWZy+/jxo5vX+qQA1eTWvLZV01m1zy9fvnD2ESBw7fubwOPj465/TfNnz56dsp3JLTlJNsltfv36FSRA1e6yBJj12a9fv2YKULVKSW/Xrl2uH1Lr+vr6OPsIELj2w/oA4319w8PDjeUbN250y7Q+C2sC3717N5qYmHC/L1y4cFozWk1fSdKawGoa+wRo+1YtTxw5ciT3KfDnz58bYT2AAAEBBglQ7Nu3zy1btGhR9M8//7hlahKn1QB37NjR+FzaQ5Bjx4411uuJb9o+RkdHvQK8ffu29yGISTI+xZ8icxEgQECAXgGqn019e1ouGRoKcVH/oJq9qtkdPXp0Wh/b0NCQa0ZbGMz379+nrJckFUKjmpn2laxR5tXqrly54r536dKl7gFNclsdd39/v2tSa/+S84cPHzj7CBC49rn4uQi4BgABAgIEQICAAAEQICBAAAQICBAAAQICBECAgAABECAgQAAECAgQoEsEGJJVuVmZl5VLMD4OOO27rl275kaWaPSJpc2q6njqllEaAQICbCNRhOzXMsz8+PFjWnZpBIgAASqvAfpSzwtfenz7jMb+KvW9tlNGmRcvXkxZn0xqkPZ73jahxxNaLgQIUGMBhqSeD0mPn7UPSbBqAYYcT0i5ECBAzQUYkno+JD2+fUbJSdV0tVRY8RctpQkouSxkm5DjCSkXAgSouQBDUs+HpMe3ZfF0VGXkFrJNyPGElAsBAtRcgCGp50PS41clt5BtQo4npFwIEKDmAgxJPR+SHr+I3PSE1xKnlhFgkXT9oSn1ESBADQUYkno+JD1+iLhWrFjRWGaZp8sIMOR4QsqFAAFqLkDhSz0vfOnxQ8SlByP6DjVh7d0dZQQYcjyh5UKAADUSINTqIuCPAAgQECAAAgQECIAAAQECIEBAgAAIEBAgAAIEBAiAAAEBAiBAQIAA3SHAkLT07XxDc1MjQIDSAgwdaoYAESBAVwnQl3FZtcP169e7VFJbt26N3rx5M+2zz549cynmbSyvUBr8tWvXujG+SoevMb9lpKu09YsXL45WrlzpvidrnHDecQICBCglQCUOiK+zt7KlfXbPnj1uubIyp+13ZGSkkACTGV6WL1+eKcC84wQECFCqCayMKr9+/YoePXrk5ufPnz9tmxMnTrj5d+/euZ/qT9Tyw4cPu1T4+pklz7zjsPx9tv9jx45lCjDvOAEBApQSoCUpTdvO5pVZOY5lXp6cnHTz+pklz7zjsCzPllJfgs06hrzjBAQIMOOHICF5+tIEaOLKE6BJMk2AVrPME6Dv2AEBAgLMFWBeWvoiArQ3tKnpq2apNYHjoTYmN/UXahs1YZP700MNawJrm0OHDiFABAhQrQBD0tIXEaC9/jI5jY6ONrbRk1pfevrLly9PWa5szwgQAQJUKsCQtPRFBCgUBrNu3Tq3T4kr+bKiV69euRcZKX19b2/vlJeWx1EKe4XBaB+vX78u9eY5QIAAHTcUzt7j++LFCzd/7949Ny8hAgIE6GoB7t69O7WJrHAYQIAAXS3AT58+RQcOHIgWLFjgniyr5if5ffv2jbOJAAG6W4CAAAEQICBAAAQICBAAAQICBECAgAABECAgQICqBFh0NEVaWv2qvwMQIEBbCrCMzBAgAgRoCwEq9bzS2mvS70k5KRWVanhKaaXxvRrHq1pfXGTJhAZ5n4l/zr5b45GHhoamHJdvHy9fvnSJFbRO22jbZH7CGzduRKtWrXLbaHyyhtQhQAAE6IgnIsjKzCLxJNfpXR95Asz7TNbnNOl4Qr5X6L0jyfWbNm1qrFcShrTviEsUAQLUWIAbNmxwN8bx48fdvH7mNU/fvn3r1ml4WmhzNu8zye9VHsDQfVjChGStz7DchMo7KB4/fuzm9+7diwABEOD/S+Tjx49uXjJJE5pqTSdPnmwIMyQ1Vshn7HuV+l7zaqqG7uPgwYONFFlK5XXmzJnoy5cvjfWWnTo5aXwxAgRAgA1JfP36NVOA1i94+vRpl8svRIChn9GLk4REmEyd79uHPivp7dq1K1q2bJlb19fX11hvmaeTUzynIAIEqLEA7e1rqk2JI0eOTBONakz2fo6HDx9myiyeVj/0M5KbUOp7zcffL+zbR5zPnz9Pq0FaH2IyIWuNLwL+CIAA49y+fdv7EEQvJo8v7+npmVJrTEur7/tM1nfqeEK/1+Qdn+ICTb5b2KYdO3YgQAAE+L8o9bxeLq5QlIsXL04ToPrh9MRVtaudO3dGb968cesHBgbc+rS0+r7P2Hf8/fff7rP6/mQYjG8fajb39/c3wmQkNnuNpnH16lWXUl/NXn2HXsAU7ydEgAA1FyAgQAAECAgQAAECAgRAgIAAARAgIEAABAgIEAABAgIEQICAAAEQICBAAARY4Q3rO24ySyNAgNoKEBAgQGkBVpFWPjT9/bNnz1z6+3jCAo3VVSorpeVSRhpLjxX/nPalRKnaRseqMcFZkrT5W7duuezRdjwvXryYcsxKtbV48WKXcEHHVQfZIkBAgAmqSCtfNP39nj173HJJKrlO+f2Sn1MSg/g2yvTsE2By0jEaySwxy5cvR4AAdRRg1Wnl89LfK+ef1RiFpbNSjdISnvb29k77nDK4/Pr1K3r06NG0pKlZAlSSVNUmlakmeTz2vXY8x44dQ4AAdRRgVWnlQ9LfJyVrGZvzblhNlmQ1T3jJ+XharOQ29r22jYSMAAFqKMAq0sqXSZkf37dqd3kCzFsW8l1ZArSaKAIEqKkA45RNKx+a/j6JNUXv3r0bTUxMNPr7mi1APVCxJrDke+jQIQQIUEcBVpFWPjT9fZK0hyDqj2u2AC9fvjzlO5UxGgEC1FCAVaSVD01/n4bS4Cs0xsJg8vr7qhKg0GsAFAajcr1+/boWb4tDgIAAofHk22ID9RRa8xIiAgRAgF3N7t27U5v18eY3AgRAgF3Jp0+fogMHDriHN2p6q+Yn+X379g0BAiBAQIAACBAQIAACBAQIgAABAQIgQECAAAgQECAAAgQECIAAAQECIEBAgAAIEBAgAAIEBAiAAAEBAiBAQIAACBAQIAACBAQIgAABAQK0uwCHh4ej1atXu3eCKLno8ePHpyQXPXv2rHvhudbr/R96V4it1ztA9HY2LY+v//Hjh1uvt7bpdZv23hC9d1gvSAcECNByAd65cyc1vfy+ffsa8ktbrxcxif3796eu/+uvv9x6yTBt/fPnzzmrCBBgZgI0oegVlVaL07uA7YVBafKJv2VNL1HX74ODg25e7w/WvN4yJ/SWOf2ud/8KiSv+7mF7QdHjx4/d/JMnT6Z83l6xOTY25ubtBUYmWECAADMWYHKSBEMEuH37dvdujZ8/f7p5/dQ6vSs4DRPkn3/+6eb1Ok3Nj46Ounn91LyWCzV74+tNoN3+BjcECDCLAty1a5eTlzVpJZ4ynDp1qlGjTKJ+QK1btWpV46XpExMT0bp166aIdf369dGrV6/cevUnpsnXapCAAAFmLMD4y9DjNTxfDTCOHmZo+YULF1K/Ky5Ya8KqZrd06dIp+9X8yMhI4zOSqmp8krLe5qZmcVlBI0AABJgqu7IC/PLli+vr07Jz585N2dcff/zhmsjaJr5/E5hqg2lNYNUW09DTYfUbLl++nLOKAAGaK0AfEpuarNpetbskv//+u1unpqy4cuVKo5YnrI/Panx6GBIXpJrHeiCihyMKidH7e7X+4MGDnFUECNBaAWaFqdjn7alucjp//rxbryZt2noTnDWr45NqlC9fvuSsIkCA1gow2X+X1kRW6IpCbOwByNDQUGPd5OSk6+NTk1ZNW+1P81puTd6jR4+6GqEmhd1YiA4gQIAZCRAQIAACBAQIgAABAQIgQECAAAgQECAAAgQECIAAAQECIEBAgAAIEBAgAAIEBAiAAAEBAiBAQIAACBAQIAACBAQIgAABAQIgQECAAM279rkBkB9ArQXIjYD8AGotQLshmOozASBAQAYACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIgAARIH8GAASIAAEAASJAAECAXS++5AQACBABAgACrJMEAQABIkAAQIAIEAAQIAIEAATYvRIEAASIAAGgngJMCwth6t4JAAFSC6LmC1BnAXIjIEGAml7/3ABcBFwDgAABAda2/Ez17PtGgFBrAXL91/ucI0CorQS49rnmESDUUgRc9/B/TWIuBC4EBAgIEBAgZQYEGFvZmObOnRstWLAg2r9/f/Tp06dOKBhnGBlQZqhGgPFp7969CBAZUGbofgHGGRsbc8vmzZs3ZfmNGzeiVatWuVriunXronv37k3b39WrV6Nly5a5zx48eDD6+fPnlPW3bt2K1q5d6/axevXq6M6dO6nH8+zZs2jJkiXRli1bGusuXbrklmnS78ljf/nyZbR161a37/nz50fbt2+P3r9/zxWAAAEBhgvw6dOnbplkZ9y/fz+1lqht43JLrj9z5kxj/YMHD1L3MTIyklkj3bNnj1t+/fp1b8CjxJpct2nTJq4ABAgIsHgT+OLFi43ttm3b5pZJYuLx48fTmsmbN292y1QzfPXqlfu9t7e3sV41Mi07fPiwqxnqp+a17+TxnDhxws2/e/fO/dywYYNbfvz4cTevn0kBzpkzx81T60MG3VRmunpmWYBr1qyJbt68OWU7NWnTttUDE0NNz7wTZfuYnJx08/qpeTVXk8eTlJjJ7ePHj25e65MXhprcmte2ajqr9vnlyxeuAASIABGgvwk8Pj7u+tc0f/bs2SnbmdySk2ST3ObXr19BAlTtLkuAWZ/9+vVrpgBVq5T0du3a5fohta6vr48rAAFmXvdpfc30dddUgCLe1zc8PNxYvnHjRrdM67OwJvDdu3ejiYkJ9/vChQunNaPV9JUkrQmsE+gToO1bF5s4cuRI7n/Gz58/N8J6AAH6Wj7W10xfd80FKPbt2+eWLVq0KPrnn3/cMjWJ007Kjh07ci+MY8eONdbrv2DaPkZHR70CvH37tvfCMEnGp/h/Vi4EBJi8zpJ9zfR1I0DXz6a+PS2XDOPVfvUP6gSoZnf06NFpfWxDQ0Ou6m5Ng+/fv09rGqhZoZqZ9pWsUebV6q5cueK+d+nSpe4BTXJbHXd/f79rFmj/kvOHDx+4AhBg5nWflAh93TUTICCDOgswCX3dCBAQYG0FSF83AgQEWFsB0teNAAEB1laAgr5uBAgIkDIDAgRkQJkBAQIyoMyAAAEZUGZAgIAMKDMgwIoOsGnbN+s4Oy1LBwIEBAgIEAECApx6E1sKHsUf6fe0bdJS9+Sl/Xn48OGUTBeGYpi0XOvTROJL95MmntD0Q9pO67Wdov5fvHjR2EZDlvRdFl+l9fEsIHkCVPok/W7xWIrVSg6SRwaUGdpUgMlJosjaxoQWkvZn+fLlTiYWSKqhOwow1RjGLLH40v0kty+TfsgmSc6wYVDxSbIMEaANUFc6I2FpjQ4dOoQMKDO0uwBtKI9+JsWQlbonJO3P6dOnp6TXt8j2f/3rX5li8aX7SW5fJP2QBpBrGxuulHzxk/H27dtp6/MEaMOjLHuOpRTT0CZkUM8yV9VF0m776UoBWvodNeFCU/eEpP2xTBgm1PXr17v5169fZ54YX7qf5PZF0g/FhwxlvRDq5MmTjbxseX1+8Xkdn35fvHixm1dXgY7fsnogQASIANtYgErs6BNgkpC0P0KperTcal3q38s7Mb50Pz4BhqYfSi6z9OOqtVqiy1ABCo39tGawfkqiyKB9y5yX+l790PYPON5FomVaZ+Slxg95aJa2zJcS33fsRfaDAP/vj6KTp9Q9auYms0tk/eFC0v7YydLyFStWuJ+6aEL/M6Wl+0luXzb9UHKZJYGVQO0BThEBWveBiVA1SQTYnmUOSX2v82fZofV6CP0+ODjYWO9LjV9GgCEp8UOOPWQ/CDDKfjigXGc+QYWk/bEandLrW63sx48fuReBL91Pcvuy6YeSy1auXDnl8z09PVOSU/ou6ORxpP1XRoDtUeaQ1Pe6TnVN6B+a/nnr4Vw8CaovNX4ZAYakxA859pD9IMDYCVCtTFVl9WFdu3YtuIbmS/tj2AmwRI95+/el+8kKgymafii5TP9BLZRm586d0Zs3b9z6gYGBoAtaKZHsAY72kXxTGAJsnzKHpL4XkputGxsbm7LOlxq/jABDUuKHHHvIfhBgxDtHq8b+O6v/spP6w+omwJDU9+L8+fONdcoBmLaPrNT4PgHaw7o0ueWlxA859pD9IEAEWCmq8dlT7suXLyPANi5zSOp79T+r60aJSVW70u9almwCZ6XGzxKXmq6SphKtZnX/5KXEL5K2PzS1fm0FqP8UWbFwUAw12XWT6GFIVq0AAbZHmUNS39vDND1QuHDhgvtdIol3u+Slxk8KR9EPvgcTISnxQ449ZD8IEJBBjcucl/p+fHzcfVY1KcMeLGidkZcaPykcPSixUBo9LIk/qY3jS4nvO/Yi+0GAgAwoMyBAQAaUGRAgIAPKDAgQkEGHXNwIEBAg1FeAWU86ue6h6QJsxtMljcpIjimezeNTrJYGm3ejALOk0a0TIMCOE2CV+yyzL4U8pA3bowZIDRC6SIC+9PPCl3qnbLqerFRCeRf0bKQBevLkidteGUCSZcxLqR9yY7Y6P123CrBOZYYKBehLPx+SeqdMup68VEJZ0pitNECWuCEtm0xeSn0ESK0XOkyAvvTzIal3yqTrKZpKKHS/VaQBsrGW8bRdRVPqIwPKDB0gQF/6+ZDUO2XS9RRNJRS63yrSAKkrICttkS8tFzVABAgdJEBf+vmQ1Dtl0vUUTSUUut8q0gClyTk0nTkCRIDQQQKMk5Z+PiT1zkzS9fhSCakZagPMZysNUF4NMFSAyIAyQwcI0Jd+PiT1Tpl0Pb5UQvb+kPirJmcrDZD1Nab1ASJABAhdJEBf+nnhS71TNl1PXiohPWRQGh8dU1zIs5EGyF4MpYcsCBABQk2awPC/PH/+3P3RVONEBpQZEGDtUCykMgIjA8oMCLB2qPmrIHFkQJkBAQIyoMyAAAEZUGY/im89ffp04yGfRig9evQoeD0gQECAHVvmgYGB1FAsPWALWQ8IEBBg08rc7Ow+PT09bt3Y2Jib15j3eEyrbz0gQECATRdgs7L72JBMyyhkoVWLFy8OWg8IEBBg0wXYrOw+8SxE8cmGmfrWwywJUEk/rQmg/z46Md++fatsvdY9fPiQs4AA21KAzcruI6meOnXK3ROS6oEDB1yz1wTrWw+zIED7r5ecrB9ipuvFoUOHovXr13MWEGBbCtC3rKwAk2hcuYZvLl++vNR6aIIAlfZKywcHB928ZVzWuOAq1lsNMZldGRBgpwmwKHpdg+4DvV5BIS9K9BHPUuRbD7MgQL3/Q8lE7V0c+qntVq5cWcl6oXT1Wqa0VIAA6yJAS6iRTNyrd/CErIdZEGAS9UlYaEBV61W11zIFegICrIsAdd0rU5H69DSptRQPsfGth1kWoP1HunDhQuXrk81iQICUGdpCgMqlpxyAWn/u3LnK19sB8HgfGVBmaCsBSl56Qqt1eqJb9fr4AcRfXATIgDJDywWYNR7Rtp3peqEsz5rXAxNABpQZ2kaAShmfJ7CZrhcKf9G8HpAAMqDM0DYCnA3sRUY26BuQAWWG2ghQ8X968xwgA8oMtROg0sqPjIxwFpABZYb6CRCQAWUGBAjIgDIDAgRkQJkBAQIyoMyAAAEZUGZAgIAMKDMgQEAGlBkQICADygwIEJAB5Yay5x4BQq1FwPVf73OOAKH2Esh7sxtT902Jc48AESDXANT22ufi5yLgGoCaXvvcAMgPoNYC5EZAfgC1FqDdEEz17AwGqL0AqQkBAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAiAABEgACBABAgACBABAgACRIAAgAC7U3zJCQAQIAIEAARYJwkCAAJEgACAABEgACBABAgACLB7JQgACBABAkA9BZgWFsLUvRMAAqQWRM0XoM4C5EZAggA1vf65AbgIuAYAAQICBECAgAABECAgQAAECAgQAAECAgRAgIAAu6n8TPUcAJApwGvXrkVLliyJ5syZE23btq3wxZQ1n8bTp0+j7du3V35hN2u/WfsuOsKiXUZk1FmAVADqfc4zBTh37ly34Y8fP6KfP382VYDNEkEzBVPFvhEg5YbWnvtUAWZVGzOqkLnC893keVXUGzduRKtWrXIyXrduXXTv3r3GupcvX7ra6ZYtWxrLNm7c6JZpXejY13fv3rma3Pz58933aB+q3SWP79mzZ65GrO8r8ve5evVqtGzZsmjevHnRwYMHp/wzSds+r8xW7q1bt7r1OmYd+/v37xEBZYZyFZD2FOD9+/dT18XldPLkSbfswYMH0fDwsPt9cHDQK9Y4El5yu9WrV2ce3549e4L/Prdu3Zq23ZkzZzL/NiFlXrt27bT1mzZtQgaUGaoSYKjsqhBg1jbqdzS5icePH7v5vXv3NrZR83zlypWuprRixQonh1+/fpVuYr59+9Ztr9pach8nTpxo1BhD/xabN29286rFvXr1yv3e29ubuX1ImVXD1bKZ1voQIAJEgC0QYGjNUhJKqw0tWLBgynaSi60bGxsr1cemGpZqkxs2bMg83qRwQv4W1o8aKv6QMqsZrWXW/FeN8suXL8iAMsNsC3BycrJpAjR5JCfd+HHOnz/fWDc0NFRYgJcuXXLbnD59ulFLC6nBFhFgvFYasn1emdWHKOnt2rXL9S1qfV9fHzKgzNBsAdoNqiaabuqjR49W2gRWk/b79+9T+ubUL5bF58+fo0WLFkVLly51tST9rmV5+02iz2kbNW0fPnxYWIDxfWc1ge/evRtNTEy43xcuXJi575AyJ8uv7XVekAFlhiYLUE8ffcGFZQSo/jvbbt++fW7ZzZs3U79nx44djc8dPnzYLbt+/Xp04cIF9/uRI0dy95tEfYjx/ff09LifX79+zT3+tH2HPAQ5duxY5t8mpMwm1fgUfxKODCgzNEmAaiJaqIk68yWeKgR4584dV4tTTSZ+MyuEZM2aNe77VHNSjdP6u8bHx91+JQTD+vC0Lm+/yf4/PTzRNjt37ozevHnj9jEwMJB7/Gn7TttWzXKFz1gYTLwmmhU2k1Vm8fHjx6i/v78RtiM5fvjwARlUVGYGABTfdycPAGAoHCDAlG4eBgA0b98IEBBgG5aZAQD1GwCAAAEBtpEAGQAwuwMAECAgQE/zjAEA3TsAAAECApwFATIAIHv7Vg4AQICAAAve4AwA6J4BAAgQEKDnBmcAQP4xd/IAAAQICNAjQAYA5B9zJw8AQICAAD0CZABA/jF38gAABBh4E8QpO1oAAVJmaLv7nAuhqADLjhZABpQZOkSAvkhxX2R2SOT2TKO/q/gOoSdiqtFpsqdjviZSWj+Q+j6sWaGgUjUX0j4bj65HBpQZ2lCAvkhxX2S2b30V0d9VfEe8Pyckgj5rOz0hTFs3MjKS+VlF1yMDygxt3gROixT3RWb71lcR/V3Fd1gH8vHjx928foYOY4qj2qeW6QmdmsX2pC7eR5gVXY8MKDO0oQDzIsV9kdm+9VVEf1fxHSZRPWUSkmkZAdp3KUhWWLCsmubJz1U5nAcZUGZoggB9keK+yGzf+iqiv6v4DhOXxT9VJUDV7rIEiAwoM7S5AH2R4nF8kdlp66uO/i77HRZgqdqkUEBpGQFac1tNX40WsCZwPHkkAqTM0CEC9EWK+yKzfeuriP6u4jtu375d6CFIlsj0xDdtH6OjowgQAUKnCdAXKe6LzA6J3J5p9HcV3yGuXLni1inC/eLFi6UEKBQGo1AbHYu+M1nzRICUucrroN3201UCBGRAmREgAgRkULMyzyQlfbzlEZoSPjQHYUjAftWB/wgQEGCNyjzTlPTWFVIkJXyIAEMC9psR+I8AAQHWqMxVpKQvmhI+RIAhAfvNCvxHgIAAa1LmKlLSF00JHyLAkID9ZgX+I0BAgDUpcxUp6YumhA9JuR8SsN+swH8ECAiwJmWuIiV90ZTwISn3QwL2mxX4jwABAdakzFWkpC+aEj4k5X5IwH6zAv8RICDAGpV5pinpRZGU8CEp90VIwH4zAv8RYP4OMuebtY+i72NQGEB8TC4gQP7xQ+UCrPCgKv1MXf/DIQPKDDMQoC+qPKT2pkjzxYsXu7gppYIPrb1ZtLqq6b4XP+fNp/V1qEz6aeOGFRKQjNVCBpQZaizAkKhyn4iSnbLLly8PlldyUr9IVQK0RKq2T+tzOXToEALsrosbAUI5AYZElftEZI/cLQW8noSFyisZqb5+/fpSAkybt6d09mJn/dS8npAhwO4SYN6LzAEB/jaTiHifaCy+yZqaliU5RFYWqa7PJhOdzlSAeiqmeTXNhb3j14JD6yrALGl06wQI8LeZRMSHCtBe/lNEgJY9w/rn8lLLF50X6tO0ZrB+KpShzhcCNUBAgDFCosp9olGz1ZrAinBXH1uorPQuEqHPJjM9lxWgBrFbPJY1x02EyvCBAOkDBAToCIkq94nn8uXLUz6rAM2yD0Hi/XNFBaiMHbbM+v2SKezT8qYhQMoMNRWg8EWVhzQ1FXWuvjbt5/Xr18HN6L///tuFwOh7ZxIGY7LTvtQkt5qkaoKWGUPL4wkrkQFlBgQ4Y0wwL168cPOWQsgePrQae9Kt12rW/UKgzIAAK2b37t2pzdn4wPBWoRqf9VGqqY4AKTMgwEr59OlTdODAARc6o7Aa1fwkv2/fvrW88HqqrDRGOp6svG3IgDIDAgRkQJkBAQIyoMyAAAEZUGZAgIAMKDMgQEAGlBkQICADygwIEJBBTcqsN7/19fW50Kqenh4XWpU2skivoFRIGPccAgQE2BVl1guNTGrx6dSpU9O21TBMUnEhQECAbVtmE5SS5q5evdqNE1dmJBvOmcSyi1tA/ZMnT1xNMJlebXBw0L0WAgEiQECAbS/A5CQJpqFMQxrzPjk5mfldz58/d9uMjo4iQAQICLD9BagEGerHs7RpGsqZhmVK0pBPbaPhlWr+Wh+gsg7pJVzWJEaACBAQYNsL0F7j4JOWZTxKTvZOGzWRlXTXhIgAESAgwLYXoG+ZoRpf/G2J6gPUvJ4G5zWpue8QICDAjheg3pIYzyg+Pj6OABEgIMB6CNAecCTlZq+CDdk/IEBAgB0pQDEyMuKS60qEevWCXuiVlWMSAdZAgDt37kw9ycPDw43YKiVHVUdxPDnq2bNno97eXrde7+odGBhoi+SpCJAyAwL0oqj433//PfW/XPItbMm3tEl+aev7+/s5U8iAMsPsCrBoRLx9ZtOmTakC1FhJLVNEvND7huMvPNfrNvX73bt3G30r9sY2QAaUGVoiwNCIeKHaml6bmSbA7du3uzGTFg+ln9pGw4PSMEH++eefnClkQJmhNQIMjYhP+2weioy3GmYS9QNqnSLov379yplCBpQZWiPA0Ij4IgJUiIDWX7hwIXV9XLjWRwjIgDLDrAuwaM0ubzs1j9XXp3Xnzp2bsu6PP/5wTWRtE99PSI0TkAFlhrYWoMRmLyJX7S6JPT22MZRXrlxx84qrAmRAmaGjBaiYvrwhQTaGMjmdP3+eM4UMKDN0tgBVk/ONidR4SoXc2AOQoaEhzhIyoMww+wIEZECZAQECMqDMgAABGVBmQICADCgzIEBABpQZECAgA8oMCBCQAeWGzjn3CBBqLQKu/3qfcwQItZdA3ouLmLpvSpx7BIgAuQagttc+Fz8XAdcAIEBAgAAIEBAgAAIEBAiAAAEBAiBAQIAA3XPtcwMgP4BaC5AbAfkB1FqAdkMw1TMiHqD2AqQmBAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgNB+55+pfScEiACBc885QoDcBMB551whQG4E4JxzzhAgNwNwzjlnCJCbATjnnDMEyM0AnHPOGQLkZgDOOecMAXIzAOecc4YAuRmAc845Q4DcDJzz3zKXVzEiIfmZkH08ffo02r59e+VlbdZ+ESACBARYmQCbNfRrNoaUIUD+sNBFAiwqFJ/wfPvNE+6NGzeiVatWRXPnzo3WrVsX3bt3r7Hu5cuX0Zw5c6ItW7Y0lm3cuNEt07rZHluLAPnDAgKsTID3799PXadmrXHy5Em37MGDB9Hw8LD7fXBw0CtW7lMEiAA550FN4GYLMGubbdu2NeQmHj9+7Ob37t3b2ObHjx/RypUrXe1wxYoV0dq1a6Nfv37RBEaACBDaU4Bp+0/b77x581KPZ8GCBVO2U7PY1o2NjRWu1SJAbgbgnJeqqU1OTjZNgOr3SxOg+vjinD9/vrFuaGgIASJABAjNEaBJSc1SNTWPHj1aaRNYTdrv37+7ZXqgoWXqC8zi8+fP0aJFi6KlS5e6mqF+17K8/XKfIkAEyDkvJcCtW7d6m8plBKj+O9tu3759btnNmzdTv2fHjh2Nzx0+fNgtu379enThwgX3+5EjR3L3y32KABEg57yUAF+9etUINent7XXiqUKAd+7ccbU41TDjYS1Xr16N1qxZ475v4cKFrsb55csXt258fNztd/PmzY3tN2zY4JZpXd5+uU8RIALknAMC5A8LnHNAgPxhgXMOCJA/LHDOAQHyhwXOOSBA/rDAOQcEyB8WOOeAAPnDAuccECB/WOCcAwLkDwv1POdpaeeLJiHolqQFCJA/LNTsnFchLwSIABEgtPScv3v3ztXk5s+f78bOasxvPPuySerZs2fRkiVL3NjarKQIaULTuN5ly5a5PH8HDx6Mfv78mSvAvHT4QmnvlZxB63XMOvb3799znyJABAjFz7mln4pPq1evniYpm/bs2RMswFu3bk3b7syZM5kCDEmHr+zPyfWbNm3iPkWACBBmds7fvn3rtlNtLSmpEydONGqMWbW35DJlbNG8anHKKKPflU0ma/uQdPjKEKNl3VrrQ4AIEGb5nKuGpRcNWVqptLRWSeGECNASqeYdU3x9SDp8NaMtQ7Sa46pRWqos7lMEiACh0Dm/dOmSW3f69OlGLS0kr18RAcZfWBSyfV46fPUhSnq7du1yfYta39fXx32KABEgFD/nql1pnZq2Dx8+LCzAeNr5rCbw3bt3o4mJCfe7Epxm7TskHX4cpcHX9hIn9ykCRIBQ+Jzr9ZLx2lZPT4/7+fXr11wBpqWdD3kIcuzYsUwBhqTDN6nGp07O+owAESC08Jyr/09PVlWL2rlzZ/TmzRu37cDAQK4A09LOp22rN7YpfMbCYOIvKcoKm8lKhy8+fvwY9ff3N8J2JMcPHz5wnyLAsD9o3vtfgX96gAARIHAzAQLsdgkCNxMgQAQI3EyAABEgcDMBAkSAwM0ECJA/LHDOAQHyhwXOOXSXANPCQpi6d+JmAgTIBcEFRdln/bur+P5220/HChD5IUHKjQBrKUDkB3W8BvLKnJeGXinoLfeeoawtWqZ1RpHU9yGptIRSdWkcsSZL21U0hX7ofhAgIIMaljkkDb2SpVqm5uHhYff74OBgY33R1PchArx+/bq3Lzfk2EP2gwABGdS0zCFp6JXzT2mzVMNSGixlj4knOS2a+j5EgJad+vjx425eP8uk0A/ZDwIEZFDTMoekoReSm60bGxubsq5o6vsQAdq7P5T+Siglf5kU+iH7QYCADGpa5pA09OL8+fONdcrxl7aP0NT3yfnJyclMuVli1jRxhRx7yH4QICCDmpY5JA29Us8vWrTIJUBV7Uq/a1myCRya+t7EpaarpKmkp1np9PVARRw5cqRUCv2Q/SBAQAY1LXNIGvrDhw+7ZXqgcOHCBfe7RGIUTX2vF5v7Hkzcvn3bu03IsYfsp12F2FYC1JMlvYW+qoLN9gloxnd0anwXApxKXhr68fFx91nVpAx7sKB1RpHU93pQYqE0elgSf1Ib58qVK+54VPO8ePFiqRT6IftJa/IjwCYKpFuGZiFAar3dgB7qrF69ut4CVFCnqubqn9ALV1Tbs5dBZ1WfqwroLBPgmXe8RWqdar7o5Gs/+q/84sWLaf9huy3AFQFCnD/++CN68uRJvQWo2Kak5DZt2jRjAYYEYpYJ8Mw73iICTE6SYF7fTjcEuCJAqOs5yxSgxQtl1aJCazdlAjrLBHj6jjdUgLt27XK1Or3mUPOq6RndGuCKAAEBJlDzzjpDNe5RNZ14Z2pZAYYEYpYJ8PQdb6gA4+9UzQpXKLrPmf49mh3gigABASZQLUgSUY1IfV7arq+vr9DNXTags0yAp+94q5BVtwa4IkBAgDkoyFPb6UZM3twaF2mP+KsK6CwT4Ok73ioE2K0BrggQEGDGDRWf4imANAjclu/bt88tqyqgs0yAp+94qxBgpwe4IgMEyDkLFKD6kvr7+11IiWoyutni/WN6SKBASq0z0VQV0FkmwNN3vFUIUHRygCsyQICcsxJNYODCosz+f6Jpo6N4/woCBARYl5spqBUBCBAQYNuV2YLp1XUh/v77bzd/7tw5N//69Ws3r5E4Sbn5Bgeodrh+/XrXdaK+4Tdv3nhF+uzZM9fdEu/L9o0IevfunauFWleQumDiAfMhI6bU162/hbbRqCh1d6UdX96oqaIjsxAgIMAWl/nf//63W67+U6FA83jAuQnx9OnThQWovtn4OgW3+wRo0549e9zykBFBFjEQn+Ljen0jphSxkPYdIyMjmceXNmqq6MgsBAgIsMVlfv78eWM0kFi+fLmrsakWJnbv3t2omaU1b/OawHpopVCoR48euXnVinwCPHHiRKNWJ0JGBMV5+/bttNFMvhFTqqlpvVJ+KbbWUn/FhR0yaqroyCwECAiwDcpskQ3//PNPQy42QkjLFWSfJbw8AeZFC2QJMCmP0HT9qhHqxU02PDL+Xb4RU/YdCtoXFrwfF3bIqKmiI7MQICDANiiz1XjsBlZtTz8PHTrUqMmVEaBvWcj6kBFBlgVIzXQbrx7fl2/EVFKAqn1mCTDvmIuOzEKAgADboMzWB6Y+O2v66ga2PryHDx96BRgfHVWlAENGBKk2qG0kLh1r3neljZiyZrb+EajJbv8Q4uE9RcsUMjILAQICbIMy66bv6emZ0remkU6a1/L4OPDkTZ82OqpKAYaMCNLrOuPrrCw2Rtw3Ysr685LT6OhoIQEWHZmFAAEBtkmZTXh634ewp78mtaybPm10VJUCFL4RQer/sxCWnTt3unAb7WtgYMCtDxkxpfAWhdhovb4rWeMMKVPRkVkIEBAgZQYECMiAMgMCBGQwozL5mpnAdYoAoasFmJdyDbhOESDkDufq5gkQIAIEaoCAAIELqxsFWKcyc50iQECAlJlzhgABGVBmzlnbClDjJfP6aTTkSAO67f0bymyhVEKADDq1zBqZkfxejRlW2itd5xoxoZ8ataH7A7pYgFnJHe14dBGkrVPONkCAnVRmZWX5/fffU/sl9+/fn3qd//XXX1yYrRRgSNrrtO1Dww30BjOtO3XqVOp6G8Q9Njbm5pX6O208JiDAKsvcjOvesiGn3Q+WOFTJTcWTJ0+8CVO5TmdRgHlpr2ciQP2H0zq930BNXA0i/89//tNYb3nJLAuFZetdvHgxVwICbLoAq7zulRRACQvS7gdLHW/XuX5qXsuhDQSYl/Z6Jljq7eT03//+160/fvx46vqZ5hQDBBgiwGZc92kCnJiYcJlX4te4Xp5kL2aCFgswL+31TGqAusBUm7MHG0rzo22VU03o4lPzWNvo4jtw4IBrFlclYECAs33dpy1XjU+tn/jnNB9/CRG0UIC+ZWUFmLWPrBqenoqpv0QvqgEE2GwBNuO6T1uuLqC0JnBvby8XZicJsCg68erotXeOWg1Q1X+hZoHWq1NYITHHjh1rvKsBEGC7CHCmTWDr67Yan73pjZZOlwtwcHAw9b/m7du33XrFRqW9/UovXAYE2C0CVNdO2n3AP/ouF6A4e/ase+GMmrZKva233sebvEr3rf+EmvRGqaxQBECAnSpAvX1Nfd3q2tF9oP4/zdtb2aBFAgQuLMoMCBC4sCgzIEDgwqLMgACBC4syAwIELizKDAgQuLAoMyBA4MKizIAAARlQZkCAgAwoMyBAQAaUGRAgIAPKDAgQkAFlBgQIyIAyAwIEZECZAQECMqDMgAABGVBmaJ4AuRi4qCg71PVc/cbFwEXF3wDqeo5+S34RU30m4Lqv+3XKXUAtAKC+9z5/AgQIgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAIAAESAAIEAECAAIEAECAAJEgACAABEgACBABAgACBABAgACRIAAgAARIAAgQAQIAAgQAQIAAkSAAAiQPwICBECACBAAEGCNxJecAAABIkAAQIB1kiAAIEAECAAIEAECAAJEgACAALtXggCAABEgACDA0GYjU/tNANAkAXKDUaMFqKUAubGQIEAtBcgNhQQBECAgQAAECAgQAAECAgRAgIAAARAgIEAABAgIsLXlZyJgv6kCTBZq7ty50YIFC6L9+/dHnz59mrKt5o8cORItXLgwmjdvXrR+/fro1q1bwRcsIEDKzjlqawHGp7179za2+/btW7Rq1arU7UyCCBAJUG7OVUcKMM7Y2Jhbplqe8e9//9st2759e/TPP/9EP378iPbs2eOWrV27Nmi/4uXLl9HWrVtdTXP+/Pluf+/fv+dKQgTIj3PWHgJ8+vSpW6Yan7Fu3Tq3TAIzJK6+vj63fagAJctkzXDTpk1cRcgAAXLO2qsJfPHixcZ2qrEVKWiWAOfMmeOWU+tDBpSZc9aWAlyzZk108+bNKdtVJcCDBw+65RLhli1bojNnzkRfvnzhKkIGCJBz1tom8Pj4eLRkyRI3f/bs2SnbrV692i1/8eJFY9m7d+9cH16RJvDPnz+d9Hbt2hUtW7bMbaNmNCADBMg5a6kAxf379xvLhoeHG8tPnjzZkJXCYfRUePfu3W6ZwmFCBRjn8+fPjdAbQAYIkHPWcgGKffv2uWWLFi1yT3yFmqkrV65MbTLfu3cvWICbN2+e9nk1hQEZIEDOWVsI8OPHjy4YWsslQ0M1P/Xh9fT0uD68jRs3uhpj6H5t3/39/S4ERjW/HTt2RB8+fOAqQgZB12lIwL6Pa9euua4eXcPbtm3jQquzAIELqxMFmBWwH4I90FMsq/qkAQECF1ZHCDBOWsC+uHHjhothlegUvxrvoskboZT3ufhnnz175mqQ8a6b0M9q1JQeKGo7taDiDxXF1atX3cNBlUmtraSgfd/TioEGCBAQYAsEmBawH3+IF58sUiFLgL7PpX1WI6HKftYmSdCQHJPrFTERWjbRioEGCBAQYAubwPGAffXpadmDBw/c/OPHj6c1k9NkWuRzJ06ccPMKAyv6WYV/qVZ3586dabVXe0CoWt2rV6/c7729vYWOsRUDDRAgIMAWCDAtYF9CSdtWD0zyBFjkc0m5FPls/IFf8jh8gw1CvqcVAw0QICDAWWwC5wXsm0SSk4SQJ8Cyn5vJZ7ME+OvXr9S/Qcj3tGKgAQIEBDiLAkz2h8UD9tWnpmVZ4VlZMir7uZl8NrnMmsB3796NJiYm3O/KvVnke+LM1kADBAgIcJYFKNIC9tUkTqslKd40b19lPzeTzyaXpT0EOXbsWKHvacVAAwQICLAFAswK2FcoifoH1TRUDero0aNT+sGyRFb2c2U/m7ZsaGjINe8tDOb79++FvqcVAw26SoDNyN5c1T5naz/tksEaAQLnrAtqgJ0mQC4sygzUAKfMzySCPWufPildunTJNQc06fe0bXyR8aH7qeJvgAwoMwLsUgHOJIK9jACvX7/ufblSSGR8yH6q+BsgA8qMALtYgDOJYC8jwA0bNrj548ePu3n9TG4TEhkfsp8q/gbIgDIjwC4W4Ewi2MsI0Ib06KmWUPR9cpuQyPiQ/VTxN0AGlBkBdrEA87bxRbD79jk5OZkpt69fv2aKKyQyPmQ/VfwNkAFlRoA1FaAvgj1LXGq6SpqKZcrapx6oiCNHjkzbJiQyPmQ/CJCbCRBg6ZvfF8Ge3F75ynwPJm7fvu3dJiQyPmQ/CJCbCRDgjG7+vAj25PZ6UKLam5qqelgSf1Ib58qVK64muXTpUpfyKG0bX2R86H4QIDdT2eMtcsyKUFCS0tn47iq/qzYCBGRAmZsnwCr/cbbLiCYECMhgFsrsSxevrhhlRFYfswLWFa6UJoRkSvsqUt0b9q5sG4urlo4vG3XI94giAf153+X7OyFAQIBtVmZfsL0eqKXd9CMjI5lSsJT2VaS6N+zBXHySZPKk1IyA/qztQv5OCBAQYJuV2Rdsr1qXlh0+fNjVDPVT8/HXXmaltK8i1X0ab9++nRYwXzYdfxUB/aF/JwQICLDNyhyaLl4xpcJiS9UUTQohmdK+ilT3cVRzO3nyZENavgdqsxXQH/p3QoCAANtUgFnB9skbW7W4LAGGiCL+nUVS3Vvf3OnTpxs1VZ8AZyugP/TvhAABAbZpEzgr2N6akWrSSZLWtIuHgRQVYJlU95agVWJ5+PBhpgD1UnYLFWt2QH/8u0L+TggQEGCbldkXbG8JKpLT6OhoaQGWSXW/cuXKKdv29PRMqbmtWLGisc6yWDcroD/tu0L+TggQEGAbltmXLl6SVAiJmpQKjk/WqIoKUBRNda/+Pwsx2blzZ/TmzRu3fmBgoCEgBeRrfTzcphkB/Vnf5fs7IcAWkRa5nnaBFa2uh+wXAVJmQIAt/0P6jrOMuDolBT4yQICcsxYIUE+uFi9e7F4vePny5VJjYfMi4OPbZ6WVz+rbSPs9uU2Z6Pv479ZZbQGwht6upeVab4RE7CMDysw56xAB6ob2da6GCDAvAj5LRPG08jMRYJno++TxL1++3EnN+l30Umn1x2jolRESsY8MKDPnrIMEaMGa6nQVaRHmRbOh5EXA56WVD/keX3M2NPo+uUxxW5pX57KwTuZ//etfjW1CIvaRAWXmnHWQAC3C3KLgFWleVoAhEfB5aeVnIsCi0fdpTfh4jXT9+vVu/vXr141tQiL2kQFl5px1kAAtCt0ya+iGL5PCvkwEfFXbVPHdoq+vzy2z2qkSt6b9rfIi9pEBZeacdZAAN23a1AgqlQT/+uuvUinsQyPgQ+QWj1wP2aZM9H3WO4a1zAJIFZsVJyRiHxlQZs5ZBwlQN7nvIUhICntfBHyIANMi10O2KRN9n3Y8+gegJ+E2NlLCjBMSsY8MKDPnrIMEKM6dO+cizPXEMy0MJiSFvS8CPkSAaZHrIduUib7P6ku0h0A25jLtH4YvYh8ZVF/mTglm79SY01oLkJPIhdXuZW7Ve1kAAQICbGmZfbGcqh3qqb2e0qu7Ri2AOEWD122/loJeNX39nrZNVnr95HYKq9J+1F2jFpVaGjoedc88efKksX3ogIL496ps8QgLi+SIJ4xFgAUOUhdSPI4OEGA7C1Biia+LZzcuE7ye1d+tUUxZ2yTT6+ftSxJOzhtFBxToe9Vdo9/VNSWsi+rQoUMIsM43EwKsRxNY/bCKTnj06NG05J5lgteT6bb0Mx4jGt8mK71+cjvVQi1IX9O1a9caIWeq6aWRF9Qf/15LFWYP+PRT80qhhQARIALscgHmvYO6TPC6bWPp59W0LJpePzlvmayz5uOEBPXHv1cP4bRM4/mFmsZ6SGdREAgQASLALhZg3rIyweu2jfrqfAL0HWfR+TJB/cKa1db8lTzrcJ0iQARYKwH6gtmzknQUCV63fahvTTU1NTc1H08q2iwBlhlQEG+mmwhVg0SACBABtmGZfO+xSCM0mD25rEzwetZDEL2PpNkCLDOgQCRT3TczTRsCBAQ4QwHmpV5LIzSYPW1Z0eB124c+p/409a3poUWIyGcqwDIDCoRqxZbYRJ+1sf0IsMUH2coI/k6PZ8zLg9jNU7vXUtsVe+KtlHN1+Ufd9gIkgp8aYBU1QASYj2p8lsJNw1kRYOBBvnz50kXPq9qsp1yqrdkjdl+E+UzT3M80gj/v2NMuZN/2CLB9+wBnk04cCKDrWYk89DAk6+XxCDAF9TckJaUUWcIXYT7TNPczjeDPO/a0m823PQKkzFAzASYzQsfxRZjPNM39TCP484497bt923NhUWaomQCtlic56OnamTNnGk/IfBHmM01zP9MI/rxjT9unb3suLMoMNROgam4SgWpxygeo7ZQa3siLMK8qzX3aspAIft+xJ/fp254LizJDzQQYR6+CTA7OzoswryrNfdqyohH8acee1+Getj0XFmWGmglw8+bN02pZ8SE/eRHmVaW5T1sWEsHvO/bkPn3bc2FRZqiZABXa0t/f30jAKMHE+/TyIsyrSnOftcwXwe879uQ+fdtzYXVumdMC7mdyDEXeRY0AuzwQulUR5lxYCLCstKoUINRYgK2MMOfCQoBGXhC7L97UJzdLfa/J0lH5aoAzDdLnOu0QAbYywhwBIkAjL4h9JgKMv+Ewb3hefL6KIH2u0w5qAgMCbHWZiwa9hy6zrMt6SZGw16LmCbCKIH2uUwQInLPgMhcNeg9dZqKy9PcSlk+AVQTpc50iQOCcBZe5aNB72rLJyclMmdnophABVhGkz3WKAIFzVqrMeUHv8YB7E5Waquq/VhhVVmyoamziyJEjXgFWEaTPdYoAgXMWXGZfEHtawL2ewvoecCixR9GHIFUE6XOdIkDgnAWX2RfEnhZwr7eqqbampqlyWMaf+Ma5cuWKC7TX5y9evBgUBjPTIH2u0zYSoJoIimlqJlVG6s/GCW2HoFoECJyzWRCgQgGsD6QTpNJJAkQGlJlz1sYCfPLkiVs3PDw8TQBqDqh6r1f1qTmhGClV59Xfos/FyYuMz+pf0btPVSu0ZoKaK/Fg0jR8n/Gl6S+yD+F7LUAz0/IjQOCcNVmAFvg5OjqaKyxLhxWfN3yR8VkCtKdp8UnSysP3GV+a/iL7EL7XAjQzLT8CBM5ZkwVoMlD4QPKmVa3u7du3jXm9G/X169fTHumHRMb7mpX2PUVeRpP2mZA0/aH7EL7XAjQzLT8CBM5ZkwWoZlhWAKmN/c2aN0Ii47MEqFqikqzakKS0p29pL4/2fSYvLVboPoTvtQDNTMuPAIFz1mQBWrBoXq2lisj4rCwcWnb69GnXxxgiwNDP5JWn6D7yXgvQzLT8CBA4Zy2sAYbOh0TGp0Xqq4aoZXoo8fDhw6Cnr77PhAiw6D7yXgsQp+q0/AgQOGdNFqD136X1AYbOh0TGp0Xq6+lyfPuenp4p4zLT8H0mRIBF95H3WoBmpuVHgMA5a7IAT5w44dbpwUVZAQpfZHxapL764fRUVMt27twZvXnzxu13YGAgsxy+z4QIsOg+8l4L0My0/AiwuZw9e9aFM+k8qG9X5//bt2+N9RMTE657QudK/yTVEoife+gCAT5//tytUy0OsmnFawEQYHPll9Zq0T8nob5h6yqJT6dOneJm6CYBCsWhHT58mDOZQateC4AAp9fi8wLc07bPikFVzVs1u7t3706pCFh/rD2tt0zoCvzX9vEHYNAlAlTzV01CSKdVrwVAgH6hxQPciwgwiQXz//nnn25efdbq9lAOQehyAQIXVqcIMDTAvQjqB9S+NOzRHoRZX/aBAwfcd+gfoJq/9AEiQECALROgL8C9TA0wLlSLULCHXsnJ3h0CCBAQ4KwL0LcsVIB//PGHe8iRHLVjNUrV+OLj2S1piJ4GAwIEBNjWAvTx+++/T6nRKSmq5hWqJTSOPR7zOT4+jgARICDA7hCg1eiS0/nz5916PRVOawYrbhYQICDAjhagUO1OITX2AGRoaGjK+pGRERf+JBGqZqix47MZBcB12gUC1BC7IuEIgACBc9Y1AsxKlsqFjgwoM+es5QKsOsI+iXUuM4QIGVBmzlnbCrBZEfZ//fVXo49FIQbqS/nPf/7DVYMMKDPnrH0E2IwIe6GX/qTJ8r///S9XDjKgzJyz9hBgMyLshcSqdPKPHj1y80qbpW011hKQAWXmnLWFAH3Lygowax9ZWZABAQLnrG0FWBT1/SmbiprW8Rqg4qsAGVBmzllXC3BwcDC1tmivlQRkgAA5Z10rQKHsu3oDmiLqlTZf7xsGZECZOWctFyBwYVFmQIDAhUWZAQECFxZlBgQIyIAyAwIEZECZAQECMqDMgAABGVBuaP25QoBcXJQdanuOECAXWFeXn6l9p7a4RriZECBAbe8RbiYECIAAuZkQIAAC5GZCgAAIkJsJAQIgQG4mBAiAAAEBAtRRgNxQyA+g1gLkxkJ+ALUWoN1gTETYA3Q6/wMYUuzDfuHHfwAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-25 12:09:15 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-11-25 12:09:15 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-11-25 11:10:57 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-11-25 11:10:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-11-15 09:58:36 +0100" MODIFIED_BY="[Empty name]">Details of initial search for review</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-25 11:10:57 +0100" MODIFIED_BY="[Empty name]">
<P>We searched each of the following databases:</P>
<OL>
<LI>The Cochrane MS Group Specialised Register (1995 to December 2009);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) "The Cochrane Library" (4, 2009);</LI>
<LI>MEDLINE (PubMed) (January 1995 to December 2009);</LI>
<LI>EMBASE (January 1995 to December 2009);  </LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-11-25 10:35:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-06-08 12:54:13 +0200" MODIFIED_BY="[Empty name]">Keywords for searching the MS Group Specialised Register</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-08 14:24:41 +0100" MODIFIED_BY="[Empty name]">
<P>{spms} OR {secondary progressive} OR {secondary-progressive} OR {progressive secondary multiple sclerosis} OR {SP-MS}</P>
<P>AND</P>
<P>{interferon\*} OR {interferon beta} OR {interferon beta1} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1b} OR {interferon beta-1a} OR {rebif} OR {avonex} OR {recombinant} OR {beta\*}</P>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;RCTs &amp;#160;included in quantitative synthesis (meta-analysis)&lt;br&gt;n = 5&amp;#160;&lt;/b&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;studies included&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;n = 59&lt;/b&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;full-text articles assessed for eligibility&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;n 123&lt;/b&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Records provisionally selected &amp;#160;(n = 222)&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Records identified through database searching&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;n=2389&lt;/b&gt;&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;&lt;b&gt;records excluded&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;n = 99&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;b&gt;full-text articles excluded&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;n 64&lt;/b&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;b&gt;Full-text articles excluded, with reasons&lt;br&gt;n =18&amp;#160;&lt;/b&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;b&gt;References correlated to the primary studies&lt;br&gt;n =36&amp;#160;&lt;/b&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>